- entity: node
  type: pdq_cancer_information_summary
  title: 'Fatigue (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: fatigue
  moderation_state:
    value: published
  field_pdq_url:
    value: /about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq
  field_pdq_cdr_id:
    value: 62734
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Supportive care
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2017-06-29'
  field_browser_title:
    value: 'Fatigue'
  field_page_description:
    value: 'Fatigue is the most common side effect of cancer treatment, but it can also be a presenting symptom. Fatigue has a negative impact on all areas of function and can last well beyond treatment. Get comprehensive information about fatigue and interventions in this summary for clinicians.'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/about-cancer/treatment/side-effects/fatigue/fatigue-pdq">Go to Patient Version</a></div><p id="_2" tabindex="-1">Fatigue is the most common side effect of cancer treatment with chemotherapy, radiation therapy, or selected biologic response modifiers.[<a href="#cit/section_1.1">1</a>]  Cancer treatment&#x2013;related fatigue generally improves after therapy is completed, but some level of fatigue may persist for months or years following  treatment. Research indicates that for at least a subset of patients, fatigue may be a significant issue long into survivorship.[<a href="#cit/section_1.2">2</a>,<a href="#cit/section_1.3">3</a>] Fatigue is also seen as a presenting symptom in cancers that produce problems such as anemia, endocrine changes, and respiratory obstruction and is common in people with advanced cancer who are not undergoing active cancer treatment.  Cancer treatment&#x2013;related fatigue is reported in 14% to 96% of patients undergoing cancer treatment [<a href="#cit/section_1.4">4</a>-<a href="#cit/section_1.10">10</a>] and in 19% to 82% of patients posttreatment.[<a href="#cit/section_1.1">1</a>,<a href="#cit/section_1.2">2</a>]</p><p id="_237" tabindex="-1"> Several studies have documented significantly worse fatigue in cancer survivors compared with  noncancer populations, as described in one review article.[<a href="#cit/section_1.1">1</a>]  For example, a Norwegian cross-sectional study [<a href="#cit/section_1.11">11</a>] compared the prevalence of fatigue in long-term survivors of testicular cancer (n = 1,431) at an average of 11 years posttreatment with the prevalence of fatigue in age-matched men in the general Norwegian population (n = 1,080). The prevalence of chronic cancer-related fatigue (CRF) was 17.1% (95% confidence interval [CI], 15.2&#x2013;19.1%) among testicular cancer survivors, compared with 9.7% (95% CI, 8.0&#x2013;11.5%) in the general population. Chronic CRF was also associated with multiple psychosocial problems, somatic complaints, and poor quality of life.[<a href="#cit/section_1.11">11</a>]</p><p id="_154" tabindex="-1">Fatigue, like pain, is viewed as a self-perceived state. Patients may describe fatigue  as feeling:[<a href="#cit/section_1.12">12</a>]</p><div class="pdq-content-list"><ul id="_330"><li>Tired.</li><li>Weak.</li><li>
            Exhausted.</li><li> Lazy.</li><li>Weary.</li><li>Worn-out.</li><li>Heavy.</li><li>Slow.</li><li>Like they do not have any energy or any get-up-and-go.</li></ul></div><p id="_331" tabindex="-1">Health
            professionals have included fatigue within concepts such as: </p><div class="pdq-content-list"><ul id="_332"><li>Asthenia.</li><li>
            Lassitude.</li><li>Malaise.</li><li>Prostration.</li><li>Exercise intolerance.</li><li> Lack of energy.</li><li>Weakness.</li></ul></div><p id="_333" tabindex="-1">Research on fatigue in people with cancer has included primarily self-reports of fatigue, with fewer but increasing data exploring biologic or physiologic correlates.  Such correlates have included measures of muscle weakness, maximal oxygen uptake, cytokines, and cortisol.</p><p id="_155" tabindex="-1">Fatigue experienced as a side effect of cancer treatment is differentiated from fatigue experienced by healthy people in their daily lives. <em>Healthy fatigue</em> is frequently described as acute fatigue that is eventually relieved by sleep and rest; cancer treatment&#x2013;related fatigue is categorized as chronic fatigue because it is present over a long period of time, interferes with functioning, and is not completely relieved by sleep and rest.[<a href="#cit/section_1.13">13</a>]  Also, the level of CRF is often disproportionate to the level of activity or energy exerted.[<a href="#cit/section_1.13">13</a>]  Although the label <em>chronic fatigue</em> is accurate, using this label does not mean that people with cancer who experience fatigue have chronic fatigue syndrome.  Using the phrase <em>chronic fatigue</em> can be confusing to both patients and health professionals.  Terms such as <em>cancer fatigue</em>, <em>cancer-related fatigue</em>, and <em>cancer treatment&#x2013;related fatigue</em> have all been used in the clinical literature, research literature, and educational materials for patients and the public.</p><p id="_156" tabindex="-1">Fatigue has a negative impact on all areas of function, including the following:[<a href="#cit/section_1.14">14</a>-<a href="#cit/section_1.17">17</a>]</p><div class="pdq-content-list"><ul id="_334"><li> Mood.</li><li>Physical function.</li><li>Work performance.</li><li>Social interaction.</li><li>Family care.[<a href="#cit/section_1.18">18</a>]</li><li> Cognitive performance.</li><li>School work.</li><li>Community activities.</li><li>Sense of self.</li></ul></div><p id="_335" tabindex="-1">The pattern of fatigue associated with cancer treatment varies according to type and schedule of treatment. For example, people treated with cyclic chemotherapy regimens generally exhibit peak fatigue in the days following treatment, then report lower levels of fatigue until the next treatment; however, those undergoing external-beam radiation therapy report gradually increasing fatigue over the course of therapy of the largest treatment field.  Few studies of people undergoing cancer treatment have addressed the issue of fatigue as a result of the emotional distress associated with undergoing a diagnostic evaluation for cancer and the effects of medical and surgical procedures used for that evaluation and for initial treatment.  Because most adults enter the cancer care system following at least one surgical procedure and because surgery and emotional distress are both associated with fatigue, it is likely that most people beginning nonsurgical treatment are experiencing fatigue at the beginning of treatment.[<a href="#cit/section_1.19">19</a>,<a href="#cit/section_1.20">20</a>]</p><p id="_160" tabindex="-1">Recommendations for fatigue management focus on identifying factors that may be contributing to fatigue.  Because the only definitive causal mechanism demonstrated through research to date is chemotherapy-induced anemia, most clinical recommendations for managing fatigue caused by something other than chemotherapy-induced anemia rely on careful development of clinical hypotheses, as outlined in the National Comprehensive Cancer Network guidelines on fatigue.[<a href="#cit/section_1.21">21</a>] The only level 1 intervention for CRF at this time is exercise. (Refer to the <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_94">Exercise</a> section of this summary for more information.)  Much more research is needed to better define fatigue and its trajectory, understand its physiology, and determine the best ways to prevent and treat it.</p><p id="_1_4" tabindex="-1">In this summary, unless otherwise stated, evidence and practice issues as they relate to adults are discussed.  The evidence and application to practice related to children may differ significantly from information related to adults.  When specific information about the care of children is available, it is summarized under its own heading.</p><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Prue G, Rankin J, Allen J, et al.: Cancer-related fatigue: A critical appraisal. Eur J Cancer 42 (7): 846-63, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16460928&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16460928&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Baker F, Denniston M, Smith T, et al.: Adult cancer survivors: how are they faring? Cancer 104 (11 Suppl): 2565-76, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Foss&#xE5; SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21 (7): 1249-54, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.5">Miaskowski C, Portenoy RK: Update on the assessment and management of cancer-related fatigue. Principles and Practice of Supportive Oncology Updates  1 (2): 1-10, 1998.</li><li id="section_1.6">Irvine DM, Vincent L, Bubela N, et al.: A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nurs 14 (4): 188-99, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.7">Vogelzang NJ, Breitbart W, Cella D, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (3 Suppl 2): 4-12, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.8">Detmar SB, Aaronson NK, Wever LD, et al.: How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J Clin Oncol 18 (18): 3295-301, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10986063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10986063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.9">Costantini M, Mencaglia E, Giulio PD, et al.: Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). Qual Life Res 9 (2): 151-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10983479&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10983479&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.10">Cella D, Lai JS, Chang CH, et al.: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94 (2): 528-38, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11900238&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11900238&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.11">Orre IJ, Foss&#xE5; SD, Murison R, et al.: Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 64 (4): 363-71, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18374735&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18374735&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.12">Barsevick AM, Whitmer K, Walker L: In their own words: using the common sense model to analyze patient descriptions of cancer-related fatigue. Oncol Nurs Forum 28 (9): 1363-9, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11683307&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11683307&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.13">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.14">Pickard-Holley S: Fatigue in cancer patients. A descriptive study. Cancer Nurs 14 (1): 13-9, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2013047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2013047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.15">Glaus A: Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Support Care Cancer 1 (6): 305-15, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8156248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8156248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.16">Given B, Given CW, McCorkle R, et al.: Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29 (6): 949-56, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.17">Curt GA: The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 5 (Suppl 2): 9-12, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10896323&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10896323&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.18">Passik SD, Kirsh KL: A pilot examination of the impact of cancer patients' fatigue on their spousal caregivers. Palliat Support Care 3 (4): 273-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17039982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17039982&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.19">Ancoli-Israel S, Liu L, Marler MR, et al.: Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14 (3): 201-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.20">Jacobsen PB, Hann DM, Azzarello LM, et al.: Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 18 (4): 233-42, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10534963&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10534963&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.21">National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 2.2017. Fort Washington, Pa: National Comprehensive Cancer Network, 2017. <a href="https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf" title="https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf">Available online with free registration</a>. Last accessed January 4, 2018.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _7
      field_pdq_section_title:
        - format: plain_text
          value: 'Pathogenesis of Fatigue'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_7" class="pdq-sections"><p id="_8" tabindex="-1">Except for chemotherapy-induced anemia, the  mechanisms responsible for fatigue in people with cancer are not known.  Understanding the causes of fatigue in people with cancer is especially challenging because each individual may experience multiple possible causes of fatigue simultaneously.  This multifactorial etiologic hypothesis is apparent in the various models that have been proposed for the study of fatigue.[<a href="#cit/section_2.1">1</a>,<a href="#cit/section_2.2">2</a>]
            Energy balance, stress, life demands, sleep, neurophysiologic changes, disruption of circadian rhythms, cardiac issues, and neuroimmunologic changes are generally incorporated in these models, based on the rationale that these factors are associated with fatigue in contexts other than cancer.[<a href="#cit/section_2.3">3</a>] The cancer literature supports some of these variables.</p><p id="_254" tabindex="-1">There is a burgeoning amount of evidence, particularly in women with breast cancer and men with prostate cancer, that fatigue is associated with markers of increased immune inflammatory activity.  When fatigued individuals with a history of breast cancer are compared with breast cancer survivors without fatigue, different patterns emerge with respect to interleukin-6, interleukin-1 receptor antagonist, C-reactive protein, neopterin, and soluble tumor necrosis factor receptor-II.[<a href="#cit/section_2.4">4</a>-<a href="#cit/section_2.6">6</a>]  Although the precise relationships&#x2014;and the clinical meaning of those relationships&#x2014;are not yet known, increased cytokines likely contribute to the symptoms of asthenia, fatigue, and lethargy, as supported in animal models of cytokine-induced sickness behavior [<a href="#cit/section_2.7">7</a>,<a href="#cit/section_2.8">8</a>] and in humans.[<a href="#cit/section_2.9">9</a>]  There have not yet been large, well-controlled studies that have evaluated the effects of general anti-inflammatory agents on fatigue or cytokine biomarkers.</p><p id="_255" tabindex="-1">     Other studies demonstrate a change in the regulation of cortisol by the hypothalamic pituitary adrenal axis.  One key study put fatigued and nonfatigued breast cancer survivors through a stress battery in a laboratory setting.   Nonfatigued survivors mounted a significant cortisol increase in response to acute stress, while fatigued survivors had a very blunted response.[<a href="#cit/section_2.10">10</a>]  Another study has shown fatigued breast cancer survivors have flattened cortisol slopes, having higher levels of cortisol at the end of the day than do  nonfatigued survivors.[<a href="#cit/section_2.11">11</a>]  It is the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis that may account for the prolonged inflammatory cytokine milieu; understanding the body&#x2019;s response to numerous chronic stressors in cancer may help in managing fatigue.</p><p id="_257" tabindex="-1">Finally, another theory is that serotonin is negatively impacted through chronic exposure to proinflammatory cytokines.  One hypothesis is that the relationship between central nervous system concentrations of serotonin and fatigue have a U-shaped relationship, suggesting that very high and very low levels of serotonin may be associated with cancer-related fatigue.[<a href="#cit/section_2.12">12</a>] However, studies that have evaluated serotonergic agents have not demonstrated a benefit for fatigue.[<a href="#cit/section_2.2">2</a>] The role and relationship of many important neurotransmitters such as dopamine, norepinephrine, and serotonin with HPA axis functioning and cytokine expression have yet to be fully understood.</p><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Miaskowski C, Portenoy RK: Update on the assessment and management of cancer-related fatigue. Principles and Practice of Supportive Oncology Updates  1 (2): 1-10, 1998.</li><li id="section_2.2">Morrow GR, Andrews PL, Hickok JT, et al.: Fatigue associated with cancer and its treatment. Support Care Cancer 10 (5): 389-98, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12136222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12136222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Aistars J: Fatigue in the cancer patient: a conceptual approach to a clinical problem. Oncol Nurs Forum 14 (6): 25-30, 1987 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3320982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3320982&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Bower JE, Ganz PA, Aziz N, et al.: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64 (4): 604-11, 2002 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12140350&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12140350&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Evans WJ, Lambert CP: Physiological basis of fatigue. Am J Phys Med Rehabil 86 (1 Suppl): S29-46, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17370370&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17370370&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Bower JE, Ganz PA, Tao ML, et al.: Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 15 (17): 5534-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19706826&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19706826&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933: 222-34, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12000023&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12000023&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12 (2): 123-37, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3050629&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3050629&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Eisenberger NI, Inagaki TK, Mashal NM, et al.: Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun 24 (4): 558-63, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20043983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20043983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Bower JE, Ganz PA, Aziz N: Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 67 (2): 277-80, 2005 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15784794&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15784794&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Bower JE, Ganz PA, Dickerson SS, et al.: Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30 (1): 92-100, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15358446&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15358446&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Jager A, Sleijfer S, van der Rijt CC: The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 44 (2): 175-81, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18162394&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18162394&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _12
      field_pdq_section_title:
        - format: plain_text
          value: 'Contributing Factors'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_12" class="pdq-sections"><p id="_13" tabindex="-1">Although fatigue is clearly prevalent in patients with cancer, it has been
            difficult to identify consistent correlates of fatigue in this patient
            population.  The factors most often implicated have been the following:[<a href="#cit/section_3.1">1</a>-<a href="#cit/section_3.9">9</a>]</p><div class="pdq-content-list"><ul id="_136"><li>Cancer
            treatment.</li><li>Anemia. </li><li>Medications.</li><li>Cachexia/anorexia.</li><li>Metabolic disturbances.</li><li>Hormone deficiency or excess.</li><li>Psychological distress.</li><li>Physical deconditioning.</li><li>Sleep disturbances.</li><li>Excessive
            inactivity.</li><li>Pulmonary impairment.</li><li>Neuromuscular dysfunction.</li><li>Pain and other symptoms.</li><li>Proinflammatory cytokines.</li><li>Nutritional deficiencies.</li><li>Dehydration.</li><li> Infection.</li><li>Concomitant medical illness.</li><li>Cardiac impairment.</li></ul></div><section id="_14"><h3 id="_14_toc">Cancer Treatment</h3><p id="_171" tabindex="-1">The association of fatigue with the major cancer treatment modalities of surgery, chemotherapy, radiation therapy, and biologic response modifier therapy caused speculation that fatigue resulted from tissue damage or  accumulation of the products of cell death.  Interest in the effects of cancer treatment on the production of proinflammatory cytokines is based on recognition of the strong fatigue-inducing effect of some biologic response modifiers such as interferon-alpha and the finding of elevated levels of proinflammatory cytokines in people experiencing persistent fatigue following cancer treatment.[<a href="#cit/section_3.10">10</a>,<a href="#cit/section_3.11">11</a>]</p><p id="_252" tabindex="-1">Many people with cancer undergo surgery for diagnosis or treatment. Despite the high incidence of postoperative fatigue observed in clinical practice, little research exists that examines causes and correlates of postoperative fatigue in people with cancer.[<a href="#cit/section_3.12">12</a>] It is clear, however, that fatigue is a problem postsurgery that improves with time and is compounded by fatigue experienced from other cancer treatments.[<a href="#cit/section_3.12">12</a>]</p><p id="_17" tabindex="-1">Fatigue has long been associated with radiation exposure and is reported as being one of the most common and activity-limiting side effect of radiation therapy for cancer.[<a href="#cit/section_3.4">4</a>,<a href="#cit/section_3.13">13</a>]  Most of the research describing the fatigue trajectory during radiation therapy has been conducted with women who have breast cancer and men who have  prostate cancer.[<a href="#cit/section_3.13">13</a>,<a href="#cit/section_3.14">14</a>]  Fatigue increases throughout radiation therapy, peaking around midcourse; it remains at this level until radiation therapy is completed, improving somewhat during the 2 months after completion of treatment.[<a href="#cit/section_3.13">13</a>-<a href="#cit/section_3.15">15</a>] A study that investigated the trajectory of fatigue in men (n = 82) who were undergoing radiation therapy for prostate cancer found significant interindividual variability.[<a href="#cit/section_3.14">14</a>] The authors used hierarchical linear modeling, a highly sophisticated analytical  method, to identify predictors for prolonged fatigue trajectories. Younger men with a high level of fatigue at radiation therapy initiation were at increased risk of higher levels of morning and evening fatigue during the course of radiation therapy. Additionally, level of depression at radiation therapy initiation predicted the level of morning fatigue during the course of radiation therapy.[<a href="#cit/section_3.14">14</a>]</p><p id="_258" tabindex="-1">A second study that included 73 women who were undergoing adjuvant radiation therapy for breast cancer found similar differences in the patterns and predictors of morning versus evening fatigue.[<a href="#cit/section_3.16">16</a>]  Participants were recruited to the study at the time of their simulation visit and completed baseline questionnaires.  Data were then collected on 2 subsequent days, in the morning and at bedtime, each week during radiation therapy; every 2 weeks for 2 months after radiation therapy; and once a month for 2 additional months thereafter.  Fatigue was measured with the Lee Fatigue Scale.  For the group as a whole, over the 25 weeks of data collection, morning fatigue decreased slightly during radiation therapy and was constant for 4 months afterwards, while evening fatigue increased through radiation therapy and then declined slightly after treatment.  Evening fatigue was higher for those who:</p><div class="pdq-content-list"><ul id="_292"><li>Were working.</li><li>Had children at home.</li><li>Had higher depression scores.</li></ul></div><p id="_293" tabindex="-1">Morning fatigue was higher for those who:</p><div class="pdq-content-list"><ul id="_294"><li>Had more trait anxiety.</li><li>Were experiencing sleep disturbance.</li><li>Were younger.</li><li>Had lower body mass indices.</li></ul></div><p id="_295" tabindex="-1">Advanced disease and comorbidities also added to the severity of morning fatigue.[<a href="#cit/section_3.16">16</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>]</p><p id="_217" tabindex="-1">  A
            number of research studies document the existence of a fatigue syndrome that is
            not specific to the disease type or radiation site and that
            demonstrates a gradual decline in fatigue in the patient after treatment is
            completed.[<a href="#cit/section_3.15">15</a>,<a href="#cit/section_3.17">17</a>-<a href="#cit/section_3.20">20</a>]  Some of these studies suggest, however, that not all
            patients return to pretreatment energy levels.  Specific etiologic factors and
            correlates of fatigue associated with radiation therapy have not been
            identified.[<a href="#cit/section_3.12">12</a>]  Risk factors for persistent low energy in cancer patients
            include older age, advanced disease, and combination-modality therapy.[<a href="#cit/section_3.21">21</a>]
            </p><p id="_18" tabindex="-1">Fatigue is a dose-limiting toxicity of treatment with a variety of
            biotherapeutic agents.  Biotherapy exposes patients with cancer to exogenous
            and endogenous cytokines.[<a href="#cit/section_3.22">22</a>]  Biotherapy-related fatigue usually occurs as
            part of a constellation of symptoms called flulike syndrome.  This syndrome
            includes:[<a href="#cit/section_3.23">23</a>]</p><div class="pdq-content-list"><ul id="_336"><li> Fatigue.</li><li>Fever.</li><li> Chills.</li><li> Myalgias.</li><li>Headache.</li><li> Malaise.</li></ul></div><p id="_337" tabindex="-1">Mental
            fatigue and cognitive deficits have also been identified as biotherapy side
            effects.[<a href="#cit/section_3.24">24</a>]  The type of biotherapeutic agent used may influence the type and
            pattern of fatigue experienced.
            </p><p id="_253" tabindex="-1">Treatment with chemotherapy is a predictor of fatigue and can be exacerbated by the coexistence of pain, depression, and/or anxiety.[<a href="#cit/section_3.25">25</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>][<a href="#cit/section_3.26">26</a>]  A longitudinal, descriptive study reported highest levels of fatigue at the midpoint of a patient&#x2019;s chemotherapy cycles, with fatigue improving after treatment but not quite returning to baseline levels 30 days after the last treatment.[<a href="#cit/section_3.25">25</a>] In another longitudinal study of women with stage 0 to stage II breast cancer who received chemotherapy with or without radiation therapy (N = 103) versus radiation therapy alone (N = 102) versus a control group (N = 193),[<a href="#cit/section_3.27">27</a>] increases in fatigue were demonstrated 3 years posttreatment for the group that received chemotherapy with or without radiation therapy, compared with the two other groups.  Mean scores for fatigue severity as measured by the Fatigue Symptom Inventory (range, 0&#x2013;10) increased over the 3 years as follows:</p><div class="pdq-content-list"><ul id="_327"><li>From 2.31 to 2.86 in the group that received chemotherapy with or without radiation.</li><li>Only from 1.96 to 2.06 in the radiation therapy&#x2013;alone group.</li><li>Only from 2.20 to 2.22 in the noncancer control group.</li></ul></div><p id="_326" tabindex="-1">There were statistically significant group-by-time effects for the group that received chemotherapy with or without radiation therapy. This increase in fatigue was not explained by hormone therapy and approached clinically meaningful values.[<a href="#cit/section_3.27">27</a>]  It is not currently known what specific patient characteristics are associated with risk for long-term increased fatigue or more severe fatigue and who will experience fatigue resolution.</p></section><section id="_20"><h3 id="_20_toc">Anemia</h3><p id="_21" tabindex="-1">Evidence suggests that anemia may be a major factor in cancer-related fatigue
            (CRF) and quality of life in cancer patients.[<a href="#cit/section_3.28">28</a>-<a href="#cit/section_3.30">30</a>]  Anemia can be related to the
            disease itself or caused by the therapy.  Occasionally, anemia is simply a
            co-occurring medical finding that is related to neither the disease nor the
            therapy.  Anemia is often a significant contributor to symptoms in persons with
            cancer.  For individual patients, it can be difficult to discern the actual
            impact of anemia because there are often other problems that confound the ability
            to weigh the specific impact of anemia.  The impact of anemia varies depending
            on factors such as:[<a href="#cit/section_3.31">31</a>]</p><div class="pdq-content-list"><ul id="_338"><li> The rapidity of onset.</li><li> Patient age.</li><li>Plasma-volume status.</li><li> The number and severity of comorbidities.</li></ul></div><p id="_238" tabindex="-1">A retrospective review was
            conducted to understand the problem of anemia in patients undergoing radiation
            therapy.  Anemia was prevalent in 48% of the patients initially, and increased
            to 57% of the patients during therapy.  It was more common in women than men
            (64% vs. 51%); however, men with prostate cancer experienced the greatest
            increase in anemia during radiation therapy.[<a href="#cit/section_3.32">32</a>]  In certain cancers, such as
            cancer of the cervix and cancer of the head and neck, anemia has been found to
            be a predictor of poor survival and diminished quality of life in patients
            undergoing radiation therapy.[<a href="#cit/section_3.33">33</a>-<a href="#cit/section_3.36">36</a>]
            </p></section><section id="_22"><h3 id="_22_toc">Nutrition Factors</h3><p id="_23" tabindex="-1">Fatigue often occurs when the energy requirements of the body exceed the supply
            of energy sources.[<a href="#cit/section_3.37">37</a>,<a href="#cit/section_3.38">38</a>]  In people with cancer, three major mechanisms may be
            involved:</p><div class="pdq-content-list"><ul id="_339"><li>Alteration in the body&#x2019;s ability to process nutrients efficiently.</li><li>
            Increase in the body&#x2019;s energy requirements.</li><li>Decrease in intake of energy
            sources.</li></ul></div><p id="_340" tabindex="-1">Causes of nutritional alterations are listed in <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_118">Table 1</a>.</p><table id="_118" class="table-default expandable-container"><caption>Table 1.  Nutrition/Energy Factors</caption><colgroup><col width="33.33%"><col width="66.66%"></colgroup><THead><tr><th> Mechanisms </th><th>Causes</th></tr></THead><tbody><tr><td>Altered ability to process nutrients</td><td> Impaired glucose, lipid, and    protein metabolism</td></tr><tr><td rowspan="4">Increased energy requirements </td><td>Tumor consumption of and
            competition for nutrients</td></tr><tr><td>Hypermetabolic state due to tumor    growth</td></tr><tr><td>Infection/fever</td></tr><tr><td> Dyspnea</td></tr><tr><td rowspan="4">Decreased intake of energy sources</td><td>Anorexia</td></tr><tr><td>Nausea/vomiting</td></tr><tr><td>Diarrhea</td></tr><tr><td> Bowel obstruction</td></tr></tbody></table></section><section id="_26"><h3 id="_26_toc">Psychologic Factors</h3><p id="_27" tabindex="-1">Numerous factors related to the moods, beliefs, attitudes, and reactions to
            stressors of people with cancer can also contribute to the development of
            chronic fatigue.  Anxiety and depression are the most common comorbid psychiatric disorders of CRF.[<a href="#cit/section_3.39">39</a>] Often, fatigue is the final common pathway for a range of physical and emotional etiologies.
            </p><p id="_28" tabindex="-1">Depression can  be a comorbid, disabling syndrome that affects approximately 15%
            to 25% of persons with cancer.[<a href="#cit/section_3.40">40</a>]  The presence of depression, as manifested
            by loss of interest, difficulty concentrating, lethargy, and feelings of
            hopelessness, can compound the physical causes for fatigue in these individuals
            and persist long past the time when physical causes have resolved.[<a href="#cit/section_3.41">41</a>]</p><p id="_341" tabindex="-1">Anxiety
            and fear associated with a cancer diagnosis, as well as its impact on the
            person&#x2019;s physical, psychosocial, and financial well-being, are sources of
            emotional stress.  Distress associated with the diagnosis of cancer alone may
            trigger fatigue.  A study of 74 early-stage breast cancer patients with no
            history of affective disorder assessed various symptoms of adjustment
            approximately 2 weeks after diagnosis; about 45% noted moderate or high levels
            of fatigue.  This fatigue may have been secondary to the increased cognitive
            strain of dealing with the diagnosis or to insomnia, reported as moderate to severe by about 60% of the patients.  Therefore, fatigue may begin before
            treatment as a result of worry or other cognitive factors, both primary and secondary
            to insomnia.  Various forms of treatment may compound this fatigue.[<a href="#cit/section_3.42">42</a>]</p><p id="_342" tabindex="-1"> In cancer survivors, fatigue may also be increased above levels seen in the general population.[<a href="#cit/section_3.43">43</a>,<a href="#cit/section_3.44">44</a>]  In testicular cancer survivors, anxiety and depression were predictive of fatigue, suggesting a possible role for psychiatric intervention in fatigue management.[<a href="#cit/section_3.45">45</a>]  (Refer to the PDQ summaries on <a href="/about-cancer/coping/feelings/depression-hp-pdq">Depression</a> and <a href="/about-cancer/coping/feelings/anxiety-distress-hp-pdq">Adjustment to Cancer: Anxiety and Distress</a> for
            more information.)</p><p id="_259" tabindex="-1">Psychologic and symptom distress have also been found to be significant predictors of fatigue.[<a href="#cit/section_3.46">46</a>,<a href="#cit/section_3.47">47</a>]  In a study of 101 women about to undergo surgery for breast cancer, younger age, presurgery distress, and expectations about fatigue significantly predicted fatigue levels 1 week after surgery.  In the regression model, age, distress and expectancy each uniquely contributed to fatigue, with distress and expectancy  accounting for 25% of the variance.[<a href="#cit/section_3.46">46</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>]  In a longitudinal study with women who had gynecologic cancer, symptom and psychologic distress significantly predicted fatigue before, during, and after treatment with chemotherapy, explaining up to 80% of the variance in fatigue scores after chemotherapy treatment.[<a href="#cit/section_3.47">47</a>] Factors similar to those seen in patients with early-stage cancer are also contributors to fatigue in patients with advanced, incurable cancer.[<a href="#cit/section_3.48">48</a>] </p></section><section id="_29"><h3 id="_29_toc">Cognitive Factors</h3><p id="_30" tabindex="-1">Impairment in cognitive functioning, including decreased attention span and
            impaired perception and thinking, is commonly associated with fatigue.[<a href="#cit/section_3.49">49</a>,<a href="#cit/section_3.50">50</a>]
            Although fatigue and cognitive impairments are linked, the mechanism underlying
            this association is unclear.  Mental demands inherent in the diagnosis and
            treatment of cancer have been well documented, but little is known about the
            concomitant problem of attention fatigue in people with cancer.  Attention
            problems are common during and after cancer treatment.  Some of the reported
            attention problems may be caused by the fatigue of directed attention.[<a href="#cit/section_3.51">51</a>,<a href="#cit/section_3.52">52</a>]
            Attention fatigue may be relieved by activities that promote rest and recovery
            of directed attention.  Although sleep is necessary for relieving attention
            fatigue and restoring attention, it is insufficient when attention demands are
            high.  Empirical literature suggests that the natural environment contains the
            properties for restoring directed attention and relieving attention fatigue.
            </p></section><section id="_31"><h3 id="_31_toc">Sleep Disorders and Inactivity</h3><p id="_343" tabindex="-1">Causative or contributing factors in CRF may be:</p><div class="pdq-content-list"><ul id="_344"><li>Disrupted sleep.</li><li>Poor sleep hygiene.</li><li>Decreased nighttime sleep or excessive daytime sleep.</li><li>Inactivity.</li></ul></div><p id="_32" tabindex="-1">Patients with less daytime activity and more nighttime
            awakenings were noted to consistently report higher levels of CRF.  Those with
            lower peak-activity scores, as measured by wristwatch activity monitors,
            experienced higher levels of fatigue.[<a href="#cit/section_3.6">6</a>]
            </p><p id="_260" tabindex="-1">Sleep disorders clearly contribute to fatigue [<a href="#cit/section_3.53">53</a>] and may differentially affect fatigue ratings, depending on the time of the rating.  A study that evaluated fatigue in women undergoing radiation therapy for breast cancer found that sleep had a greater influence on morning fatigue values than on evening fatigue scores.[<a href="#cit/section_3.16">16</a>] In a similar study of men undergoing radiation therapy for prostate cancer, sleep contributed to both morning and evening fatigue levels.[<a href="#cit/section_3.14">14</a>]  However, fatigue and sleep can also be distinct problems.  One study that resulted in significant improvement in sleep with the use of cognitive behavioral therapy did not significantly affect fatigue.[<a href="#cit/section_3.54">54</a>]</p><p id="_324" tabindex="-1">Refer to the PDQ summary on <a href="/about-cancer/treatment/side-effects/sleep-disorders-hp-pdq">Sleep Disorders</a> for more information.</p></section><section id="_33"><h3 id="_33_toc">Medications</h3><p id="_34" tabindex="-1">Medications other than chemotherapy may contribute to fatigue.  Opioids used in the treatment of cancer-related pain are often
            associated with sedation, though the degree of sedation varies among
            individuals. Opioids are known to alter the normal function of the hypothalamic secretion of gonadotropin-releasing hormone.[<a href="#cit/section_3.55">55</a>]</p><p id="_345" tabindex="-1">Hypogonadism may be found in patients with advanced cancer and can contribute to fatigue during cancer treatment.[<a href="#cit/section_3.56">56</a>]  One case-control study examined the effects of chronic oral opioid administration in survivors of cancer and, consistent with the research on intrathecal administration, found marked central hypogonadism among the opioid users with significant symptoms of sexual dysfunction, depression, and fatigue.[<a href="#cit/section_3.57">57</a>] One trial (<a href="/clinicaltrials/NCT00965341">NCT00965341</a>) has studied whether testosterone replacement therapy  affects fatigue in men with advanced cancer and low testosterone levels; results are pending.</p><p id="_230" tabindex="-1"> Other medications&#x2014;including tricyclic antidepressants,
            neuroleptics, beta blockers, benzodiazepines, and antihistamines&#x2014;may produce
            side effects of sedation.  In addition, concurrent medications such as analgesics, hypnotics, antidepressants, antiemetics, steroids, or anticonvulsants&#x2014;many of which act on the central nervous system&#x2014;can significantly compound the problem of fatigue. The coadministration of multiple drugs with varying
            side effects may compound fatigue symptoms.
            </p></section><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Blesch KS, Paice JA, Wickham R, et al.: Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum 18 (1): 81-7, 1991 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2003120&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2003120&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Groopman JE: Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 12 (3): 335-44; discussion 345-6, 351, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Irvine DM, Vincent L, Bubela N, et al.: A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nurs 14 (4): 188-99, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Hickok JT, Morrow GR, McDonald S, et al.: Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management. J Pain Symptom Manage 11 (6): 370-7, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8935141&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8935141&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Von Hoff D: Asthenia: incidence, etiology, pathophysiology, and treatment. Cancer Therapeutics  1: 184-97, 1998.</li><li id="section_3.6">Berger AM, Farr L: The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum 26 (10): 1663-71, 1999 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10573683&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10573683&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Engstrom CA, Strohl RA, Rose L, et al.: Sleep alterations in cancer patients. Cancer Nurs 22 (2): 143-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10217030&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10217030&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Dimsdale JE, Ancoli-Israel S, Ayalon L, et al.: Taking fatigue seriously, II: variability in fatigue levels in cancer patients. Psychosomatics 48 (3): 247-52, 2007 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17478594&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17478594&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Jacobsen PB, Donovan KA, Small BJ, et al.: Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 110 (8): 1851-9, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17847016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17847016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Collado-Hidalgo A, Bower JE, Ganz PA, et al.: Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12 (9): 2759-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16675568&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16675568&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Wood LJ, Nail LM, Gilster A, et al.: Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 33 (3): 535-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16676010&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16676010&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Winningham ML, Nail LM, Burke MB, et al.: Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 21 (1): 23-36, 1994 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Donovan KA, Jacobsen PB, Andrykowski MA, et al.: Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J Pain Symptom Manage 28 (4): 373-80, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15471655&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15471655&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Miaskowski C, Paul SM, Cooper BA, et al.: Trajectories of fatigue in men with prostate cancer before, during, and after radiation therapy. J Pain Symptom Manage 35 (6): 632-43, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18358683&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18358683&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Greenberg DB, Sawicka J, Eisenthal S, et al.: Fatigue syndrome due to localized radiation. J Pain Symptom Manage 7 (1): 38-45, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1538180&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1538180&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Dhruva A, Dodd M, Paul SM, et al.: Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nurs 33 (3): 201-12, 2010 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20357659&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20357659&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Haylock PJ, Hart LK: Fatigue in patients receiving localized radiation. Cancer Nurs 2 (6): 461-7, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=259440&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=259440&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">King KB, Nail LM, Kreamer K, et al.: Patients' descriptions of the experience of receiving radiation therapy. Oncol Nurs Forum 12 (4): 55-61, 1985 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847996&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847996&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Nail LM: Coping with intracavitary radiation treatment for gynecologic cancer. Cancer Pract  1 (3): 218-24, 1993.</li><li id="section_3.20">Larson PJ, Lindsey AM, Dodd MJ, et al.: Influence of age on problems experienced by patients with lung cancer undergoing radiation therapy. Oncol Nurs Forum 20 (3): 473-80, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8497416&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8497416&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Fobair P, Hoppe RT, Bloom J, et al.: Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4 (5): 805-14, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Piper BF, Rieger PT, Brophy L, et al.: Recent advances in the management of biotherapy-related side effects: fatigue. Oncol Nurs Forum 16 (6 Suppl): 27-34, 1989 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2480583&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2480583&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Haeuber D: Recent advances in the management of biotherapy-related side effects: flu-like syndrome. Oncol Nurs Forum 16 (6 Suppl): 35-41, 1989 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2687812&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2687812&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Mattson K, Niiranen A, Iivanainen M, et al.: Neurotoxicity of interferon. Cancer Treat Rep 67 (10): 958-61, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6194882&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6194882&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Berger AM, Lockhart K, Agrawal S: Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens. Oncol Nurs Forum 36 (5): 563-70, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19726396&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19726396&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">So WK, Marsh G, Ling WM, et al.: The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Oncol Nurs Forum 36 (4): E205-14, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19581224&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19581224&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Goedendorp MM, Andrykowski MA, Donovan KA, et al.: Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer 118 (15): 3833-41, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22086766&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22086766&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Vogelzang NJ, Breitbart W, Cella D, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (3 Suppl 2): 4-12, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Demetri GD, Kris M, Wade J, et al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16 (10): 3412-25, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Johnston E, Crawford J: The hematologic support of the cancer patient. In: Berger A, Portenoy RK, Weissman DE, eds.: Principles and Practice of Supportive Oncology. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 549-69.</li><li id="section_3.32">Bush RS: The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12 (11): 2047-50, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3771322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3771322&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Fein DA, Lee WR, Hanlon AL, et al.: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13 (8): 2077-83, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7636551&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7636551&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Girinski T, Pejovic-Lenfant MH, Bourhis J, et al.: Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16 (1): 37-42, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2912956&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2912956&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Dubray B, Mosseri V, Brunin F, et al.: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201 (2): 553-8, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8888257&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8888257&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Dunst J: Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 27 (2 Suppl 4): 4-8; discussion 16-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10847301&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10847301&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Watanabe S, Bruera E: Anorexia and cachexia, asthenia, and lethargy. Hematol Oncol Clin North Am 10 (1): 189-206, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8821567&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8821567&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.38">MacDonald N, Alexander HR, Bruera E: Cachexia-anorexia-asthenia. J Pain Symptom Manage 10 (2): 151-5, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7730686&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7730686&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.39">Reich SG: The tired patient: psychological versus organic causes. Hosp Med  22 (7): 142-54, 1986.</li><li id="section_3.40">Henriksson MM, Isomets&#xE4; ET, Hietanen PS, et al.: Mental disorders in cancer suicides. J Affect Disord 36 (1-2): 11-20, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Cella D, Davis K, Breitbart W, et al.: Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19 (14): 3385-91, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11454886&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11454886&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Cimprich B: Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs 22 (3): 185-94; quiz 195, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Sugawara Y, Akechi T, Okuyama T, et al.: Occurrence of fatigue and associated factors in disease-free breast cancer patients without depression. Support Care Cancer 13 (8): 628-36, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15668753&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15668753&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">Foss&#xE5; SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21 (7): 1249-54, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.46">Montgomery GH, Schnur JB, Erblich J, et al.: Presurgery psychological factors predict pain, nausea, and fatigue one week after breast cancer surgery. J Pain Symptom Manage 39 (6): 1043-52, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20538186&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20538186&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Prue G, Allen J, Gracey J, et al.: Fatigue in gynecological cancer patients during and after anticancer treatment. J Pain Symptom Manage 39 (2): 197-210, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19995675&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19995675&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Peters ME, Goedendorp MM, Verhagen SA, et al.: Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. Psychooncology 23 (7): 773-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Rhodes VA, Watson PM, Hanson BM: Patients' descriptions of the influence of tiredness and weakness on self-care abilities. Cancer Nurs 11 (3): 186-94, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3401854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3401854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.50">Fan HG, Hou&#xE9;d&#xE9;-Tchen N, Yi QL, et al.: Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23 (31): 8025-32, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258100&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258100&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Holmes S: Preliminary investigations of symptom distress in two cancer patient populations: evaluation of a measurement instrument. J Adv Nurs 16 (4): 439-46, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2061507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2061507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Oberst MT, James RH: Going home: patient and spouse adjustment following cancer surgery. Top Clin Nurs 7 (1): 46-57, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3844889&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3844889&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Ancoli-Israel S, Liu L, Marler MR, et al.: Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14 (3): 201-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Berger AM, Kuhn BR, Farr LA, et al.: One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol 27 (35): 6033-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19884558&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19884558&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.55">Katz N, Mazer NA: The impact of opioids on the endocrine system. Clin J Pain 25 (2): 170-5, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19333165&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19333165&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">Strasser F, Palmer JL, Schover LR, et al.: The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107 (12): 2949-57, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17103445&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17103445&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100 (4): 851-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14770444&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14770444&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _35
      field_pdq_section_title:
        - format: plain_text
          value: 'Assessment'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_35" class="pdq-sections"><p id="_36" tabindex="-1">Assessment of fatigue is multidimensional in nature,[<a href="#cit/section_4.1">1</a>] and a number of tools originally developed for fatigue research have also been used in clinical practice. Most of these tools include symptom dimensions other than fatigue intensity, such as the impact or consequences of fatigue, timing of fatigue, related symptoms, and self-care actions.[<a href="#cit/section_4.2">2</a>-<a href="#cit/section_4.10">10</a>] Research has also contributed a validated 10-item measure for children.[<a href="#cit/section_4.11">11</a>]
            </p><p id="_270" tabindex="-1">However, much of the time in clinical practice, because of perceived provider/patient burden, screening most often relies on a single-item fatigue intensity rating.[<a href="#cit/section_4.12">12</a>-<a href="#cit/section_4.15">15</a>] According to National Comprehensive Cancer Network (NCCN) guidelines, ratings of fatigue of 4 or higher on a scale of 0 to 10 (where 10 is very severe fatigue) are further evaluated for known contributing factors such as pain, emotional distress, anemia, sleep, nutrition, and level of activity. These comorbidities are then treated.[<a href="#cit/section_4.16">16</a>]  One study of ambulatory outpatients with solid tumors (N = 148) evaluated the usefulness of single-item screening for symptoms such as fatigue and pain.[<a href="#cit/section_4.12">12</a>] Investigators found that the single-item assessment can assist as a first screening step to identify patients requiring comprehensive assessment of symptoms. Patients identified by using single-item screening tools undergo comprehensive assessments to detect clinically relevant symptomatology.[<a href="#cit/section_4.12">12</a>,<a href="#cit/section_4.13">13</a>]</p><section id="_277"><h3 id="_277_toc">Multiple-Item Tools</h3><p id="_278" tabindex="-1">Ambiguous literature
            and a previous lack of specific tools to measure fatigue have created
            difficulties in establishing assessment and management guidelines.
            Comprehensive assessment of the fatigued patient starts with obtaining a
            careful history to characterize the individual&#x2019;s fatigue pattern and to
            identify all factors that contribute to its development.  The following may
            be included in the initial assessment:</p><div class="pdq-content-list"><ul id="_279"><li>Self-report of fatigue pattern, including onset, duration, intensity, and aggravating and alleviating factors.</li><li>Type and degree of disease- and of treatment-related symptoms and/or side
            effects.
            </li><li>Treatment history.</li><li>Current medications.</li><li>Sleep and/or rest patterns, relaxation habits, customs, and rituals.</li><li>Nutrition intake and any appetite or weight changes.</li><li>Effects of fatigue on activities of daily living and lifestyle.</li><li>Psychiatric evaluation, including evaluation for depression.
            </li><li>Complete physical examination, including gait, posture, and range of
            motion.</li><li>Compliance with treatment.</li><li>Job performance.</li><li>Financial resources.</li><li>Other contributing factors (e.g., anemia, dyspnea, muscle wasting).</li></ul></div><p id="_280" tabindex="-1">Specific attention is paid to underlying factors that contribute to
            fatigue and may be correctable, including the following:[<a href="#cit/section_4.17">17</a>,<a href="#cit/section_4.18">18</a>]</p><div class="pdq-content-list"><ul id="_296"><li>Anemia.</li><li>Depression.</li><li>Anxiety.</li><li>Pain.</li><li>Dehydration.</li><li>Nutritional deficiencies (e.g., protein, calories,
            vitamins).</li><li>Sedating medications (e.g., opioids, benzodiazepines).</li><li>Neurotoxic
            therapies.</li><li>Infection.</li><li>Fever.</li><li>Sleep disturbances.</li><li>Immobility.</li></ul></div><p id="_281" tabindex="-1">Proposed criteria for cancer-related fatigue (CRF) are listed <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_282">below</a>.  These
            criteria have been adopted for inclusion in the <em>International Statistical Classification of
            Diseases and Related Health Problems, Tenth Revision, Clinical Modification</em> (ICD-10-CM).[<a href="#cit/section_4.19">19</a>]</p><p id="_297" tabindex="-1">Defining
            CRF as a diagnostic syndrome has some potential advantages
            and disadvantages.[<a href="#cit/section_4.20">20</a>]   One of the possible advantages is that it would enable
            clinicians to document the presence or absence of fatigue in a reproducible
            fashion.  It may also be useful in establishing appropriate reimbursement for
            management of this finding.  The potential disadvantage of this approach is
            that it may deter management of fatigue that does not reach the threshold for
            ICD-10 diagnosis.  The alternative to the syndrome-based approach (commonly used for depression) is a
            symptom-based approach, which is commonly used for
            phenomena such as pain and nausea. The utility of the following ICD-10 criteria for CRF has not been validated.</p><p id="_282" tabindex="-1"><strong>ICD-10 Criteria for Cancer-related Fatigue</strong></p><p id="_283" tabindex="-1">The following symptoms have been present every day or nearly every day during
            the same 2-week period in the past month:</p><div class="pdq-content-list"><ol id="_284" class="upper-alpha"><li>Significant fatigue, diminished energy, or increased need to rest,
            disproportionate to any recent change in activity level, plus five or more of the
            following:<div class="pdq-content-list"><ol id="_285"><li>Complaints of generalized weakness, limb heaviness.</li><li>Diminished concentration or attention.</li><li>Decreased motivation or interest to engage in usual activities.</li><li>Insomnia or hypersomnia.</li><li>Experience of sleep as unrefreshing or nonrestorative.</li><li>Perceived need to struggle to overcome inactivity.</li><li>Marked emotional reactivity (e.g., sadness, frustration, or irritability)
            to feeling fatigued.</li><li>Difficulty completing daily tasks attributed to feeling fatigued.</li><li>Perceived problems with short-term memory.</li><li>Postexertional fatigue lasting several hours.</li></ol></div></li><li>The symptoms cause clinically significant distress or impairment in social,
            occupational, or other important areas of functioning.</li><li>There is evidence from the history, physical examination, or laboratory
            findings that the symptoms are a consequence of cancer or cancer therapy.</li><li>The symptoms are not primarily a consequence of comorbid psychiatric
            disorders such as major depression, somatization disorder, somatoform disorder,
            or delirium.</li></ol></div><p id="_286" tabindex="-1">As with other self-reported symptoms such as pain, it may be necessary to
            encourage the patient and other family members to report symptoms of fatigue to
            the medical staff.  Information regarding the potential for fatigue due to the
            underlying disease or treatments, possible options for management, and the
            importance of reporting these symptoms is given to patients at the
            initiation of treatment.[<a href="#cit/section_4.17">17</a>]  Patients may not mention the fatigue they
            experience unless they are prompted by a health professional.</p><p id="_298" tabindex="-1">Several barriers hamper appropriate management of CRF. Some of these barriers were identified in phase 1 of an ongoing three-phase project related to the implementation of evidence-based (NCCN) guidelines for fatigue management.[<a href="#cit/section_4.21">21</a>] The most commonly identified barriers were the following:[<a href="#cit/section_4.21">21</a>,<a href="#cit/section_4.22">22</a>]</p><div class="pdq-content-list"><ul id="_299"><li>Patient&#x2019;s belief that the physician would introduce the subject of fatigue if it was important (patient barrier).</li><li>Lack of fatigue documentation (professional barrier).</li><li>Lack of supportive care referrals (system barrier).</li></ul></div><p id="_287" tabindex="-1">Although there is no universally accepted standard for the measurement of
            fatigue, there are a variety of instruments that have been developed to assess
            fatigue and related sequelae.[<a href="#cit/section_4.2">2</a>-<a href="#cit/section_4.6">6</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>];[<a href="#cit/section_4.7">7</a>-<a href="#cit/section_4.10">10</a>]  Fatigue is also commonly assessed in multidimensional quality-of-life instruments.  Selected instruments for assessing fatigue are listed
            below.</p><div class="pdq-content-list"><ul id="_288"><li>Brief Fatigue Inventory.[<a href="#cit/section_4.4">4</a>]</li><li>The Functional Assessment of Cancer Therapy-Anemia.[<a href="#cit/section_4.7">7</a>]</li><li>The Functional Assessment of Cancer Therapy-Fatigue.[<a href="#cit/section_4.8">8</a>]</li><li>The Piper Fatigue Scale (long and short versions).[<a href="#cit/section_4.3">3</a>,<a href="#cit/section_4.23">23</a>]</li><li>The Schwartz Cancer Fatigue Scale.[<a href="#cit/section_4.9">9</a>]</li><li>Fatigue Symptom Inventory.[<a href="#cit/section_4.6">6</a>]</li><li>The Profile of Mood States Fatigue/Inertia Subscale.[<a href="#cit/section_4.10">10</a>]</li><li>Lee&#x2019;s Visual Analogue Scale for Fatigue.[<a href="#cit/section_4.2">2</a>]</li><li>Cancer Fatigue Scale.[<a href="#cit/section_4.5">5</a>]</li><li>Multidimensional Fatigue Symptom Inventory-Short Form.[<a href="#cit/section_4.24">24</a>]</li></ul></div></section><section id="_78"><h3 id="_78_toc">Evaluation of Anemia</h3><p id="_79" tabindex="-1">The proper evaluation of anemia in cancer patients includes the following:</p><div class="pdq-content-list"><ul id="_346"><li>A careful history
            and physical examination.</li><li>An evaluation of the complete blood count and red
            blood cell indices.</li><li>An examination of the peripheral blood smear.</li></ul></div><p id="_347" tabindex="-1">  In
            combination, the information from these investigations is often diagnostic.</p><p id="_80" tabindex="-1">One commonly used method for classifying anemia is to categorize the anemia by
            the size of the red blood cell as measured by the mean corpuscular volume
            (MCV).  Microcytic anemias are associated with an MCV of 79
            fL or lower and include iron-deficiency anemia, thalassemia, and anemia of
            chronic disease.  Macrocytic anemias are associated with an MCV higher than 101 fL and include anemias related to vitamin B<sub>12</sub> or folate
            deficiency, myelodysplasia, and liver disease.  Most anemias are normocytic,
            meaning that the MCV is in the normal range.  This category includes
            the following:[<a href="#cit/section_4.25">25</a>]</p><div class="pdq-content-list"><ul id="_300"><li>Myelophthisic anemia (i.e., anemia due to neoplastic replacement of the bone marrow).</li><li>Most chemotherapy-related anemias.</li><li>Anemia due to renal or hepatic dysfunction.</li><li>Hemolytic anemia.</li><li>Aplastic anemia.</li></ul></div><p id="_301" tabindex="-1">However, a mixed red blood cell population
            consisting of both microcytic and macrocytic cells (anisocytosis) may
            indicate a combined etiology, for example, chronic blood loss (microcytic) with
            resultant reticulocytosis (macrocytic).  In this situation, the MCV may be in
            the normal range, but the red blood cell size distribution width would be
            elevated.</p><p id="_81" tabindex="-1">The peripheral blood smear examination, though often overlooked, remains an
            important step in the evaluation of anemia.  For example, nucleated blood cells
            and teardrop-shaped red blood cells suggest myelophthisic anemia.
            Macro-ovalocytes and hypersegmented neutrophils often indicate megaloblastic
            anemia.  Small target cells and basophilic stippling are associated with
            thalassemia.</p><p id="_82" tabindex="-1">Additional studies that are sometimes required to characterize anemia in a
            given patient include testing of vitamin B<sub>12</sub> or folate levels; serum iron,
            transferrin, and ferritin levels; erythropoietin level, the direct and indirect
            Coombs test, and/or examination of a bone marrow aspirate and biopsy.  In
            cancer patients, the underlying etiology is often multifactorial.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Portenoy RK, Miaskowski C: Assessment and management of cancer-related fatigue. In: Berger A, Portenoy RK, Weissman DE, eds.: Principles and Practice of Supportive Oncology. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 109-18.</li><li id="section_4.2">Lee KA, Hicks G, Nino-Murcia G: Validity and reliability of a scale to assess fatigue. Psychiatry Res 36 (3): 291-8, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2062970&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2062970&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Piper BF, Dibble SL, Dodd MJ, et al.: The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25 (4): 677-84, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599351&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599351&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Mendoza TR, Wang XS, Cleeland CS, et al.: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85 (5): 1186-96, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10091805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10091805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Okuyama T, Akechi T, Kugaya A, et al.: Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 19 (1): 5-14, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10687321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10687321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Hann DM, Denniston MM, Baker F: Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. Qual Life Res 9 (7): 847-54, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11297027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11297027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (3 Suppl 2): 13-9, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253779&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Cella D: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales. Version 4. Evanston, Ill: Evanston Northwestern Healthcare, 1997.</li><li id="section_4.9">Schwartz AL: The Schwartz Cancer Fatigue Scale: testing reliability and validity. Oncol Nurs Forum 25 (4): 711-7, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599354&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599354&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">McNair D, Lorr M, Droppelman L, et al.: Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service, 1971.</li><li id="section_4.11">Hinds PS, Yang J, Gattuso JS, et al.: Psychometric and clinical assessment of the 10-item reduced version of the Fatigue Scale-Child instrument. J Pain Symptom Manage 39 (3): 572-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Butt Z, Wagner LI, Beaumont JL, et al.: Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 35 (1): 20-30, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17959345&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17959345&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Kirsh KL, Passik S, Holtsclaw E, et al.: I get tired for no reason: a single item screening for cancer-related fatigue. J Pain Symptom Manage 22 (5): 931-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11728796&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11728796&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Strasser F, M&#xFC;ller-K&#xE4;ser I, Dietrich D: Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. J Pain Symptom Manage 38 (4): 505-14, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19822275&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19822275&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Temel JS, Pirl WF, Recklitis CJ, et al.: Feasibility and validity of a one-item fatigue screen in a thoracic oncology clinic. J Thorac Oncol 1 (5): 454-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409899&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409899&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Cella D, Peterman A, Passik S, et al.: Progress toward guidelines for the management of fatigue. Oncology (Huntingt) 12 (11A): 369-77, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10028520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10028520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Groopman JE: Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 12 (3): 335-44; discussion 345-6, 351, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Portenoy RK, Itri LM: Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4 (1): 1-10, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10337366&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10337366&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Sadler IJ, Jacobsen PB, Booth-Jones M, et al.: Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 23 (5): 406-16, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12007758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12007758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Borneman T, Piper BF, Sun VC, et al.: Implementing the Fatigue Guidelines at one NCCN member institution: process and outcomes. J Natl Compr Canc Netw 5 (10): 1092-101, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18053431&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18053431&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Passik SD, Kirsh KL, Donaghy K, et al.: Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 24 (5): 481-93, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12547048&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12547048&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Reeve BB, Stover AM, Alfano CM, et al.: The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. Breast Cancer Res Treat 136 (1): 9-20, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22933027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22933027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Stein KD, Jacobsen PB, Blanchard CM, et al.: Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27 (1): 14-23, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14711465&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14711465&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Armitage JO: Management of anemia in patients with cancer. Clinical Oncology Updates  1: 1-12, 1998.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _83
      field_pdq_section_title:
        - format: plain_text
          value: 'Intervention'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_83" class="pdq-sections"><p id="_84" tabindex="-1">Much of the information regarding interventions for fatigue relates either to
            healthy subjects or to persons in whom muscle fatigue is the primary etiology of
            the problem or fatigue is secondary to treatment-related anemia.[<a href="#cit/section_5.1">1</a>,<a href="#cit/section_5.2">2</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>];[<a href="#cit/section_5.3">3</a>,<a href="#cit/section_5.4">4</a>]  Without
            a determination of the causative mechanisms of fatigue in oncology patients,
            interventions must be directed to symptom management and emotional support.
            Although some recommendations for the management of fatigue in oncology
            patients have been made, these are theoretical or anecdotal in nature and in
            general have not been the focus of scientific evaluation.
            </p><p id="_355" tabindex="-1">Published in 2013, a  study conducted in patients with advanced cancer (N = 152) demonstrated that managing symptoms (e.g., pain, nausea, and decreased appetite) can have a significant positive impact on fatigue.  In this 12-week study, patients were randomly assigned to receive either monitoring and protocolized treatment of physical symptoms coordinated by a nurse or care as usual (symptom management included in the standard oncologic care). Patients in the intervention group received tailored treatment for any of the identified troublesome symptoms. Fatigue levels, as measured by the Multidimensional Fatigue Inventory, showed significant improvement in the intervention group compared with the group receiving care as usual. The intervention group also showed improvements in the following:[<a href="#cit/section_5.5">5</a>] </p><div class="pdq-content-list"><ul id="_364"><li>Specific fatigue dimensions.</li><li>Interference by fatigue with daily life.</li><li>Overall symptom burden.</li><li>Symptoms of depression and anxiety.</li></ul></div><p id="_365" tabindex="-1">Similar studies are needed to investigate whether treatment of specific physical and psychological symptoms can alleviate fatigue and to identify patient populations that might benefit from such management. One message of this study may be that fatigue can be a primary symptom or a secondary symptom (a result of other bothersome problems).  Therefore,  assessing patients for the appropriate target symptom for intervention is probably the most efficient way to help patients improve health-related quality of life.</p><p id="_85" tabindex="-1">Because the etiology and mechanisms regarding fatigue/asthenia in cancer patients
            are indeterminate, there is considerable variation in practice patterns
            regarding the management of this symptom.  The focus of medical management is
            often directed at identifying specific and potentially reversible correlated
            symptoms, as in the following examples:</p><div class="pdq-content-list"><ul id="_302"><li> Patients with fatigue and pain may have titration of
            pain medications.</li><li>Patients with fatigue and anemia may receive a transfusion of
            packed red blood cells, nutritional interventions including iron-rich foods,
            supplemental iron or vitamins to correct an underlying deficiency, or
            injections of epoetin alfa.</li><li>Patients with depressed mood and fatigue may be
            treated with antidepressants or psychostimulants.</li></ul></div><p id="_303" tabindex="-1">It is often helpful to
            consider discontinuation of drugs that may be safely withheld.  There is no
            agreed-upon approach for the evaluation and treatment of fatigue, but an increasing number of clinical trials are designed to address this issue
            in cancer patients.</p><section id="_380"><h3 id="_380_toc">Treatment of Anemia</h3><p id="_381" tabindex="-1">Anemia in patients with cancer is best managed by treatment of the underlying cause. When the cause is obscure or there is no specific remedy, then treatment is supportive. Nutritional interventions, including the intake of nutrient-rich foods and supplements, are considered in addition to other treatment modalities. Transfusion of packed red blood cells is the most widely used and most rapid way to alleviate symptoms in cancer patients with symptomatic anemia. The likelihood of success in raising the level of hemoglobin is very high with transfusion, and the risks of complications are low. Nevertheless, repeated transfusions can be cumbersome, and the risks of blood-borne infection can be worrisome for patients. Other risks include an acute transfusion reaction, transfusion-associated graft-versus-host disease, subtle immune modulation that occurs with transfusion, and iron overload in patients who receive repeated transfusions.[<a href="#cit/section_5.6">6</a>]</p><p id="_382" tabindex="-1">Several large, community-based studies have examined the effectiveness of epoetin alfa and darbepoetin alfa [<a href="#cit/section_5.7">7</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>];[<a href="#cit/section_5.8">8</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>] in the treatment of cancer-related anemia in patients receiving chemotherapy.[<a href="#cit/section_5.2">2</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>];[<a href="#cit/section_5.9">9</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>];[<a href="#cit/section_5.10">10</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>] A few of the  studies of epoetin alfa employed an open-label, nonrandomized design
            and included objective endpoints (hemoglobin response, transfusion
            requirements) and subjective evaluation of fatigue and quality of life.  In
            this setting, epoetin alfa has been effective at increasing hemoglobin levels
            and decreasing transfusion requirements.  In addition, epoetin alfa has been
            associated with improved functional status and quality of life,
            independent of tumor response.  Several studies of epoetin alfa and darbepoetin alfa employed a randomized, controlled design. These studies varied in terms of medication dosage and frequency of administration. A review and meta-analysis of randomized and open-label studies concluded that these agents are effective in the management of CRF [<a href="#cit/section_5.11">11</a>] but also raised serious concerns about safety data and adverse outcomes associated with these agents. The authors concluded that the risks associated with  these agents outweigh their benefits for the treatment of CRF and therefore are not to be used.</p><p id="_383" tabindex="-1">The FDA has conducted a comprehensive review of safety information from studies of these agents.[<a href="#cit/section_5.12">12</a>] The review showed that in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers, erythropoiesis-stimulating agents (ESAs) shortened overall survival and/or increased the risk of tumor progression or recurrence. The review also showed that ESAs increase the risk of serious cardiovascular and thromboembolic events when they are administered to target higher hemoglobin levels (13.5&#x2013;14 g/dL).</p><p id="_384" tabindex="-1">On the basis of these findings, the FDA mandated revised ESA labeling to include an updated warning, a new boxed warning, and modifications to the indications and dosing instructions. The boxed warning includes information on the higher mortality risks caused by cardiovascular/thromboembolic events and tumor progression or recurrence. The 2010 American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) guidelines recommend the following:[<a href="#cit/section_5.13">13</a>]</p><div class="pdq-content-list"><ul id="_386"><li>In accordance with the FDA-approved label,[<a href="#cit/section_5.14">14</a>] the use of these agents should be restricted to the treatment of anemia (hemoglobin level &lt;10 g/dL) caused by concomitant palliative myelosuppressive chemotherapy and should be discontinued upon completion of a course of chemotherapy. (The above does not hold for low-risk myelodysplastic syndrome.)[<a href="#cit/section_5.13">13</a>]</li><li>In accordance with the FDA-approved label, the lowest possible dose should be used, with the goal of avoiding red blood cell transfusions, because the higher doses increase the risk of cardiovascular and thromboembolic events.</li><li>Initial dose and modification should follow FDA-approved labeling.[<a href="#cit/section_5.15">15</a>,<a href="#cit/section_5.16">16</a>]  ESAs should be discontinued if there is no response after 6 to 8 weeks (&lt;1&#x2013;2 g/dL increase in hemoglobin or no decrease in transfusion requirements).</li><li>The FDA-approved label states that ESAs are not indicated for patients receiving curative myelosuppressive chemotherapy.  However, the 2010 ASCO/ASH recommendations state that clinical judgment, goals of therapy, and patient preference should guide ESA use in the curative and palliative settings.[<a href="#cit/section_5.13">13</a>]</li></ul></div><p id="_387" tabindex="-1">A Cochrane review concluded that ESAs provide a clinically significant reduction in fatigue for anemic patients receiving chemotherapy.[<a href="#cit/section_5.11">11</a>] However, on the basis of safety concerns raised by the FDA and in view of identified side effects, this review further concluded that ESAs should not be used in clinical practice for fatigue.[<a href="#cit/section_5.11">11</a>]
            Clinicians  initiate discussions with patients and family members about the  risks and benefits of ESAs.</p><p id="_388" tabindex="-1">In February 2010, the FDA approved and mandated a risk management program to inform health care providers and their patients about the risk of ESAs.[<a href="#cit/section_5.12">12</a>,<a href="#cit/section_5.17">17</a>] This program includes a specific medication guide for patients that, along with the FDA public health advisory,[<a href="#cit/section_5.18">18</a>] states that ESAs are not approved or indicated for the treatment of fatigue in patients with cancer.</p></section><section id="_86"><h3 id="_86_toc">Psychostimulants</h3><p id="_261" tabindex="-1">One of the most popular categories of  pharmacologic interventions evaluated for cancer-related fatigue (CRF) is psychostimulants (see <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_289">Table 2</a>). Psychostimulants are drugs that interact with neurotransmitters and receptors in the brain to increase cortical function.  Different types of psychostimulants work through various mechanisms to produce activity in the brain consistent with short-term improvement in energy level and psychomotor activity.  These medications may  also improve mood, attention, and concentration in some populations. Psychostimulants  on the market include the following:</p><div class="pdq-content-list"><ul id="_313"><li>Methylphenidate.</li><li>Dextroamphetamine.</li><li>Pemoline.</li><li>Modafinil.</li><li>Armodafinil.</li><li>Nonprescription caffeine.</li></ul></div><p id="_262" tabindex="-1">Initial support for the hypothesis that psychostimulants may improve CRF arises largely from clinical anecdotal experiences. These medications are not approved by the U.S. Food and Drug Administration (FDA) for the treatment of CRF. However, preliminary evidence from  randomized controlled studies [<a href="#cit/section_5.19">19</a>-<a href="#cit/section_5.21">21</a>]
            suggests that these medications might be helpful in a subpopulation of patients experiencing more severe fatigue. There are at least seven published randomized clinical trials evaluating psychostimulants for CRF: six with methylphenidate and one with modafinil.  Only one of these randomized trials [<a href="#cit/section_5.19">19</a>] has shown significant differences between the placebo group and methylphenidate group with respect to the outcome of fatigue.</p><p id="_310" tabindex="-1">The one  study that  demonstrated significant improvements over placebo for CRF used a mean dose of 27.7 mg of the D-isomer of methylphenidate as a study intervention.[<a href="#cit/section_5.19">19</a>]  The population that benefited was women who had completed chemotherapy for breast or ovarian cancer.  The study design incorporated a titration to effect, so some patients who may have benefited may have received more than 27.7 mg of the drug.  Furthermore, 11% of participants on this trial withdrew because of adverse events, compared with 1% in the placebo arm.  Conversely, an equally large randomized controlled trial randomly assigned patients with early and advanced disease, both on and off treatment, to receive 54 mg of a long-acting methylphenidate preparation equaling 27 mg of the D-isomer or a placebo; this trial found no differences between the two groups in any of the fatigue outcomes.[<a href="#cit/section_5.22">22</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>] There were significant differences between groups for nervousness and appetite loss, with the methylphenidate arm scoring worse on both of those side effects.</p><p id="_264" tabindex="-1">The newer so-called wake-promoting agents, modafinil and armodafinil, are just beginning to be studied for CRF.  Modafinil is a centrally acting, nonamphetamine, central nervous system stimulant.[<a href="#cit/section_5.23">23</a>] Armodafinil is the R-enantiomer of modafinil and an alpha-1 adrenoceptor agonist.[<a href="#cit/section_5.24">24</a>] Modafinil and armodafinil are approved by the FDA  for narcolepsy, obstructive sleep apnea, and shift-work disorders. Neither of  these agents is approved by the FDA for the treatment of CRF. These agents are also not indicated for use in children and adolescents.  The mechanism of action  of modafinil and armodafinil is different from that of amphetamines, but the exact mechanisms by which these agents improve wakefulness are not known.   On the basis of a couple of promising open-label pilot trials,[<a href="#cit/section_5.25">25</a>,<a href="#cit/section_5.26">26</a>] a large randomized controlled trial evaluated modafinil for CRF using 200 mg versus placebo in more than 850 patients receiving chemotherapy.  Patients had to have fatigue ratings of at least 2 out of 10 to be eligible for this study.  During four cycles of chemotherapy, this study failed to show significant differences between arms.[<a href="#cit/section_5.21">21</a>] Because armodafinil is newer to the marketplace, research on its possible role in CRF has not yet been published.  More research is needed to identify whether modafinil and armodafinil can ameliorate fatigue and which populations of cancer survivors can benefit most from them.</p><p id="_265" tabindex="-1">With both methylphenidate and modafinil, there have been exploratory data suggesting that patients with more severe fatigue or more advanced disease may receive more benefit from these drugs.[<a href="#cit/section_5.21">21</a>,<a href="#cit/section_5.22">22</a>] A  small (n = 13), randomized, placebo-controlled study [<a href="#cit/section_5.20">20</a>] using  methylphenidate (titrated up to 30 mg/day) as an intervention failed to show statistical difference on the primary outcome measure, the Brief Fatigue Inventory (BFI) total score, or activity interference subscale. However, the methylphenidate group  showed significant reductions in the BFI severity subscale scores compared with the reductions seen in the placebo group.  The mean severity score at baseline was 6.5 for the methylphenidate group and 5.7 for the placebo group, placing these patients in a more severe fatigue category.  A secondary analysis of the phase III trial that evaluated modafinil versus placebo for CRF also revealed that patients with more severe fatigue may have benefited from modafinil.[<a href="#cit/section_5.21">21</a>]  More research is needed to further evaluate whether psychostimulants are beneficial for patients experiencing more severe CRF.</p><p id="_267" tabindex="-1">The side effects most commonly described with psychostimulants include the following:[<a href="#cit/section_5.19">19</a>,<a href="#cit/section_5.21">21</a>,<a href="#cit/section_5.22">22</a>,<a href="#cit/section_5.27">27</a>,<a href="#cit/section_5.28">28</a>]</p><div class="pdq-content-list"><ul id="_348"><li> Insomnia.</li><li>Euphoria.</li><li>Headache.</li><li>Nausea.</li><li>Anxiety.</li><li> Mood lability.</li></ul></div><p id="_349" tabindex="-1"> High doses and long-term use may produce:</p><div class="pdq-content-list"><ul id="_350"><li> Anorexia.</li><li>Nightmares.</li><li>Insomnia.</li><li>Euphoria.</li><li>Paranoia.</li><li>Possible cardiovascular complications.</li></ul></div><p id="_351" tabindex="-1">Patients with cancer carry a higher risk of cardiovascular complications, depending on the type of cancer and cancer treatment (e.g., cardiotoxic chemotherapy regimens). Cardiovascular complications with psychostimulants can arise even in patients without any significant risk factors.[<a href="#cit/section_5.20">20</a>] In the study using methylphenidate as an intervention for the treatment of CRF in patients with prostate cancer, 6 of 16 subjects (27%) in the methylphenidate group were discontinued because of increased blood pressure and tachycardia. It is important to note that none of these subjects were being treated with known cardiotoxic chemotherapeutic regimens such as anthracyclines.[<a href="#cit/section_5.20">20</a>] Careful and continuous monitoring of certain cardiovascular parameters (mainly blood pressure and heart rate) is critical when psychostimulants are used to treat CRF. In certain complex cases, consulting with cardiology services may be considered. Cardiovascular issues are thought to be less of a risk with modafinil and armodafinil.  Risk-benefit ratio may be considered and patients may be evaluated for response and side effects when these agents are used to treat CRF.</p><p id="_268" tabindex="-1">The package inserts for all Schedule IV stimulant medications carry boxed warnings indicating risk of abuse potential and/or risk of psychological dependence. Additionally, boxed warnings for certain stimulant medications (methylphenidate and dexmethylphenidate products) indicate risk of psychotic episodes.[<a href="#cit/section_5.27">27</a>] Other stimulant medications (amphetamine, dextroamphetamine, lisdexamfetamine dimesylate, methamphetamine, and mixed salts of amphetamine products) carry boxed warnings alerting clinicians that misuse of these medications may cause serious cardiovascular adverse events, including sudden
            death.[<a href="#cit/section_5.29">29</a>]</p><table id="_289" class="table-default expandable-container"><caption>Table 2.   Centrally Acting Stimulants for Adult Cancer Patients</caption><colgroup><col width="33.33%"><col width="33.33%"><col width="33.33%"></colgroup><THead><tr><th>Drug</th><th>Dosage</th><th>Comments/Primary Side Effects</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="3">AUC = area under the curve; MAOI = monoamine oxidase inhibitor; SSRI = selective serotonin reuptake inhibitor.</td></tr></TFoot><tbody><tr><td rowspan="2">Dextroamphetamine (Dexedrine)</td><td>2.5 mg/d (start)</td><td rowspan="2">Schedule II.  Major potential interactions with citalopram and venlafaxine.</td></tr><tr><td>5&#x2013;30 mg/d in 2 to 3 divided doses</td></tr><tr><td rowspan="2">Methylphenidate (Ritalin)</td><td>2.5 mg/d (start)</td><td rowspan="2">Schedule II. High-fat meals may increase AUC. Peak concentration 102 hours after ingestion. Do not use with MAOIs as it can precipitate hypertensive crisis. Antidepressants that increase norepinephrine can cause increased amphetamine side effects. Concomitant use with SSRI can result in increased SSRI concentrations.</td></tr><tr><td>Titrate up to 54 mg/d (27 mg D-isomer)</td></tr><tr><td rowspan="2">Modafinil (Provigil)</td><td>50&#x2013;100 mg (start)</td><td rowspan="2">Schedule IV. Avoid driving/operation of machinery until effects are known. Do not take at bedtime. Peak concentration in 2&#x2013;4 hours. Food slows absorption by about 1 hour but does not affect bioavailability. Decreases efficacy of birth control pills.</td></tr><tr><td>100&#x2013;200 mg every morning</td></tr><tr><td rowspan="2">Armodafinil (Nuvigil)</td><td>50 mg (start)</td><td rowspan="2">Schedule IV. Avoid driving/operation of machinery until effects are known. Do not take at bedtime. Peak concentration in 2 hours if fasting, slowed to as many as 4 hours if fed, but food does not affect bioavailability. Decreases efficacy of birth control pills.</td></tr><tr><td>25&#x2013;250 mg every morning</td></tr></tbody></table><p id="_90" tabindex="-1">On the basis of limited clinical experience and acknowledging a lack of evidence in randomized controlled trials, it might be reasonable to consider a psychostimulant such as methylphenidate or modafinil for the treatment of severe fatigue, particularly for short periods of time (a couple of weeks) in patients with advanced disease. When the use of these medications is being considered, it is important to obtain informed consent, with careful discussion of risks, benefits, and alternatives. Continuous monitoring of cardiovascular parameters is crucial when these medications are used, especially in patients with preexisting cardiovascular issues and in patients being treated with known cardiotoxic chemotherapeutic regimens (e.g., anthracyclines). In certain cases, consulting with cardiology services might be necessary.  Longer-term psychostimulant therapy is not advisable at this time because there is limited information about its potential negative effects and longer-term benefits.</p></section><section id="_356"><h3 id="_356_toc">Other Pharmacologic Interventions</h3><section id="_366"><h4 id="_366_toc">Bupropion</h4><p id="_367" tabindex="-1">Bupropion is a stimulating antidepressant with a primarily dopaminergic and noradrenergic mechanism of action. Preliminary evidence from a small open-label study (N = 21) suggests that the sustained-release (SR) form of bupropion has potential as an effective therapeutic agent for treating CRF with or without comorbid depressive symptoms.[<a href="#cit/section_5.30">30</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>]  Seizure, a rare but serious side effect of this agent, did not occur in this study (the maximum dose of bupropion SR used in this study was 300 mg).</p></section><section id="_368"><h4 id="_368_toc">Dexamethasone</h4><p id="_369" tabindex="-1">Dexamethasone is a potent anti-inflammatory agent that has recently been evaluated for the treatment of fatigue in patients with advanced cancer.  Eighty-four patients were randomly assigned to receive either dexamethasone 4 mg twice per day or a placebo for 14 days.  The primary endpoint was improvement in fatigue from baseline to day 15, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale.  Investigators also evaluated depression, anxiety, and symptom distress.  In the group who received dexamethasone, mean scores on the FACIT-F scale were significantly improved by day 8 (<em>P</em> = .005) and at day 15 (<em>P</em> = .008).  Physical well-being and physical distress were also significantly better in the group who received dexamethasone.  Emotional scores and overall symptom distress were not significantly different.  Adverse events, as measured by the Common Terminology Criteria for Adverse Events, version 3.0, did not differ between groups.</p><p id="_370" tabindex="-1">One limitation of this study was that it was only 2 weeks long, and longer-term use of dexamethasone is well known to be associated with unwanted side effects.  Therefore, the risk versus benefit of treating  fatigue with dexamethasone for more than 2 weeks requires investigation.   Because fatigue has been associated with high levels of inflammation, this study is noteworthy in its evaluation of dexamethasone as an anti-inflammatory  agent to alleviate fatigue.[<a href="#cit/section_5.31">31</a>] The investigators did not assess inflammatory biomarkers; therefore, the proof of concept that modifying inflammation can reduce fatigue needs replication.</p></section><section id="_371"><h4 id="_371_toc">Dietary supplements</h4><p id="_372" tabindex="-1">Dietary supplements comprise other, often popular, pharmacologic interventions for CRF.</p><section id="_373"><h5 id="_373_toc">L-carnitine</h5><p id="_374" tabindex="-1">L-carnitine is a widely used dietary supplement believed to be helpful for the treatment of CRF because of its role in cellular energy metabolism and carnitine&#x2019;s ability to decrease pro-inflammatory cytokines.  Promising pilot data led to the development and completion of a large (N = 376) phase III study in a multisite cooperative group setting.  Participants with moderate to severe fatigue were randomly assigned to receive either 10 g levocarnitine or a placebo for 4 weeks.  The primary endpoint was change in average fatigue.  Despite increases in mean levels of  L-carnitine, there was not a statistically significant difference in fatigue between arms, with both arms reporting improved fatigue during the study.[<a href="#cit/section_5.32">32</a>]</p></section><section id="_375"><h5 id="_375_toc">Ginseng</h5><p id="_376" tabindex="-1">Ginseng, another popular supplement used to treat fatigue, has also been the subject of evaluation in large, multisite clinical trials. On the basis of  a promising phase II dose-finding study,[<a href="#cit/section_5.33">33</a>] a phase III, randomized, placebo-controlled trial was completed involving 364 patients with cancer who either were undergoing anticancer treatment or had completed treatment.  Participants were randomly assigned to receive either 2,000 mg of American ginseng (specifically, Wisconsin ginseng) in the form of ground root in a capsule or a matching placebo.  The primary endpoint was change in fatigue scores as measured by the Multidimensional Fatigue Symptom Inventory-Short Form.  At 4 weeks, the group receiving ginseng showed a trend toward significant improvement, while at 8 weeks, there was a significant and clinically meaningful difference favoring the ginseng group.  There were no discernible side effects during the course of the trial, either within or between groups.[<a href="#cit/section_5.34">34</a>]</p></section></section></section><section id="_94"><h3 id="_94_toc">Exercise</h3><p id="_95" tabindex="-1"> Preliminary studies [<a href="#cit/section_5.35">35</a>-<a href="#cit/section_5.37">37</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>];[<a href="#cit/section_5.38">38</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>];[<a href="#cit/section_5.39">39</a>,<a href="#cit/section_5.40">40</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>];[<a href="#cit/section_5.41">41</a>,<a href="#cit/section_5.42">42</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>] suggest that exercise (including light- to
            moderate-intensity walking programs) has potential benefits for people with
            cancer. The benefits shown in these studies and observed in clinical settings
            include improved physical energy, appetite stimulation, and/or enhanced
            functional capacity, with improvements in quality of life and in
            many aspects of psychologic state (e.g., improved outlook and sense of well-being, enhanced sense of commitment, and the ability to meet the challenges of
            cancer and cancer treatment).</p><p id="_304" tabindex="-1">Several reviews and National Comprehensive Cancer Network guidelines outline numerous studies that support the beneficial effects of exercise on fatigue.[<a href="#cit/section_5.43">43</a>,<a href="#cit/section_5.44">44</a>]   Reductions in fatigue of about 35% and improvements in vitality of 30% have been shown in randomized trials, with stronger effects being shown during cancer therapy in some studies and after therapy in other studies.[<a href="#cit/section_5.43">43</a>,<a href="#cit/section_5.45">45</a>] Many initial trials of exercise programs focused on women with breast cancer, but later studies included men with prostate cancer, multiple myeloma, and colorectal cancer.[<a href="#cit/section_5.46">46</a>] Some studies have had methodologic weaknesses, including the following:[<a href="#cit/section_5.47">47</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>][<a href="#cit/section_5.48">48</a>]</p><div class="pdq-content-list"><ul id="_232"><li>Selection biases and nonrepresentative
            samples.</li><li>Recruitment of  patients into randomized trials.</li><li>Poor adherence to exercise interventions.</li><li>Highly varied assessments of research variables and outcome measures.</li><li>Lack of adequate control groups.</li></ul></div><p id="_233" tabindex="-1">
            Two randomized controlled trials demonstrated the benefit of exercise in reducing fatigue during breast cancer treatment.  A trial of a 12-week aerobic exercise program compared with usual care showed a nonsignificant improvement in fatigue 3 and 6 months later.[<a href="#cit/section_5.49">49</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]  Another trial comparing low-intensity and moderate- to high-intensity physical exercise with usual care showed that higher-intensity exercise (30 minutes per day, 5 days per week) was beneficial in reducing fatigue.[<a href="#cit/section_5.50">50</a>]  Limitations of both studies included the lack of a placebo control group and low participation rates.  Low participation is a common finding in exercise studies of cancer patients, suggesting the need for tailored approaches to overcome barriers. The benefits shown in these studies are buttressed by a Cochrane review of 56 studies (including 4,068 participants), which concluded that aerobic exercise significantly reduced fatigue during or after cancer treatment.[<a href="#cit/section_5.51">51</a>]</p><p id="_234" tabindex="-1"> In a study of 545 breast cancer survivors who were, on average, 6 months postdiagnosis, increased physical activity was consistently related to both improved physical functioning and reduced fatigue and bodily pain.  Prediagnosis physical activity was associated with better physical functioning at 39 months but generally unrelated to symptoms.  Increased physical activity after cancer was related to less fatigue and pain and better physical functioning.  Significant positive associations were found with moderate to vigorous recreational physical activity but not household activity.  This study suggests that breast cancer survivors may be able to decrease fatigue and bodily pain and be better able to pursue daily activities by increasing their recreational physical activities after cancer.[<a href="#cit/section_5.52">52</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>]</p><p id="_96" tabindex="-1">Exercise for patients with advanced or terminal disease is difficult to study
            but may yield similar benefits.  The ability of patients with advanced cancer
            who are in hospice care and on a physical therapy regimen to carry out
            activities of daily living has been reported to improve in one study.[<a href="#cit/section_5.53">53</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>]
            Improved satisfaction with the physical therapy regimen was reported when
            family involvement in the program increased. A randomized study suggested that exercise improved fatigue during breast cancer treatment.[<a href="#cit/section_5.54">54</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>] An observational study of patients with advanced cancer found that fatigue was less severe in patients who engaged in physical exercise.[<a href="#cit/section_5.55">55</a>]</p><p id="_272" tabindex="-1">When educating  patients about activity with respect to CRF, one important goal to consider is inclusion of 3 to 5 hours per week of moderate activity. It is critical that:</p><div class="pdq-content-list"><ul id="_306"><li>Patients choose a type of exercise they enjoy.</li><li>Providers discuss specific implementation strategies (type of exercise, time of day, days of the week, location of activity) to enable patients to make frequent activity a reality.</li></ul></div><p id="_307" tabindex="-1">Beginning with lighter activity for shorter periods of time and building in intensity and length of time may be required.  Studies have confirmed this can be safely done both during active treatment and after treatment is completed.[<a href="#cit/section_5.45">45</a>]</p><p id="_269" tabindex="-1">Variations of exercise that have a mind-body component include complementary modalities such as qigong, tai chi, and yoga, popular interventions that are being studied for their effects on CRF.  These modalities are unique in that they incorporate cognitive and spiritual elements with movement, stretching, and balance.  One fairly large study evaluated medical qigong for CRF in a heterogeneous group of 162 patients either undergoing cancer treatment or having finished cancer treatment.[<a href="#cit/section_5.56">56</a>]  This study reported significant improvements in fatigue and several other aspects of quality of life for the intervention group versus usual care.</p><p id="_305" tabindex="-1">The qigong intervention was delivered in 90-minute group sessions twice a week for 10 weeks, for 1,800 minutes of treatment.  The usual-care group did not receive any group meetings or additional provider interaction.  It is therefore difficult to say what qigong uniquely provided over and above nonspecific or group-interaction effects.  It is also not known how much survivors would need to continue performing qigong to maintain benefits.  There were no adverse events in this study, so other than time and resource expenditure, it is difficult to pinpoint a downside to encouraging patients to adopt such an activity.  One important strength of the study evaluating qigong was the collection of serum to measure markers of inflammation.  At the end of 10 weeks, the C-reactive protein of patients in the medical qigong group decreased 3.6 mg/L, while patients in the usual-care group experienced an increase in this marker of 19.57 mg/L.  This was a statistically significant difference.[<a href="#cit/section_5.56">56</a>]</p><p id="_362" tabindex="-1">A second, smaller study (N = 96) that compared a qigong group to a wait-list control group evaluated fatigue using the BFI as a secondary outcome and also assessed a biologic measure, salivary cortisol.  This study did not find any significant difference in fatigue or cortisol between groups.  The intervention dose in this study, comprising five 40-minute sessions over 6 weeks of radiation therapy in women diagnosed with breast cancer, was much lower than the intervention dose in the larger study described above.[<a href="#cit/section_5.57">57</a>]</p><p id="_363" tabindex="-1"> The major weakness limiting interpretation and integration of both of these studies, despite differing results,  is that there was no attempt to control for attention or any of the social aspects of the intervention.</p></section><section id="_172"><h3 id="_172_toc">Cognitive Behavior Therapy</h3><p id="_173" tabindex="-1">Cognitive behavior therapy (CBT) has long been used to treat a variety of psychophysiological problems, with therapy focusing on the thoughts (cognitions) and functional behaviors relevant to the presenting problems.  In a randomized clinical trial, 98 mixed-type cancer survivors  (intervention group = 50, wait-list control = 48) experiencing severe fatigue not attributable to a specific somatic cause were provided individual CBT.[<a href="#cit/section_5.58">58</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>] The CBT focused on each participant's unique pattern of the following six possible factors that might serve to perpetuate their post&#x2013;cancer treatment fatigue:</p><div class="pdq-content-list"><ul id="_311"><li>Insufficient coping with the experience of cancer.</li><li>Fear of disease recurrence.</li><li>Dysfunctional cognitions regarding fatigue.</li><li>Dysregulation of sleep.</li><li>Dysregulation of activity.</li><li>Low social support/negative social interactions.</li></ul></div><p id="_312" tabindex="-1">The number of therapy sessions varied according to the number of perpetuating factors (range: 5&#x2013;26 1-hour sessions; mean:  12.5 sessions); results showed a clinically significant decrease in fatigue severity and functional impairment.</p></section><section id="_97"><h3 id="_97_toc">Activity and Rest</h3><p id="_98" tabindex="-1">Health professionals can work with patients with cancer to develop an
            activity/rest program based on an assessment of the patient&#x2019;s fatigue patterns
            that allows the best use of the individual&#x2019;s energy.  Any changes in daily
            routine require additional energy expenditure.  Individuals with cancer are advised about setting priorities and maintaining a reasonable schedule.
            Health professionals may assist patients by providing information on support
            services that are available to help with daily activities and responsibilities.
            An occupational therapy consultation can be of assistance in evaluating energy
            conservation methods.  Sleep hygiene, including avoidance of lying in bed at
            times other than sleep, shortening naps to no more than 1 hour, avoiding
            distracting noise (e.g., television, radio) during sleep hours, and other measures may
            improve sleep and activity cycles.
            </p></section><section id="_99"><h3 id="_99_toc">Patient Education</h3><p id="_101" tabindex="-1">Informing patients about the risk of fatigue and providing education about strategies to reduce fatigue are valuable adjuncts to other management strategies discussed in this summary. However, a Cochrane review of educational interventions for cancer-related fatigue in adults cautions that educational interventions should be part of a more-comprehensive approach to managing fatigue.[<a href="#cit/section_5.59">59</a>]</p><p id="_102" tabindex="-1">Specific techniques for the management of fatigue include the following:
            </p><div class="pdq-content-list"><ul id="_103"><li>Differentiation of fatigue from depression.</li><li>Assessment for presence of correctable correlates or causes of fatigue
            (e.g., dehydration, electrolyte imbalance, dyspnea, anemia).</li><li>Evaluation of patterns of rest and activity during the day as well as over
            time.</li><li>Determination of the level of attentional fatigue and encouragement of the
            planned use of attention-restoring activities (e.g., walking, gardening,
            bird watching).</li><li>Providing anticipatory guidance regarding the likelihood of experiencing
            fatigue, and the fatigue patterns associated with particular treatments.</li><li>Encouragement of activity/planned exercise programs within individual
            limitations; making goals realistic by keeping in mind the state of disease
            and treatment regimens.</li><li>Education of individuals and families about fatigue related to cancer and
            its treatment.</li><li>Helping people with cancer and their families identify fatigue-promoting
            activities and develop specific strategies to modify these activities.</li><li>Suggesting individualized environmental or activity changes that may offset
            fatigue.</li><li>Maintaining adequate hydration and nutrition.</li><li>Recommending physical therapy referral for people with specific
            neuromusculoskeletal deficits.</li><li>Recommending respiratory therapy referral for people with dyspnea that is
            a contributing factor to fatigue.</li><li>Scheduling important daily activities during times of least fatigue and
            eliminating nonessential, stress-producing activities.
            </li><li>Addressing the negative impact of psychologic and social stressors and
            how to avoid or modify them.
            </li><li>Evaluating the efficacy of fatigue interventions on a regular and
            systematic basis.[<a href="#cit/section_5.60">60</a>]
            </li></ul></div></section><p id="_122" tabindex="-1">In a controlled trial of patients who reported the symptom cluster of pain and fatigue while receiving chemotherapy, a nursing behavioral intervention  produced improvements in quality of life and decreased symptom burden relative to usual care.[<a href="#cit/section_5.61">61</a>,<a href="#cit/section_5.62">62</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>] These intriguing results need to be further explored in patient populations other than women with breast or gynecologic malignancies.</p><p id="_273" tabindex="-1">As researchers and practitioners learned with pain, misconceptions and a lack of knowledge may prove to be patient- and provider-related barriers to successful assessment and management.   A quasi-experimental study tested a multisystem educational approach to improving both pain and fatigue management.[<a href="#cit/section_5.63">63</a>]  The approach consisted of the following:</p><div class="pdq-content-list"><ul id="_274"><li>Education and assessment of patients regarding the management of pain and fatigue, with phone calls every 2 weeks for 3 months.</li><li>Education of providers about pain and fatigue assessment and management, including monthly newsletters.</li><li>An effort to engage with an internal advisory board.</li><li>Efforts aimed toward research nurses to refer earlier to supportive care services.</li></ul></div><p id="_275" tabindex="-1">Over a 3-month period, the educational intervention resulted in increases in knowledge and a decrease in barriers related to management of pain and fatigue.  Of note, important patient barriers related to fatigue management included the following beliefs:[<a href="#cit/section_5.63">63</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>]</p><div class="pdq-content-list"><ul id="_276"><li>Fatigue is inevitable.</li><li>Fatigue can indicate worsening of disease.</li><li>Treating the cancer is more important than treating fatigue.</li><li>Reporting fatigue will cause a patient to be perceived as a complainer.</li></ul></div><section id="_TrialSearch_83_sid_5"><h3 id="_TrialSearch_83_sid_5_toc">Current Clinical Trials</h3><p id="_TrialSearch_83_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_5.1">Arendt J, Borbely AA, Franey C, et al.: The effects of chronic, small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study. Neurosci Lett 45 (3): 317-21, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6728321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6728321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Gibson H, Edwards RH: Muscular exercise and fatigue. Sports Med 2 (2): 120-32, 1985 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847097&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847097&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Hart LK: Fatigue in the patient with multiple sclerosis. Res Nurs Health  1 (4): 147-57, 1978.</li><li id="section_5.5">de Raaf PJ, de Klerk C, Timman R, et al.: Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial. J Clin Oncol 31 (6): 716-23, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23284036&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23284036&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Armitage JO: Management of anemia in patients with cancer. Clinical Oncology Updates  1: 1-12, 1998.</li><li id="section_5.7">Kotasek D, Steger G, Faught W, et al.: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39 (14): 2026-34, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12957457&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12957457&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Hedenus M, Adriansson M, San Miguel J, et al.: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122 (3): 394-403, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12877666&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12877666&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Demetri GD, Kris M, Wade J, et al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16 (10): 3412-25, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Osterborg A, Brandberg Y, Molostova V, et al.: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20 (10): 2486-94, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12011126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12011126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Minton O, Richardson A, Sharpe M, et al.: Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 7: CD006704, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20614448&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20614448&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">U.S. Food and Drug Administration: FDA Drug Safety Communication: Erythropoiesis-stimulating Agents (ESAs): Procrit, Epogen and Aranesp. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm" title="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.13">Rizzo JD, Brouwers M, Hurley P, et al.: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28 (33): 4996-5010, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20975064&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20975064&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Medication Guide: Aranesp (darbepoetin alfa). Thousand Oaks, Calif: Amgen Inc., 2012. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/ucm085918.pdf" title="https://www.fda.gov/downloads/Drugs/DrugSafety/ucm085918.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.15">Procrit Label and Epogen Label. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf" title="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.16">Aranesp (darbepoetin alfa) Label. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf" title="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.17">U.S. Food and Drug Administration: FDA announces new safety plan for agents used to treat chemotherapy-related anemia. Silver Spring, Md: U.S. Food and Drug Administration, 2010.</li><li id="section_5.18">U.S. Food and Drug Administration: Information on Erythropoiesis-stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). Silver Spring, Md: Food and Drug Administration, 2010. <a href="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm" title="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.19">Lower EE, Fleishman S, Cooper A, et al.: Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38 (5): 650-62, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19896571&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19896571&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Roth AJ, Nelson C, Rosenfeld B, et al.: Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 116 (21): 5102-10, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20665492&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20665492&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Jean-Pierre P, Morrow GR, Roscoe JA, et al.: A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116 (14): 3513-20, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20564068&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20564068&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.22">Moraska AR, Sood A, Dakhil SR, et al.: Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 28 (23): 3673-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20625123&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20625123&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.23">Medication Guide: PROVIGIL (modafinil) Tablets. North Wales, Pa: Teva Pharmaceuticals USA, Inc., 2015. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf" title="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.24">Medication Guide: NUVIGIL (armodafinil) Tablets. North Wales, Pa: Teva Pharmaceuticals USA, Inc., 2015. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231717.pdf" title="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231717.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.25">Blackhall L, Petroni G, Shu J, et al.: A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 12 (5): 433-9, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19416039&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19416039&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.26">Spathis A, Dhillan R, Booden D, et al.: Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 23 (4): 325-31, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19270033&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19270033&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.27">CONCERTA (methylphenidate HCl) Extended-release Tablets. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2013. <a href="https://www.janssenmd.com/pdf/concerta/concerta_pi.pdf" title="https://www.janssenmd.com/pdf/concerta/concerta_pi.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.28">Prommer E: Modafinil: is it ready for prime time? J Opioid Manag 2 (3): 130-6, 2006 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17319446&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17319446&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.29">ADDERALL XR (mixed salts of a single-entity amphetamine), CII. Lexington, Mass: Shire US Inc., 2015. <a href="http://www.shirecontent.com/PI/PDFS/AdderallXR_USA_ENG.PDF" title="http://www.shirecontent.com/PI/PDFS/AdderallXR_USA_ENG.PDF">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.30">Moss EL, Simpson JS, Pelletier G, et al.: An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 15 (3): 259-67, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16041840&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16041840&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.31">Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al.: Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31 (25): 3076-82, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23897970&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23897970&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.32">Cruciani RA, Zhang JJ, Manola J, et al.: L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol 30 (31): 3864-9, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22987089&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22987089&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.33">Barton DL, Soori GS, Bauer BA, et al.: Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18 (2): 179-87, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19415341&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19415341&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.34">Barton DL, Liu H, Dakhil SR, et al.: Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105 (16): 1230-8, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23853057&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23853057&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.35">Segal R, Evans W, Johnson D, et al.: Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 19 (3): 657-65, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157015&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157015&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.36">Milne HM, Wallman KE, Gordon S, et al.: Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 108 (2): 279-88, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17530428&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17530428&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.37">Courneya KS, Friedenreich CM, Sela RA, et al.: The group psychotherapy and home-based physical exercise (group-hope) trial in cancer survivors: physical fitness and quality of life outcomes. Psychooncology 12 (4): 357-74, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12748973&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12748973&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.38">Schneider CM, Hsieh CC, Sprod LK, et al.: Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. Cancer 110 (4): 918-25, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17582616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17582616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.39">Friendenreich CM, Courneya KS: Exercise as rehabilitation for cancer patients. Clin J Sport Med 6 (4): 237-44, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8894336&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8894336&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.40">Mustian KM, Griggs JJ, Morrow GR, et al.: Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Support Care Cancer 14 (7): 732-41, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16482444&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16482444&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.41">Winningham ML: Walking program for people with cancer. Getting started. Cancer Nurs 14 (5): 270-6, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1933847&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1933847&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.42">Galv&#xE3;o DA, Newton RU: Review of exercise intervention studies in cancer patients. J Clin Oncol 23 (4): 899-909, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15681536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15681536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.43">Cramp F, Daniel J: Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev  (2): CD006145, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425939&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425939&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.44">Kangas M, Bovbjerg DH, Montgomery GH: Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 134 (5): 700-41, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18729569&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18729569&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.45">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.46">Jacobsen PB, Donovan KA, Vadaparampil ST, et al.: Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 26 (6): 660-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18020836&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18020836&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.47">Pickett M, Mock V, Ropka ME, et al.: Adherence to moderate-intensity exercise during breast cancer therapy. Cancer Pract 10 (6): 284-92, 2002 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12406050&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12406050&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.48">Carayol M, Delpierre C, Bernard P, et al.: Population-, intervention- and methodology-related characteristics of clinical trials impact exercise efficacy during adjuvant therapy for breast cancer: a meta-regression analysis. Psychooncology 24 (7): 737-47, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25483860&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25483860&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.49">Mutrie N, Campbell AM, Whyte F, et al.: Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ 334 (7592): 517, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17307761&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17307761&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.50">van Waart H, Stuiver MM, van Harten WH, et al.: Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. J Clin Oncol 33 (17): 1918-27, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25918291&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25918291&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.51">Cramp F, Byron-Daniel J: Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11: CD006145, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23152233&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23152233&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.52">Alfano CM, Smith AW, Irwin ML, et al.: Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. J Cancer Surviv 1 (2): 116-28, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18648952&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18648952&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.53">Yoshioka H: Rehabilitation for the terminal cancer patient. Am J Phys Med Rehabil 73 (3): 199-206, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7515247&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7515247&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.54">Mock V, Frangakis C, Davidson NE, et al.: Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology 14 (6): 464-77, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15484202&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15484202&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.55">Peters ME, Goedendorp MM, Verhagen SA, et al.: Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. Psychooncology 23 (7): 773-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.56">Oh B, Butow P, Mullan B, et al.: Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Ann Oncol 21 (3): 608-14, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19880433&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19880433&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.57">Chen Z, Meng Z, Milbury K, et al.: Qigong improves quality of life in women undergoing radiotherapy for breast cancer: results of a randomized controlled trial. Cancer 119 (9): 1690-8, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23355182&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23355182&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.58">Gielissen MF, Verhagen S, Witjes F, et al.: Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 24 (30): 4882-7, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17050873&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17050873&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.59">Bennett S, Pigott A, Beller EM, et al.: Educational interventions for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11: CD008144, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27883365&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27883365&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.60">Winningham ML, Nail LM, Burke MB, et al.: Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 21 (1): 23-36, 1994 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.61">Given B, Given CW, McCorkle R, et al.: Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29 (6): 949-56, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.62">Ream E, Richardson A, Alexander-Dann C: Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage 31 (2): 148-61, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488348&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488348&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.63">Borneman T, Koczywas M, Sun VC, et al.: Reducing patient barriers to pain and fatigue management. J Pain Symptom Manage 39 (3): 486-501, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303026&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303026&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _104
      field_pdq_section_title:
        - format: plain_text
          value: 'Posttreatment Considerations'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_104" class="pdq-sections"><p id="_105" tabindex="-1">This posttreatment section has been especially prepared for those individuals
            with cancer who  have been off all antineoplastic therapy for at least
            6 months.  The rationale for creating a separate section is twofold.  First,
            the etiology of problems is different for individuals undergoing treatment
            versus those who are no longer undergoing therapy.  Second, intervention
            strategies and information can be better tailored so that there will be a
            greater likelihood of meeting the needs of these two distinct populations.</p><p id="_106" tabindex="-1">Fatigue is a separate and distinct problem for individuals after treatment is
            completed.  Many theories have been proposed to explain the etiology of fatigue
            in the patient undergoing treatment and to explain the impact of that treatment
            on quality of life.  Many of these theories, however, do not apply to the posttreatment population.  Nonetheless, fatigue continues to be a major issue for
            individuals who are no longer undergoing therapy and who are considered to be
            disease free.</p><p id="_107" tabindex="-1">There is evidence that fatigue significantly affects the quality of life of
            cancer survivors.  The experience of fatigue in cancer survivors is quite
            similar to the experience of patients with chronic fatigue syndrome in the
            general medical setting.[<a href="#cit/section_6.1">1</a>]  Few studies have been done that indicate the
            impact of fatigue on quality of life, but some examples follow:</p><div class="pdq-content-list"><ul id="_108"><li>In cancer survivors who had bone marrow transplants, 50% of 29 survivors
            reported moderate-to-severe fatigue more than 1 year after transplant.
            Fatigue was one of the three most negative items studied and had an impact
            on quality of life more than any other physical problem.[<a href="#cit/section_6.2">2</a>]</li><li>In patients who had bone marrow transplants, 56% of 125 patients reported
            ongoing fatigue 6 to 18 years after transplant.[<a href="#cit/section_6.3">3</a>]
            </li><li>Of 687 posttreatment survivors of various forms of cancer evaluated for
            quality-of-life issues, fatigue was one of the three most negative items
            affecting quality of life.[<a href="#cit/section_6.4">4</a>]</li><li>Of 90 patients with a diagnosis of Hodgkin lymphoma or non-Hodgkin
            lymphoma, 30 reported a lack of energy at a median of 32 months after
            diagnosis.[<a href="#cit/section_6.5">5</a>]</li><li>Of 403 individuals with Hodgkin lymphoma, 37% reported their energy levels
            had not returned to levels that satisfied them even after a median of 9
            years posttreatment.[<a href="#cit/section_6.6">6</a>]</li><li>In Hodgkin lymphoma survivors, 26% had persistent fatigue 6 months after
            treatment with 50% associated with psychological distress.  Increasing age and
            no prior psychological symptoms predicted fatigue &#x201C;caseness.&#x201D;[<a href="#cit/section_6.7">7</a>]</li><li>Of 162 women treated with radiation for breast cancer and 173 women treated
            with chemotherapy for breast cancer, 75% and 61%, respectively,
            described decreased stamina 2 to 10 years after the completion of
            treatment.[<a href="#cit/section_6.8">8</a>]  In a separate cross-sectional survey of women who completed therapy for breast cancer by a mean of 29 months prior to the survey, 38% had severe fatigue compared with only 11% of matched controls.[<a href="#cit/section_6.9">9</a>]</li><li>Fatigue has been reported in women survivors of autologous bone marrow
            transplantation and high-dose chemotherapy treatment for lymphomas 4
            to 10 years posttreatment.[<a href="#cit/section_6.10">10</a>]</li><li>Almost one-third of breast cancer survivors at 10 years posttreatment reported significant fatigue.[<a href="#cit/section_6.11">11</a>]</li></ul></div><p id="_109" tabindex="-1">Although many studies document the incidence of fatigue in those who are no
            longer undergoing cancer treatment, the specific mechanism of fatigue remains
            unknown.  Because fatigue is a multifaceted problem, determining its etiology
            is difficult.</p><p id="_110" tabindex="-1">The information available regarding fatigue in survivors of childhood cancer is
            from the literature describing the physiologic and cognitive effects following
            treatment.  In one study, cognitive outcomes were evaluated in children 3 to 4
            years after diagnosis of brain tumors.  Fatigue was a factor in poor school
            performance.[<a href="#cit/section_6.12">12</a>]</p><p id="_111" tabindex="-1">In another study, survivors of acute lymphoblastic leukemia who were evaluated
            for cognitive deficits after treatment were noted to have a typical fatigue
            effect.  This was thought to be a factor in the variability of their test
            scores.[<a href="#cit/section_6.13">13</a>]  Anecdotally, individuals who have received chest and total-body
            irradiation complain of fatigue, with an increased sleep requirement.</p><p id="_112" tabindex="-1">People who are successfully treated for cancer are at risk for a variety of
            organ-specific complications that are secondary to their treatment.[<a href="#cit/section_6.14">14</a>]  Fatigue in
            the posttreatment population underscores the importance of follow-up care.
            The persistence of fatigue following cancer treatment requires a thorough
            evaluation to rule out contributing physiologic conditions.</p><h6 do-not-show="toc">References</h6><ol><li id="section_6.1">Servaes P, van der Werf S, Prins J, et al.: Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 9 (1): 11-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147137&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147137&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Whedon M, Stearns D, Mills LE: Quality of life of long-term adult survivors of autologous bone marrow transplantation. Oncol Nurs Forum 22 (10): 1527-35; discussion 1535-7, 1995 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8577621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8577621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Bush NE, Haberman M, Donaldson G, et al.: Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med 40 (4): 479-90, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7725122&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7725122&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Ferrell BR, Grant M, Dean GE, et al.: Bone tired: the experience of fatigue and its impact on quality of life. Oncol Nurs Forum  23 (10): 1539-47, 1996.</li><li id="section_6.5">Devlen J, Maguire P, Phillips P, et al.: Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 295 (6604): 955-7, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3119124&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3119124&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Fobair P, Hoppe RT, Bloom J, et al.: Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4 (5): 805-14, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Loge JH, Abrahamsen AF, Ekeberg, et al.: Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J Pain Symptom Manage 19 (2): 91-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10699536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10699536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Berglund G, Bolund C, Fornander T, et al.: Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 27 (9): 1075-81, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1683557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1683557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Servaes P, Verhagen S, Bleijenberg G: Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 13 (4): 589-98, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12056710&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12056710&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">Knobel H, Loge JH, Nord&#xF8;y T, et al.: High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage 19 (6): 446-56, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10908825&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10908825&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Radcliffe J, Packer RJ, Atkins TE, et al.: Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 32 (4): 551-4, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1456739&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1456739&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Brouwers P: Neuropsychological abilities of long-term survivors of childhood leukemia. In: Aaronsen NK, Beckmann J, eds.: The Quality of Life of Cancer Patients. New York: Raven Press, 1987, pp 153-65.</li><li id="section_6.14">Baker F, Denniston M, Smith T, et al.: Adult cancer survivors: how are they faring? Cancer 104 (11 Suppl): 2565-76, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _125
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (06/29/2017)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_125" class="pdq-sections"><p id="_135" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</p><p id="_399" tabindex="-1"><strong><a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_12">Contributing Factors</a></strong></p><p id="_400" tabindex="-1">Added <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_259">text</a> to state that factors similar to those seen in patients with early-stage cancer are also contributors to fatigue in patients with advanced, incurable cancer (cited Peters et al. as reference 48).</p><p id="_394" tabindex="-1"><strong><a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_83">Intervention</a></strong></p><p id="_398" tabindex="-1">Added <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_304">Carayol et al.</a> as reference 48.</p><p id="_395" tabindex="-1">Revised <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_233">text</a> about the benefits of exercise in reducing fatigue during cancer treatment (cited Mutrie et al. as reference 49, van Waart  et al. as reference 50, and Cramp et al. as reference 51).</p><p id="_396" tabindex="-1">Added <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_96">text</a> to state that an observational study of patients with advanced cancer  found that fatigue was less severe in patients who engaged in physical exercise (cited Peters et al. as reference 55).</p><p id="_397" tabindex="-1">Revised <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_101">text</a> about the role of patient education in the management of fatigue (cited Bennett et al. as reference 59).</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" title="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care">PDQ Supportive and Palliative Care Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the pathophysiology and treatment of fatigue. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" title="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care">PDQ Supportive and Palliative Care Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="" tabindex="-1">The lead reviewers for Fatigue are:</p><div class="pdq-content-list"><ul id=""><li>Andrea Barsevick, PhD (Thomas Jefferson University)</li><li>Joseph Bubalo, PharmD, BCPS, BCOP (Oregon Health and Science University Hospital)</li><li>Esme Finlay, MD (University of New Mexico)</li><li>Heather C. Justice, MSPAP, PA-C (Milligan College)</li><li>Jayesh Kamath, MD, PhD (University of Connecticut Health Center)</li><li>Diane Von Ah, PhD, RN, FAAN (Indiana University School of Nursing)</li></ul></div><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a <a href="/publications/pdq/levels-evidence/supportive-care">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Supportive and Palliative Care Editorial Board. PDQ Fatigue. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq" title="https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389484]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Fatiga (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq
  field_pdq_cdr_id__ES:
    value: 256627
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Supportive care
  field_date_posted__ES:
    value: '2019-03-11'
  field_date_updated__ES:
    value: '2017-07-20'
  field_browser_title__ES:
    value: 'Fatiga'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos acerca de la fatiga, una afección caracterizada por extremo cansancio e incapacidad para funcionar por la falta de energía, que a menudo se observa como una complicación del cáncer y su tratamiento. '
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Descripción'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_2" tabindex="-1">La fatiga o cansancio cr&#xF3;nico es el efecto secundario m&#xE1;s com&#xFA;n del tratamiento contra el c&#xE1;ncer con quimioterapia, radioterapia o modificadores de ciertas respuestas biol&#xF3;gicas.[<a href="#cit/section_1.1">1</a>]  Por lo general, el cansancio cr&#xF3;nico relacionado con el tratamiento del c&#xE1;ncer  disminuye despu&#xE9;s de la terminaci&#xF3;n del tratamiento, pero hay un cierto grado de cansancio que puede continuar durante meses o a&#xF1;os despu&#xE9;s de concluir el tratamiento. La investigaci&#xF3;n indica que para al menos un subconjunto de pacientes, la fatiga puede ser un asunto de larga importancia durante la supervivencia.[<a href="#cit/section_1.2">2</a>,<a href="#cit/section_1.3">3</a>]  La fatiga tambi&#xE9;n se observa como un s&#xED;ntoma que se presenta en c&#xE1;nceres que causan problemas como la anemia, los  cambios endocrinos y la obstrucci&#xF3;n respiratoria, y es com&#xFA;n en las personas con c&#xE1;ncer avanzado que no se someten a tratamiento activo.  Se inform&#xF3; que el cansancio cr&#xF3;nico relacionado con el tratamiento de c&#xE1;ncer  se presenta de  14 a 96&#xA0;% de los pacientes que se encuentran en tratamiento,[<a href="#cit/section_1.4">4</a>-<a href="#cit/section_1.10">10</a>] y entre 19 y 82&#xA0;% de los pacientes despu&#xE9;s del tratamiento.[<a href="#cit/section_1.1">1</a>,<a href="#cit/section_1.2">2</a>]</p><p id="_249" tabindex="-1">Varios estudios documentaron la presencia de cansancio cr&#xF3;nico significativamente peor entre los sobrevivientes de c&#xE1;ncer en comparaci&#xF3;n con la poblaci&#xF3;n no cancerosa, seg&#xFA;n lo describi&#xF3; un art&#xED;culo anal&#xED;tico.[<a href="#cit/section_1.1">1</a>] Por ejemplo, en un estudio transversal noruego [<a href="#cit/section_1.11">11</a>]   se compar&#xF3;  la prevalencia  de la fatiga en pacientes sobrevivientes de c&#xE1;ncer de test&#xED;culo a largo plazo (n = 1431)    con un promedio de 11 a&#xF1;os despu&#xE9;s del tratamiento con la incidencia de cansancio cr&#xF3;nico en hombres de la misma edad en la poblaci&#xF3;n general noruega (n = 1080). La prevalencia del cansancio cr&#xF3;nico relacionado con el c&#xE1;ncer (CRF) fue  de 17,1&#xA0;% (intervalo de confianza  [IC] 95&#xA0;%, 15,2&#x2013;19,1&#xA0;%) en los sobrevivientes de c&#xE1;ncer de test&#xED;culo, comparada con 9,7&#xA0;% (IC 95&#xA0;%, 8,0&#x2013;11,5&#xA0;%) en la poblaci&#xF3;n general. El CRF tambi&#xE9;n se relacion&#xF3; con  varios problemas psicosociales, quejas de tipo  som&#xE1;tico y una calidad de vida precaria.[<a href="#cit/section_1.11">11</a>]</p><p id="_216" tabindex="-1">El cansancio cr&#xF3;nico, como el dolor, es algo que se ve como un estado de autopercepci&#xF3;n. Los pacientes pueden describir la fatiga como sentirse: [<a href="#cit/section_1.12">12</a>] </p><div class="pdq-content-list"><ul id="_346"><li>Cansado.</li><li>D&#xE9;bil.</li><li>
            Exhausto.</li><li> Perezoso.</li><li>Abatido.</li><li>Agotado.</li><li>Pesado.</li><li>Lento.</li><li>Falto de energ&#xED;a para seguir adelante.</li></ul></div><p id="_349" tabindex="-1">Los profesionales de la salud han incluido el cansancio cr&#xF3;nico en conceptos tales como:</p><div class="pdq-content-list"><ul id="_347"><li>Astenia.</li><li>
            Lasitud.</li><li>Malestar.</li><li>Postraci&#xF3;n.</li><li>Intolerancia al ejercicio.</li><li> Falta de energ&#xED;a.</li><li>Debilidad.</li></ul></div><p id="_348" tabindex="-1">La investigaci&#xF3;n sobre el cansancio cr&#xF3;nico en las personas con c&#xE1;ncer, incluye principalmente autonotificaciones sobre el cansancio cr&#xF3;nico, con menos datos pero un aumento de estos que exploran las interdependencias biol&#xF3;gicas o fisiol&#xF3;gicas. Estas correlaciones han incluido medidas de la debilidad muscular, absorci&#xF3;n m&#xE1;xima de ox&#xED;geno, citocinas y cortisol. </p><p id="_217" tabindex="-1">La fatiga que se siente como un efecto secundario del tratamiento para el c&#xE1;ncer, es diferente de la que siente una persona saludable en su vida diaria. <em>El cansancio saludable</em> se describe con frecuencia como una fatiga aguda que finalmente se alivia mediante el sue&#xF1;o y el descanso; el cansancio relacionado con el tratamiento contra  el c&#xE1;ncer se caracteriza como cansancio cr&#xF3;nico ya que est&#xE1; presente por per&#xED;odos largos, interfiere con el funcionamiento  y no se alivia por completo al dormir o descansar.[<a href="#cit/section_1.13">13</a>] Tambi&#xE9;n, el grado de CRF es por lo general desproporcionado respecto al grado de actividad o energ&#xED;a desplegado.[<a href="#cit/section_1.13">13</a>] Aunque el t&#xE9;rmino <em>cansancio cr&#xF3;nico</em> es correcto, usarlo no significa que las personas con c&#xE1;ncer que sienten cansancio presenten un s&#xED;ndrome de cansancio cr&#xF3;nico. Usar la frase   <em>cansancio cr&#xF3;nico</em> puede resultar confuso tanto para el paciente como para el profesional de la salud. T&#xE9;rminos tales como <em>cansancio por c&#xE1;ncer</em>, <em>cansancio relacionado con el c&#xE1;ncer</em>, <em>cansancio relacionado con el tratamiento del c&#xE1;ncer</em>   se usan en la literatura m&#xE9;dica, la literatura de investigaci&#xF3;n y los materiales educativos, tanto   para los pacientes como el p&#xFA;blico en general.</p><p id="_218" tabindex="-1">La fatiga o cansancio cr&#xF3;nico incide de manera negativa en todos los aspectos del funcionamiento, como en lo siguiente:[<a href="#cit/section_1.14">14</a>-<a href="#cit/section_1.17">17</a>]</p><div class="pdq-content-list"><ul id="_350"><li>Humor.</li><li>Desempe&#xF1;o f&#xED;sico.</li><li>Desempe&#xF1;o laboral.</li><li>Interacci&#xF3;n social.</li><li>Cuidado familiar.[<a href="#cit/section_1.18">18</a>]</li><li> Desempe&#xF1;o cognitivo.</li><li>Trabajo escolar.</li><li>Actividades comunitarias.</li><li>Sentido del yo.</li></ul></div><p id="_351" tabindex="-1">El patr&#xF3;n del cansancio cr&#xF3;nico relacionado con el tratamiento del c&#xE1;ncer var&#xED;a de acuerdo al tipo y frecuencia del tratamiento. Por ejemplo, las personas bajo un r&#xE9;gimen quimioterap&#xE9;utico c&#xED;clico, por lo general exhiben un aumento m&#xE1;ximo del cansancio cr&#xF3;nico en los d&#xED;as posteriores  al tratamiento, luego dan cuenta de un menor cansancio hasta que se suscita el pr&#xF3;ximo tratamiento; sin embargo, aquellos que se someten a radioterapia de haz externo, presentan cansancio cr&#xF3;nico gradual que aumenta durante el curso de tratamiento sobre el campo de tratamiento mayor. Pocos estudios sobre las personas que se someten a tratamiento para el c&#xE1;ncer han abordado el tema del cansancio cr&#xF3;nico como consecuencia de la aflicci&#xF3;n emocional que produce someterse a una evaluaci&#xF3;n diagn&#xF3;stica del c&#xE1;ncer y los efectos de  los procedimientos m&#xE9;dicos y quir&#xFA;rgicos que se utilizan para esa evaluaci&#xF3;n y para el tratamiento inicial. Debido a que la mayor&#xED;a de los adultos que entran al sistema de cuidados oncol&#xF3;gicos luego de al menos un procedimiento quir&#xFA;rgico, y debido a que la cirug&#xED;a y la aflicci&#xF3;n emocional est&#xE1;n ambas relacionadas con el cansancio cr&#xF3;nico, es probable que la mayor&#xED;a de las personas  que inician  un tratamiento no quir&#xFA;rgico presenten  cansancio cr&#xF3;nico al inicio de este.[<a href="#cit/section_1.19">19</a>,<a href="#cit/section_1.20">20</a>]</p><p id="_232" tabindex="-1"> Las recomendaciones para el manejo del cansancio se enfocan en identificar factores que podr&#xED;an estar contribuyendo con el cansancio cr&#xF3;nico.  Debido a que el &#xFA;nico mecanismo causal definitivo que se demostr&#xF3; mediante investigaci&#xF3;n hasta la fecha es la anemia inducida por la quimioterapia, la mayor&#xED;a  de las recomendaciones para el tratamiento del cansancio cr&#xF3;nico ocasionado por otros factores independientes de este tipo de  anemia dependen de un desarrollo cuidadoso de una hip&#xF3;tesis cl&#xED;nica, tal y como est&#xE1; delineada  en las National Comprehensive Cancer Network Guidelines on Fatigue.[<a href="#cit/section_1.21">21</a>] Hasta el momento, la &#xFA;nica intervenci&#xF3;n en grado 1 para el CRF es el ejercicio. (Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_89">Ejercicio</a>). Se necesita mucho m&#xE1;s investigaci&#xF3;n para definir mejor el cansancio y su trayectoria, entender su fisiolog&#xED;a y determinar las mejores formas de prevenirlo y tratarlo.</p><p id="_1_4" tabindex="-1">En este sumario, a menos que se indique lo contrario, se tratan temas relacionados con datos probatorios y pr&#xE1;cticas referidas a los adultos. Los datos probatorios y la aplicaci&#xF3;n a la pr&#xE1;ctica referida a los ni&#xF1;os pueden diferir significativamente de la informaci&#xF3;n pertinente a los adultos. Cuando la informaci&#xF3;n espec&#xED;fica sobre la atenci&#xF3;n de los ni&#xF1;os est&#xE9; disponible, se resumir&#xE1; bajo su propio encabezado.</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_1.1">Prue G, Rankin J, Allen J, et al.: Cancer-related fatigue: A critical appraisal. Eur J Cancer 42 (7): 846-63, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16460928&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16460928&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Baker F, Denniston M, Smith T, et al.: Adult cancer survivors: how are they faring? Cancer 104 (11 Suppl): 2565-76, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Foss&#xE5; SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21 (7): 1249-54, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.5">Miaskowski C, Portenoy RK: Update on the assessment and management of cancer-related fatigue. Principles and Practice of Supportive Oncology Updates  1 (2): 1-10, 1998.</li><li id="section_1.6">Irvine DM, Vincent L, Bubela N, et al.: A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nurs 14 (4): 188-99, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.7">Vogelzang NJ, Breitbart W, Cella D, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (3 Suppl 2): 4-12, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.8">Detmar SB, Aaronson NK, Wever LD, et al.: How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J Clin Oncol 18 (18): 3295-301, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10986063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10986063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.9">Costantini M, Mencaglia E, Giulio PD, et al.: Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). Qual Life Res 9 (2): 151-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10983479&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10983479&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.10">Cella D, Lai JS, Chang CH, et al.: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94 (2): 528-38, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11900238&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11900238&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.11">Orre IJ, Foss&#xE5; SD, Murison R, et al.: Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 64 (4): 363-71, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18374735&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18374735&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.12">Barsevick AM, Whitmer K, Walker L: In their own words: using the common sense model to analyze patient descriptions of cancer-related fatigue. Oncol Nurs Forum 28 (9): 1363-9, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11683307&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11683307&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.13">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.14">Pickard-Holley S: Fatigue in cancer patients. A descriptive study. Cancer Nurs 14 (1): 13-9, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2013047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2013047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.15">Glaus A: Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Support Care Cancer 1 (6): 305-15, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8156248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8156248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.16">Given B, Given CW, McCorkle R, et al.: Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29 (6): 949-56, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.17">Curt GA: The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 5 (Suppl 2): 9-12, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10896323&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10896323&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.18">Passik SD, Kirsh KL: A pilot examination of the impact of cancer patients' fatigue on their spousal caregivers. Palliat Support Care 3 (4): 273-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17039982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17039982&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.19">Ancoli-Israel S, Liu L, Marler MR, et al.: Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14 (3): 201-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.20">Jacobsen PB, Hann DM, Azzarello LM, et al.: Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 18 (4): 233-42, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10534963&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10534963&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.21">National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 2.2017. Fort Washington, Pa: National Comprehensive Cancer Network, 2017. <a href="https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf" title="https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf">Available online with free registration</a>. Last accessed January 4, 2018.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _7
      field_pdq_section_title:
        - format: plain_text
          value: 'Patogenia de la fatiga o cansancio crónico'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_7" class="pdq-sections"><p id="_8" tabindex="-1">Salvo en la anemia inducida por la quimioterapia, se desconoce el mecanismo responsable del cansancio cr&#xF3;nico en las personas con c&#xE1;ncer. Entender las causas del cansancio en la los pacientes de c&#xE1;ncer es un reto especial debido a que cada individuo experimenta m&#xFA;ltiples causas posibles del cansancio cr&#xF3;nico de manera simult&#xE1;nea. Esta hip&#xF3;tesis etiol&#xF3;gica multifactorial se hace presente en los modelos varios que se propusieron en el estudio del cansancio cr&#xF3;nico. Se desconoce el mecanismo preciso que causa o que fomenta el cansancio cr&#xF3;nico en los pacientes de
            c&#xE1;ncer, es probable que muchos mecanismos diferentes desempe&#xF1;en
            esta funci&#xF3;n.[<a href="#cit/section_2.1">1</a>,<a href="#cit/section_2.2">2</a>] Por lo general,  se incorpora en estos modelos  el balance energ&#xE9;tico, la tensi&#xF3;n, las demandas del diario vivir, el sue&#xF1;o, los cambios neurofisiol&#xF3;gicos, interrupci&#xF3;n del ritmo circadiano, afecciones card&#xED;acas y cambios neuroinmunitarios, sobre la base de que estos factores se relacionan con el cansancio en otros contextos diferentes al c&#xE1;ncer.[<a href="#cit/section_2.3">3</a>] La literatura sobre el c&#xE1;ncer respalda algunas de estas variables.</p><p id="_270" tabindex="-1">Hay una cantidad creciente de pruebas, en particular de mujeres con c&#xE1;ncer de mama y hombres con c&#xE1;ncer de pr&#xF3;stata, en que el cansancio  se relaciona con marcadores que indican un aumento en la actividad inflamatoria inmunitaria. Cuando las personas con cansancio cr&#xF3;nico y antecedentes de c&#xE1;ncer de mama se les compara con sobrevivientes de c&#xE1;ncer sin este tipo de cansancio, surgen patrones diferentes con respecto a la interleucina 6, interleucina 1, receptores antagonistas, prote&#xED;na reactiva C, neopterin y el receptor-II del factor de necrosis tumoral soluble.[<a href="#cit/section_2.4">4</a>-<a href="#cit/section_2.6">6</a>]  Aunque se desconoce la relaci&#xF3;n precisa (y el significado cl&#xED;nico de estas relaciones), es probable que el aumento de citocinas contribuya con los s&#xED;ntomas de cansancio, astenia y letargo, seg&#xFA;n lo confirman estudios llevados a cabo en modelos animales, inducidos mediante citocinas a una conducta de enfermedad,[<a href="#cit/section_2.7">7</a>,<a href="#cit/section_2.8">8</a>] al igual que en humanos.[<a href="#cit/section_2.9">9</a>] A&#xFA;n no se han realizado estudios grandes bien controlados que eval&#xFA;en los efectos de f&#xE1;rmacos antiinflamatorios generales sobre el cansancio o los biomarcadores de citocina.</p><p id="_271" tabindex="-1">Otros estudios muestran un cambio en la regulaci&#xF3;n del cortisol por el eje hipot&#xE1;lamo-hip&#xF3;fisis suprarrenal. Un estudio clave someti&#xF3; a sobrevivientes de c&#xE1;ncer de mama con cansancio  o sin este, a una serie de pruebas de tensi&#xF3;n en el entorno controlado de un laboratorio. Los sobrevivientes sin cansancio cr&#xF3;nico presentaron un aumento significativo del cortisol en respuesta a la tensi&#xF3;n aguda, mientras que los sobrevivientes con cansancio cr&#xF3;nico presentaron una respuesta menos activa.[<a href="#cit/section_2.10">10</a>] Otro estudio mostr&#xF3; que las sobrevivientes de c&#xE1;ncer de mama redujeron los picos de cortisol, al presentar &#xED;ndices m&#xE1;s altos de este hacia el final del d&#xED;a, que los sobrevivientes que no presentaban cansancio cr&#xF3;nico.[<a href="#cit/section_2.11">11</a>] Es la desregulaci&#xF3;n del eje hipot&#xE1;lamo-hipofisiario suprarrenal  (HHS) la que podr&#xED;a ser responsable de la inflamaci&#xF3;n prolongada en el entorno citoc&#xED;nico. Entender la respuesta corporal a numerosos tensionantes cr&#xF3;nicos durante el c&#xE1;ncer podr&#xED;a ayudar al manejo del cansancio cr&#xF3;nico.</p><p id="_272" tabindex="-1">Por &#xFA;ltimo, otra teor&#xED;a es que las citocinas inciden de forma negativa en la serotonina a trav&#xE9;s de la exposici&#xF3;n cr&#xF3;nica a citocinas proinflamatorias. Una hip&#xF3;tesis es que la relaci&#xF3;n entre las concentraciones de serotonina en el sistema nervioso central y el cansancio mantiene una relaci&#xF3;n en forma de herradura, lo que indica que las concentraciones de serotonina ya sean muy altas o muy bajas, podr&#xED;an tener relaci&#xF3;n con el cansancio cr&#xF3;nico relacionado con el c&#xE1;ncer.[<a href="#cit/section_2.12">12</a>] Sin embargo, hay estudios que evaluaron f&#xE1;rmacos seroton&#xE9;rgicos que no logran mostrar beneficio alguno contra el cansancio cr&#xF3;nico.[<a href="#cit/section_2.2">2</a>] Queda por entenderse del todo la funci&#xF3;n y la relaci&#xF3;n que desempe&#xF1;an mucho de los neurotransmisores importantes tales como la dopamina, norepinefrina y serotonina con el funcionamiento del eje HHS y la expresi&#xF3;n de la citocina.</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">Miaskowski C, Portenoy RK: Update on the assessment and management of cancer-related fatigue. Principles and Practice of Supportive Oncology Updates  1 (2): 1-10, 1998.</li><li id="section_2.2">Morrow GR, Andrews PL, Hickok JT, et al.: Fatigue associated with cancer and its treatment. Support Care Cancer 10 (5): 389-98, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12136222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12136222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Aistars J: Fatigue in the cancer patient: a conceptual approach to a clinical problem. Oncol Nurs Forum 14 (6): 25-30, 1987 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3320982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3320982&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Bower JE, Ganz PA, Aziz N, et al.: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64 (4): 604-11, 2002 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12140350&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12140350&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Evans WJ, Lambert CP: Physiological basis of fatigue. Am J Phys Med Rehabil 86 (1 Suppl): S29-46, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17370370&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17370370&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Bower JE, Ganz PA, Tao ML, et al.: Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 15 (17): 5534-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19706826&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19706826&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933: 222-34, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12000023&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12000023&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12 (2): 123-37, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3050629&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3050629&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Eisenberger NI, Inagaki TK, Mashal NM, et al.: Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun 24 (4): 558-63, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20043983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20043983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Bower JE, Ganz PA, Aziz N: Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 67 (2): 277-80, 2005 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15784794&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15784794&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Bower JE, Ganz PA, Dickerson SS, et al.: Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30 (1): 92-100, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15358446&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15358446&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Jager A, Sleijfer S, van der Rijt CC: The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 44 (2): 175-81, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18162394&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18162394&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _12
      field_pdq_section_title:
        - format: plain_text
          value: 'Factores contribuyentes'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_12" class="pdq-sections"><p id="_13" tabindex="-1">Aunque est&#xE1; claro que el cansancio es frecuente entre los pacientes de c&#xE1;ncer,
            resulta dif&#xED;cil identificar variables correlacionadas uniformes en esta
            poblaci&#xF3;n de pacientes.  Los factores que influyen con mayor frecuencia son los
            siguientes:[<a href="#cit/section_3.1">1</a>-<a href="#cit/section_3.9">9</a>]
            </p><div class="pdq-content-list"><ul id="_162"><li>Tratamiento contra el c&#xE1;ncer.</li><li>Anemia.</li><li> F&#xE1;rmacos.</li><li>Caquexia y anorexia.</li><li>Trastornos metab&#xF3;licos.</li><li>Deficiencia o exceso hormonal.</li><li>Aflicci&#xF3;n psicol&#xF3;gica.</li><li>Desacondicionamiento f&#xED;sico.</li><li>Trastornos del sue&#xF1;o.</li><li>Inactividad excesiva.</li><li>Deterioro pulmonar.</li><li>Disfunci&#xF3;n
            neuromuscular.</li><li>Dolor y otros s&#xED;ntomas.</li><li>Citocinas proinflamatorias.</li><li>Deficiencias nutricionales.</li><li>Deshidrataci&#xF3;n.</li><li> Infecci&#xF3;n. </li><li>Enfermedad m&#xE9;dica simult&#xE1;nea.</li><li>Insuficiencia card&#xED;aca.</li></ul></div><section id="_14"><h3 id="_14_toc">Tratamientos del c&#xE1;ncer</h3><p id="_221" tabindex="-1">La relaci&#xF3;n entre la fatiga o  cansancio cr&#xF3;nico con las principales modalidades de tratamiento oncol&#xF3;gico, cirug&#xED;a, quimioterapia, radioterapia y terapia con un modificador de la respuesta biol&#xF3;gica origin&#xF3; especulaciones sobre el cansancio cr&#xF3;nico como resultado del deterioro tisular o la acumulaci&#xF3;n de los residuos de la muerte celular.  El inter&#xE9;s sobre los efectos del tratamiento contra el c&#xE1;ncer en la producci&#xF3;n de citocinas proinflamatorias se basa en el reconocimiento de los fuertes efectos que inducen al  cansancio cr&#xF3;nico de algunos modificadores de la respuesta biol&#xF3;gica, tales como el interfer&#xF3;n &#x3B1;  y el hallazgo de &#xED;ndices elevados de citocinas proinflamatorias en las personas que presentan cansancio persistente luego de un tratamiento contra el c&#xE1;ncer.[<a href="#cit/section_3.10">10</a>,<a href="#cit/section_3.11">11</a>]</p><p id="_273" tabindex="-1">Muchas personas con c&#xE1;ncer se someten a cirug&#xED;a ya sea con fines de diagn&#xF3;stico o de tratamiento. A pesar de la incidencia alta del cansancio cr&#xF3;nico posoperatorio persistente que se observa en la pr&#xE1;ctica cl&#xED;nica, existen pocas investigaciones que examinen las causas e interrelaciones del cansancio posoperatorio en las personas con c&#xE1;ncer.[<a href="#cit/section_3.12">12</a>] Resulta claro, sin embargo, que el cansancio es un problema posquir&#xFA;rgico que mejora con el tiempo y se acent&#xFA;a con el cansancio cr&#xF3;nico que se siente a causa de otros tratamientos contra el c&#xE1;ncer.[<a href="#cit/section_3.12">12</a>]</p><p id="_17" tabindex="-1">Desde hace tiempo el cansancio se  relaciona con la exposici&#xF3;n a la radiaci&#xF3;n y se tienen informes que es el efecto secundario m&#xE1;s com&#xFA;n que limita la capacidad de acci&#xF3;n del paciente sometido a radioterapia contra el c&#xE1;ncer.[<a href="#cit/section_3.4">4</a>,<a href="#cit/section_3.13">13</a>] La mayor&#xED;a de las investigaciones que describen la trayectoria del cansancio cr&#xF3;nico  durante la radioterapia, se llevan a cabo con mujeres con c&#xE1;ncer de mama y hombres con c&#xE1;ncer de pr&#xF3;stata.[<a href="#cit/section_3.13">13</a>,<a href="#cit/section_3.14">14</a>] El cansancio cr&#xF3;nico aumenta mediante la radioterapia, llegando a su momento pico hacia la mitad del ciclo;  este se mantiene en ese grado hasta completarse, mejorar un poco dos meses despu&#xE9;s del tratamiento.[<a href="#cit/section_3.13">13</a>-<a href="#cit/section_3.15">15</a>] Un estudio en el que se investig&#xF3; la trayectoria del cansancio en hombres (n = 82) sometidos a radioterapia contra el c&#xE1;ncer de pr&#xF3;stata encontr&#xF3; una variabilidad interindividual significativa.[<a href="#cit/section_3.14">14</a>]  Los autores utilizaron un modelo lineal jer&#xE1;rquico, un m&#xE9;todo anal&#xED;tico muy sofisticado, para identificar los factores pron&#xF3;sticos de las trayectorias del cansancio cr&#xF3;nico prolongado. Los hombres m&#xE1;s j&#xF3;venes,  con un mayor &#xED;ndice de cansancio al momento de iniciarse la radioterapia, presentaron un aumento en el riesgo de cansancio cr&#xF3;nico en las ma&#xF1;anas y en las noches durante el curso de la radioterapia.  Adem&#xE1;s, el grado de depresi&#xF3;n en el momento de iniciarse la radioterapia predijo el grado de cansancio cr&#xF3;nico matutino durante el ciclo de radioterapia.[<a href="#cit/section_3.14">14</a>]
            </p><p id="_274" tabindex="-1">En un segundo estudio en el que participaron 73 mujeres que se sometieron a radioterapia contra el  c&#xE1;ncer de mama, encontr&#xF3; diferencias similares en los patrones y predictores del cansancio matutino en relaci&#xF3;n con el vespertino.[<a href="#cit/section_3.16">16</a>] Los participantes ingresaron al estudio en el momento de un simulacro de visita donde llenaron cuestionarios iniciales. Los datos se recopilaron durante dos d&#xED;as consecutivos, en la ma&#xF1;ana y a la hora de acostarse, cada semana durante la radioterapia, cada dos semanas durante dos meses luego de la radioterapia, y una vez al mes durante dos meses adicionales en adelante. El cansancio cr&#xF3;nico se midi&#xF3; con la Lee Fatigue Scale. Para la totalidad del grupo, durante las 25 semanas de recopilaci&#xF3;n de datos, el cansancio matutino disminuy&#xF3; ligeramente durante la radioterapia y se mantuvo constante cuatro meses despu&#xE9;s, mientras que el cansancio durante las noches aument&#xF3; a trav&#xE9;s de la radioterapia y luego decay&#xF3; ligeramente durante el tratamiento. El cansancio durante las noches fue superior en aquellos que:</p><div class="pdq-content-list"><ul id="_275"><li>Estaban trabajando.</li><li>Ten&#xED;an ni&#xF1;os en la casa.</li><li>Presentaban &#xED;ndices mayores de depresi&#xF3;n.</li></ul></div><p id="_276" tabindex="-1">El cansancio matutino fue mayor en aquellos que:</p><div class="pdq-content-list"><ul id="_277"><li>Presentaron mayor ansiedad.</li><li>Presentaron trastornos del sue&#xF1;o.</li><li>Eran m&#xE1;s j&#xF3;venes.</li><li>Presentaron &#xED;ndices m&#xE1;s bajos de masa corporal.</li></ul></div><p id="_278" tabindex="-1">Presentar enfermedad avanzada y comorbilidades contribuy&#xF3; tambi&#xE9;n a la gravedad del cansancio matutino.[<a href="#cit/section_3.16">16</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: III</a>]</p><p id="_236" tabindex="-1">Una serie de estudios de investigaci&#xF3;n documentan la
            presencia de un s&#xED;ndrome de cansancio que no es espec&#xED;fico al tipo de enfermedad
            ni al sitio de radiaci&#xF3;n y que  demuestra una reducci&#xF3;n paulatina  del cansancio cr&#xF3;nico
            del paciente una vez que  termina el tratamiento.[<a href="#cit/section_3.15">15</a>,<a href="#cit/section_3.17">17</a>-<a href="#cit/section_3.20">20</a>]  No obstante,
            algunos de estos estudios indican que no todos los pacientes recuperan el
            grado de energ&#xED;a que ten&#xED;an antes del tratamiento.  No se identificaron
            factores etiol&#xF3;gicos espec&#xED;ficos ni correlaciones del cansancio vinculado con la
            radioterapia.[<a href="#cit/section_3.12">12</a>] Entre los factores de riesgo relacionados con la
            persistencia de baja energ&#xED;a en los pacientes de c&#xE1;ncer; se
            encuentran la edad avanzada, la enfermedad avanzada y el tratamiento de modalidad
            combinada.[<a href="#cit/section_3.21">21</a>]</p><p id="_18" tabindex="-1">La fatiga o cansancio cr&#xF3;nico es  un efecto t&#xF3;xico del tratamiento con una variedad de f&#xE1;rmacos
            bioterap&#xE9;uticos que limitan su dosis.  La bioterapia expone a los pacientes de c&#xE1;ncer a citocinas ex&#xF3;genas y
            end&#xF3;genas.[<a href="#cit/section_3.22">22</a>]  El cansancio cr&#xF3;nico relacionado con la terapia biol&#xF3;gica se presenta por
            lo general como parte de una constelaci&#xF3;n de s&#xED;ntomas llamados s&#xED;ndrome
            parecido a la influenza.  Este s&#xED;ndrome incluye:[<a href="#cit/section_3.23">23</a>]</p><div class="pdq-content-list"><ul id="_352"><li>Cansancio cr&#xF3;nico.</li><li>Fiebre.</li><li> Escalofr&#xED;os.</li><li> Mialgias.</li><li>Dolor de cabeza.</li><li> Malestar.</li></ul></div><p id="_353" tabindex="-1">El cansancio mental y el d&#xE9;ficit cognitivo  se identificaron como efectos secundarios de la bioterapia.[<a href="#cit/section_3.24">24</a>] El tipo de f&#xE1;rmaco bioterap&#xE9;utico que se usa puede influir en el tipo y modelo de cansancio cr&#xF3;nico que se sienta.</p><p id="_279" tabindex="-1">El tratamiento quimioterap&#xE9;utico pronostica el cansancio cr&#xF3;nico y este se exacerba ante la presencia de dolor, depresi&#xF3;n o ansiedad.[<a href="#cit/section_3.25">25</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: II</a>][<a href="#cit/section_3.26">26</a>] Un estudio longitudinal descriptivo se&#xF1;al&#xF3; los &#xED;ndices m&#xE1;s altos de cansancio cr&#xF3;nico a la mitad de los ciclos quimioterap&#xE9;uticos del paciente, el cansancio mejor&#xF3; luego del tratamiento pero sin volver a los niveles iniciales 30 d&#xED;as despu&#xE9;s del &#xFA;ltimo tratamiento.[<a href="#cit/section_3.25">25</a>] En otro estudio longitudinal de mujeres con c&#xE1;ncer de mama en estadio 0 a II que recibieron quimioterapia con radioterapia o sin esta (N = 103) versus radioterapia sola (N = 102) versus un grupo de control (N = 193),[<a href="#cit/section_3.27">27</a>] los aumentos del cansancio cr&#xF3;nico se observaron 3 a&#xF1;os despu&#xE9;s del tratamiento en el grupo que recibi&#xF3; quimioterapia con radioterapia o sin esta, en comparaci&#xF3;n con los otros dos grupos. La  mediana de puntuaci&#xF3;n en cuanto a  la gravedad del cansancio cr&#xF3;nico, seg&#xFA;n la medici&#xF3;n del Fatigue Symptom Inventory (intervalo, entre 0&#x2013;10) aument&#xF3; en el curso de 3 a&#xF1;os de la siguiente manera:</p><div class="pdq-content-list"><ul id="_342"><li>De 2,31 a 2,86 en el grupo que recibi&#xF3; quimioterapia con radioterapia o sin esta.</li><li>Solo de 1,96 a 2,06 en el grupo con radioterapia sola.</li><li>Solo de  2,20 a 2,22 en el grupo de control sin c&#xE1;ncer.</li></ul></div><p id="_343" tabindex="-1">Se observaron efectos estad&#xED;sticamente significativos en el grupo-por-efectos de tiempo para el grupo que recibi&#xF3; quimioterapia con radioterapia o sin esta. Este aumento del cansancio cr&#xF3;nico no se debi&#xF3; a la terapia hormonal y alcanz&#xF3; valores cl&#xED;nicamente significativos.[<a href="#cit/section_3.27">27</a>]  En el presente no se conoce cuales caracter&#xED;sticas espec&#xED;ficas del paciente est&#xE1;n relacionadas con el riesgo de aumento del cansancio cr&#xF3;nico  a largo plazo o cansancio cr&#xF3;nico m&#xE1;s grave y quien va a presentar una resoluci&#xF3;n del cansancio cr&#xF3;nico.</p></section><section id="_20"><h3 id="_20_toc">Anemia</h3><p id="_21" tabindex="-1">Los datos indican que la anemia puede ser un factor importante en la fatiga o cansancio cr&#xF3;nico relacionado con el c&#xE1;ncer (CRF) y en la calidad de vida de estos pacientes.[<a href="#cit/section_3.28">28</a>-<a href="#cit/section_3.30">30</a>] La anemia puede estar relacionada a la enfermedad misma o
            deberse al tratamiento. De vez en cuando, la anemia no es m&#xE1;s que una dolencia
            que se presenta al mismo tiempo, sin estar relacionada ni con la enfermedad ni con el tratamiento. A menudo, la anemia contribuye de forma significativa a los s&#xED;ntomas de
            las personas con c&#xE1;ncer.  Para cada paciente en particular, puede ser dif&#xED;cil
            discernir cu&#xE1;l es el efecto actual de la anemia, ya que suelen haber otros
            problemas que confunden la capacidad de sopesar las repercusiones espec&#xED;ficas
            de la anemia.  Estas repercusiones var&#xED;an de acuerdo a factores como:[<a href="#cit/section_3.31">31</a>]
            </p><div class="pdq-content-list"><ul id="_371"><li>Rapidez con que comienza.</li><li> Edad del paciente.</li><li>Situaci&#xF3;n del volumen plasm&#xE1;tico.</li><li>Cantidad y gravedad de las enfermedades simult&#xE1;neas.</li></ul></div><p id="_250" tabindex="-1">Se llev&#xF3; a cabo una revisi&#xF3;n retrospectiva con el fin
            de entender el problema de la anemia en los pacientes que se someten a
            radioterapia. En un principio, la anemia era prevalente en  48&#xA0;% de los
            pacientes y luego aument&#xF3; a 57&#xA0;% durante el tratamiento. La anemia fue m&#xE1;s com&#xFA;n
            en las mujeres que en los hombres (64 contra 51&#xA0;%); sin embargo, los hombres con
            c&#xE1;ncer de pr&#xF3;stata fueron quienes tuvieron el mayor aumento de anemia
            durante la radioterapia.[<a href="#cit/section_3.32">32</a>] En algunos c&#xE1;nceres como el del cuello uterino y el de
            la cabeza y el cuello, la anemia es uno de los indicadores pron&#xF3;sticos de la precariedad de la supervivencia y de la calidad de vida de los pacientes bajo radioterapia.[<a href="#cit/section_3.33">33</a>-<a href="#cit/section_3.36">36</a>]</p></section><section id="_22"><h3 id="_22_toc">Factores de la nutrici&#xF3;n</h3><p id="_23" tabindex="-1">A menudo, el cansancio cr&#xF3;nico se presenta cuando los requisitos energ&#xE9;ticos del cuerpo exceden
            el abastecimiento de las fuentes de energ&#xED;a.[<a href="#cit/section_3.37">37</a>,<a href="#cit/section_3.38">38</a>]  En las personas con
            c&#xE1;ncer, pueden participar tres mecanismos principales: </p><div class="pdq-content-list"><ul id="_355"><li>Alteraci&#xF3;n de la
            capacidad corporal para procesar nutrientes con eficacia.</li><li>Aumento de los
            requisitos energ&#xE9;ticos del cuerpo.</li><li>Disminuci&#xF3;n de la ingesti&#xF3;n de nutrientes
            energ&#xE9;ticos.</li></ul></div><p id="_356" tabindex="-1">Las causas de las alteraciones de la nutrici&#xF3;n se enumeran en el <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_138">Cuadro 1</a>.</p><table id="_138" class="table-default expandable-container"><caption>Cuadro 1.  Factores de nutrici&#xF3;n y energ&#xED;a</caption><colgroup><col width="40.00%"><col width="60.00%"></colgroup><THead><tr><th> Mecanismos   </th><th> Causas</th></tr></THead><tbody><tr><td>Alteraci&#xF3;n de la capacidad para procesar
            nutrientes
            </td><td>Alteraci&#xF3;n metab&#xF3;lica de glucosa, l&#xED;pidos y prote&#xED;nas</td></tr><tr><td rowspan="4">Mayores requisitos de energ&#xED;a </td><td>   Consumo y competencia del tumor por estos nutrientes</td></tr><tr><td>   Estado hipermetab&#xF3;lico debido al
            crecimiento del tumor
            </td></tr><tr><td>    Infecci&#xF3;n o fiebre</td></tr><tr><td>     Disnea</td></tr><tr><td rowspan="4">Reducci&#xF3;n de la ingesta de nutrientes
            energ&#xE9;ticos  </td><td>Anorexia</td></tr><tr><td>N&#xE1;useas o v&#xF3;mitos</td></tr><tr><td> Diarrea</td></tr><tr><td>Obstrucci&#xF3;n intestinal</td></tr></tbody></table></section><section id="_26"><h3 id="_26_toc">Factores psicol&#xF3;gicos</h3><p id="_27" tabindex="-1">Hay numerosos factores relacionados con el estado de &#xE1;nimo, las
            creencias, actitudes y reacciones a la tensi&#xF3;n nerviosa de las personas con
            c&#xE1;ncer que tambi&#xE9;n pueden contribuir a la presentaci&#xF3;n del cansancio  cr&#xF3;nico.  La ansiedad y la depresi&#xF3;n son los trastornos psiqui&#xE1;tricos simult&#xE1;neos m&#xE1;s comunes del CRF.[<a href="#cit/section_3.39">39</a>] A menudo, el cansancio cr&#xF3;nico es la v&#xED;a com&#xFA;n final para una variedad de etiolog&#xED;as f&#xED;sicas y emocionales.</p><p id="_28" tabindex="-1">La depresi&#xF3;n puede ser un s&#xED;ndrome concomitante e incapacitante, que afecta
            aproximadamente de 15 a 25&#xA0;% de personas con c&#xE1;ncer.[<a href="#cit/section_3.40">40</a>]  La
            presencia de la depresi&#xF3;n, que se manifiesta como p&#xE9;rdida de inter&#xE9;s, dificultad de
            concentraci&#xF3;n, letargo y p&#xE9;rdida de la esperanza, puede agravar las causas
            f&#xED;sicas del cansancio cr&#xF3;nico en estos individuos y persistir incluso despu&#xE9;s de
            resueltas las causas f&#xED;sicas.[<a href="#cit/section_3.41">41</a>]
            </p><p id="_357" tabindex="-1">La ansiedad y el temor relacionado con el
            diagn&#xF3;stico de c&#xE1;ncer como tambi&#xE9;n su efecto en el bienestar f&#xED;sico,
            psicosocial y econ&#xF3;mico de la persona, son fuentes de tensi&#xF3;n emocional.  Solo
            la ansiedad relacionada con el diagn&#xF3;stico del c&#xE1;ncer puede ocasionar cansancio cr&#xF3;nico. En un
            estudio con 74 pacientes de c&#xE1;ncer de mama en estadio temprano, sin antecedentes
            m&#xE9;dicos de trastornos afectivos, se evaluaron varios s&#xED;ntomas relacionados con
            el reajuste a su nuevo trastorno, aproximadamente dos semanas despu&#xE9;s del
            diagn&#xF3;stico; cerca de 45&#xA0;% notaron &#xED;ndices de cansancio que variaban de altos a
            moderados.  Este cansancio pudo ser el  resultado secundario del aumento en la
            tensi&#xF3;n cognoscitiva de tener que lidiar con el diagn&#xF3;stico o el insomnio, el
            que el 60&#xA0;% de los pacientes definieron como moderado o grave. Por lo tanto,
            el cansancio cr&#xF3;nico puede comenzar antes del tratamiento debido a las preocupaciones u
            otros factores cognoscitivos, tanto primarios como secundarios al insomnio. Varias formas de tratamiento pueden agravar el cansancio cr&#xF3;nico.[<a href="#cit/section_3.42">42</a>]</p><p id="_358" tabindex="-1">El cansancio tambi&#xE9;n puede aumentar en los sobrevivientes  de c&#xE1;ncer por encima de lo que se observa en la poblaci&#xF3;n en general.[<a href="#cit/section_3.43">43</a>,<a href="#cit/section_3.44">44</a>]  En los sobrevivientes  de c&#xE1;ncer de test&#xED;culo,  la ansiedad y la depresi&#xF3;n son factores pron&#xF3;sticos del cansancio cr&#xF3;nico, que indican la posibilidad de  intervenci&#xF3;n psiqui&#xE1;trica en su manejo.[<a href="#cit/section_3.45">45</a>] (Para
            obtener m&#xE1;s informaci&#xF3;n, consultar los sumarios del PDQ <a href="/espanol/cancer/sobrellevar/sentimientos/depresion-pro-pdq">Depresi&#xF3;n</a> y <a href="/espanol/cancer/sobrellevar/sentimientos/ansiedad-sufrimiento-pro-pdq">Adaptaci&#xF3;n al c&#xE1;ncer: ansiedad y sufrimiento</a>).</p><p id="_280" tabindex="-1">Se se&#xF1;al&#xF3; que la aflicci&#xF3;n a causa de factores psicol&#xF3;gicos y sintom&#xE1;ticos, predice de manera significativa el cansancio cr&#xF3;nico.[<a href="#cit/section_3.46">46</a>,<a href="#cit/section_3.47">47</a>] En un estudio con 101 mujeres a punto de someterse a una operaci&#xF3;n de c&#xE1;ncer de mama, se encontr&#xF3; que la edad menor, la aflicci&#xF3;n preoperatoria y la expectativa de cansancio,  predijeron de manera significativa el grado de cansancio una semana despu&#xE9;s de la cirug&#xED;a. En el modelo de regresi&#xF3;n, la edad, la aflicci&#xF3;n y la expectativa, cada una, y de forma &#xFA;nica, contribuyeron al cansancio, donde la aflicci&#xF3;n y la expectativa constituyeron el 25&#xA0;% de la variabilidad.[<a href="#cit/section_3.46">46</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: III</a>] En un estudio longitudinal en mujeres con c&#xE1;ncer ginecol&#xF3;gico, los s&#xED;ntomas y la aflicci&#xF3;n psicol&#xF3;gica predijeron de manera significativa el cansancio antes, durante y despu&#xE9;s del tratamiento con quimioterapia, lo que explica hasta el 80&#xA0;% de la variabilidad en el cansancio.[<a href="#cit/section_3.47">47</a>] Factores similares a los observados en pacientes de c&#xE1;ncer en estadio temprano tambi&#xE9;n contribuyen a la fatiga en pacientes de c&#xE1;ncer en estadio avanzado e incurable.[<a href="#cit/section_3.48">48</a>]</p></section><section id="_29"><h3 id="_29_toc">Factores cognoscitivos</h3><p id="_30" tabindex="-1">El deterioro de las funciones cognoscitivas, como la disminuci&#xF3;n de la
            atenci&#xF3;n y el deterioro de la percepci&#xF3;n y el pensamiento, se relaciona por lo
            general con el cansancio.[<a href="#cit/section_3.49">49</a>,<a href="#cit/section_3.50">50</a>] Aunque el cansancio y el deterioro cognoscitivo est&#xE1;n
            conectados, el mecanismo impl&#xED;cito de esta relaci&#xF3;n no es claro.  Las
            exigencias mentales inherentes al diagn&#xF3;stico y tratamiento del c&#xE1;ncer se
            documentaron bien; sin embargo, poco se sabe sobre el problema
            simult&#xE1;neo del cansancio de atenci&#xF3;n en las personas con c&#xE1;ncer.  Los
            problemas de atenci&#xF3;n son comunes durante el tratamiento contra el c&#xE1;ncer y despu&#xE9;s
            de este.  Algunos de los problemas de atenci&#xF3;n observados pueden ser por causa del
            cansancio de atenci&#xF3;n.[<a href="#cit/section_3.51">51</a>,<a href="#cit/section_3.52">52</a>]  El cansancio de atenci&#xF3;n se puede aliviar
            con actividades que promuevan el descanso y la recuperaci&#xF3;n de la atenci&#xF3;n dirigida.
            Aunque el sue&#xF1;o es necesario para aliviar el cansancio de atenci&#xF3;n y restaurar
            esa funci&#xF3;n, este resulta insuficiente cuando hay requisitos altos de
            atenci&#xF3;n.  La literatura emp&#xED;rica indica que el medio ambiente natural
            contiene las propiedades para restaurar la atenci&#xF3;n y aliviar el cansancio de
            atenci&#xF3;n.
            </p></section><section id="_31"><h3 id="_31_toc">Trastornos del sue&#xF1;o e inactividad</h3><p id="_359" tabindex="-1">
            Los factores que causan o contribuyen al CRF podr&#xED;an ser los siguientes:</p><div class="pdq-content-list"><ul id="_360"><li>Interrupciones del sue&#xF1;o.</li><li>Malos h&#xE1;bitos al dormir.</li><li>Reducci&#xF3;n de las horas
            de sue&#xF1;o nocturno y los per&#xED;odos largos de  sue&#xF1;o diurno.</li><li>Inactividad.</li></ul></div><p id="_32" tabindex="-1">Los pacientes que ten&#xED;an
            menos actividad durante el d&#xED;a a la vez que despertaban con mayor frecuencia
            durante las noches, fueron quienes informaron de manera uniforme sobre un grado m&#xE1;s alto de CRF. Aquellos pacientes con una actividad m&#xE1;xima m&#xE1;s baja, seg&#xFA;n
            las medidas tomadas por un monitor de actividad estilo reloj pulsera,
            experimentaron los grados m&#xE1;s altos de cansancio.[<a href="#cit/section_3.6">6</a>]
            </p><p id="_281" tabindex="-1">Los trastornos del sue&#xF1;o contribuyen de manera clara con el cansancio cr&#xF3;nico [<a href="#cit/section_3.53">53</a>] y pueden afectar de manera diferencial las tasas de cansancio,  dependiendo del momento de la evaluaci&#xF3;n. En un estudio en el que se evalu&#xF3; el cansancio en las mujeres que se someten a radioterapia por c&#xE1;ncer de mama se&#xF1;al&#xF3; que el sue&#xF1;o tiene una mayor influencia en los valores del cansancio matutino, que en los puntajes de cansancio nocturno.[<a href="#cit/section_3.16">16</a>] En un estudio similar con hombres sometidos a radioterapia por c&#xE1;ncer de pr&#xF3;stata, el sue&#xF1;o contribuy&#xF3; a los &#xED;ndices de cansancio cr&#xF3;nico tanto matutinos como vespertinos.[<a href="#cit/section_3.14">14</a>] Sin embargo, el cansancio cr&#xF3;nico y el sue&#xF1;o tambi&#xE9;n pueden ser problemas distintos. Un estudio que dio como resultado una mejor&#xED;a significativa en cuanto al sue&#xF1;o con el uso de terapia conductual cognitiva, no afect&#xF3; de manera significativa al cansancio cr&#xF3;nico.[<a href="#cit/section_3.54">54</a>]</p><p id="_340" tabindex="-1">Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ <a href="/espanol/cancer/tratamiento/efectos-secundarios/insomnio/trastornos-del-sueno-pro-pdq">Trastornos del sue&#xF1;o</a>.</p></section><section id="_33"><h3 id="_33_toc">Medicamentos</h3><p id="_34" tabindex="-1">Algunos f&#xE1;rmacos, adem&#xE1;s de  la quimioterapia, pueden
            contribuir al cansancio. Con frecuencia los opioides que se utilizan en el
            tratamiento del dolor relacionado con el c&#xE1;ncer, causan sedaci&#xF3;n y esta
            var&#xED;a dependiendo del individuo. Se sabe que los opioides alteran el funcionamiento normal de la secreci&#xF3;n hipotal&#xE1;mica de las hormona liberadora de gonadotropina.[<a href="#cit/section_3.55">55</a>]</p><p id="_372" tabindex="-1">En los pacientes de c&#xE1;ncer avanzado se puede encontrar hipogonadismo, lo cual puede contribuir al cansancio cr&#xF3;nico durante el tratamiento de c&#xE1;ncer.[<a href="#cit/section_3.56">56</a>] En un estudio de casos y controles, se examinaron los efectos de la administraci&#xF3;n oral prolongada de los opioides en sobrevivientes de c&#xE1;ncer y, al igual que las investigaciones sobre la administraci&#xF3;n intratecal, se encontr&#xF3; un hipogonadismo central marcado entre los pacientes que usan  opioides con s&#xED;ntomas significativos de disfunci&#xF3;n sexual, depresi&#xF3;n  y cansancio.[<a href="#cit/section_3.57">57</a>] El ensayo (<a href="/clinicaltrials/NCT00965341">NCT00965341</a>) estudi&#xF3; la posibilidad   de que la terapia de remplazo hormonal afecte el cansancio cr&#xF3;nico en los hombres con c&#xE1;ncer avanzado y concentraciones bajas de testosterona; los resultados est&#xE1;n pendientes.</p><p id="_259" tabindex="-1"> Otros medicamentos como los
            antidepresivos tric&#xED;clicos, neurol&#xE9;pticos, bloqueadores &#x3B2;, benzodiacepinas y
            antihistam&#xED;nicos pueden tambi&#xE9;n producir como efecto secundario un estado
            de sedaci&#xF3;n. Adem&#xE1;s, los medicamentos simult&#xE1;neos como analg&#xE9;sicos, hipn&#xF3;ticos, antidepresivos, antiem&#xE9;ticos, esteroideos o anticonvulsivos, muchos de los cuales act&#xFA;an en el sistema nervioso central,  pueden exacerbar el problema del cansancio cr&#xF3;nico. Tomar varios medicamentos a la vez con diversos efectos secundarios puede aumentar los  efectos del cansancio.</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Blesch KS, Paice JA, Wickham R, et al.: Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum 18 (1): 81-7, 1991 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2003120&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2003120&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Groopman JE: Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 12 (3): 335-44; discussion 345-6, 351, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Irvine DM, Vincent L, Bubela N, et al.: A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nurs 14 (4): 188-99, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1913633&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Hickok JT, Morrow GR, McDonald S, et al.: Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management. J Pain Symptom Manage 11 (6): 370-7, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8935141&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8935141&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Von Hoff D: Asthenia: incidence, etiology, pathophysiology, and treatment. Cancer Therapeutics  1: 184-97, 1998.</li><li id="section_3.6">Berger AM, Farr L: The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum 26 (10): 1663-71, 1999 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10573683&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10573683&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Engstrom CA, Strohl RA, Rose L, et al.: Sleep alterations in cancer patients. Cancer Nurs 22 (2): 143-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10217030&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10217030&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Dimsdale JE, Ancoli-Israel S, Ayalon L, et al.: Taking fatigue seriously, II: variability in fatigue levels in cancer patients. Psychosomatics 48 (3): 247-52, 2007 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17478594&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17478594&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Jacobsen PB, Donovan KA, Small BJ, et al.: Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 110 (8): 1851-9, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17847016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17847016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Collado-Hidalgo A, Bower JE, Ganz PA, et al.: Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12 (9): 2759-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16675568&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16675568&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Wood LJ, Nail LM, Gilster A, et al.: Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 33 (3): 535-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16676010&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16676010&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Winningham ML, Nail LM, Burke MB, et al.: Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 21 (1): 23-36, 1994 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Donovan KA, Jacobsen PB, Andrykowski MA, et al.: Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J Pain Symptom Manage 28 (4): 373-80, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15471655&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15471655&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Miaskowski C, Paul SM, Cooper BA, et al.: Trajectories of fatigue in men with prostate cancer before, during, and after radiation therapy. J Pain Symptom Manage 35 (6): 632-43, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18358683&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18358683&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Greenberg DB, Sawicka J, Eisenthal S, et al.: Fatigue syndrome due to localized radiation. J Pain Symptom Manage 7 (1): 38-45, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1538180&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1538180&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Dhruva A, Dodd M, Paul SM, et al.: Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nurs 33 (3): 201-12, 2010 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20357659&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20357659&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Haylock PJ, Hart LK: Fatigue in patients receiving localized radiation. Cancer Nurs 2 (6): 461-7, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=259440&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=259440&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">King KB, Nail LM, Kreamer K, et al.: Patients' descriptions of the experience of receiving radiation therapy. Oncol Nurs Forum 12 (4): 55-61, 1985 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847996&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847996&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Nail LM: Coping with intracavitary radiation treatment for gynecologic cancer. Cancer Pract  1 (3): 218-24, 1993.</li><li id="section_3.20">Larson PJ, Lindsey AM, Dodd MJ, et al.: Influence of age on problems experienced by patients with lung cancer undergoing radiation therapy. Oncol Nurs Forum 20 (3): 473-80, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8497416&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8497416&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Fobair P, Hoppe RT, Bloom J, et al.: Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4 (5): 805-14, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Piper BF, Rieger PT, Brophy L, et al.: Recent advances in the management of biotherapy-related side effects: fatigue. Oncol Nurs Forum 16 (6 Suppl): 27-34, 1989 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2480583&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2480583&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Haeuber D: Recent advances in the management of biotherapy-related side effects: flu-like syndrome. Oncol Nurs Forum 16 (6 Suppl): 35-41, 1989 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2687812&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2687812&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Mattson K, Niiranen A, Iivanainen M, et al.: Neurotoxicity of interferon. Cancer Treat Rep 67 (10): 958-61, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6194882&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6194882&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Berger AM, Lockhart K, Agrawal S: Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens. Oncol Nurs Forum 36 (5): 563-70, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19726396&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19726396&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">So WK, Marsh G, Ling WM, et al.: The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Oncol Nurs Forum 36 (4): E205-14, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19581224&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19581224&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Goedendorp MM, Andrykowski MA, Donovan KA, et al.: Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer 118 (15): 3833-41, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22086766&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22086766&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Vogelzang NJ, Breitbart W, Cella D, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (3 Suppl 2): 4-12, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253778&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Demetri GD, Kris M, Wade J, et al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16 (10): 3412-25, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Johnston E, Crawford J: The hematologic support of the cancer patient. In: Berger A, Portenoy RK, Weissman DE, eds.: Principles and Practice of Supportive Oncology. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 549-69.</li><li id="section_3.32">Bush RS: The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12 (11): 2047-50, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3771322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3771322&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Fein DA, Lee WR, Hanlon AL, et al.: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13 (8): 2077-83, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7636551&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7636551&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Girinski T, Pejovic-Lenfant MH, Bourhis J, et al.: Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16 (1): 37-42, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2912956&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2912956&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Dubray B, Mosseri V, Brunin F, et al.: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201 (2): 553-8, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8888257&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8888257&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Dunst J: Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 27 (2 Suppl 4): 4-8; discussion 16-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10847301&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10847301&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Watanabe S, Bruera E: Anorexia and cachexia, asthenia, and lethargy. Hematol Oncol Clin North Am 10 (1): 189-206, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8821567&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8821567&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.38">MacDonald N, Alexander HR, Bruera E: Cachexia-anorexia-asthenia. J Pain Symptom Manage 10 (2): 151-5, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7730686&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7730686&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.39">Reich SG: The tired patient: psychological versus organic causes. Hosp Med  22 (7): 142-54, 1986.</li><li id="section_3.40">Henriksson MM, Isomets&#xE4; ET, Hietanen PS, et al.: Mental disorders in cancer suicides. J Affect Disord 36 (1-2): 11-20, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8988260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Cella D, Davis K, Breitbart W, et al.: Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19 (14): 3385-91, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11454886&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11454886&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Cimprich B: Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs 22 (3): 185-94; quiz 195, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10376379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Sugawara Y, Akechi T, Okuyama T, et al.: Occurrence of fatigue and associated factors in disease-free breast cancer patients without depression. Support Care Cancer 13 (8): 628-36, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15668753&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15668753&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">Foss&#xE5; SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21 (7): 1249-54, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12663711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.46">Montgomery GH, Schnur JB, Erblich J, et al.: Presurgery psychological factors predict pain, nausea, and fatigue one week after breast cancer surgery. J Pain Symptom Manage 39 (6): 1043-52, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20538186&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20538186&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Prue G, Allen J, Gracey J, et al.: Fatigue in gynecological cancer patients during and after anticancer treatment. J Pain Symptom Manage 39 (2): 197-210, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19995675&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19995675&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Peters ME, Goedendorp MM, Verhagen SA, et al.: Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. Psychooncology 23 (7): 773-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Rhodes VA, Watson PM, Hanson BM: Patients' descriptions of the influence of tiredness and weakness on self-care abilities. Cancer Nurs 11 (3): 186-94, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3401854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3401854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.50">Fan HG, Hou&#xE9;d&#xE9;-Tchen N, Yi QL, et al.: Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23 (31): 8025-32, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258100&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258100&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Holmes S: Preliminary investigations of symptom distress in two cancer patient populations: evaluation of a measurement instrument. J Adv Nurs 16 (4): 439-46, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2061507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2061507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Oberst MT, James RH: Going home: patient and spouse adjustment following cancer surgery. Top Clin Nurs 7 (1): 46-57, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3844889&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3844889&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Ancoli-Israel S, Liu L, Marler MR, et al.: Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14 (3): 201-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16010529&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Berger AM, Kuhn BR, Farr LA, et al.: One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol 27 (35): 6033-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19884558&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19884558&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.55">Katz N, Mazer NA: The impact of opioids on the endocrine system. Clin J Pain 25 (2): 170-5, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19333165&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19333165&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">Strasser F, Palmer JL, Schover LR, et al.: The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107 (12): 2949-57, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17103445&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17103445&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100 (4): 851-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14770444&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14770444&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _35
      field_pdq_section_title:
        - format: plain_text
          value: 'Evaluación'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_35" class="pdq-sections"><p id="_36" tabindex="-1">La evaluaci&#xF3;n del cansancio es de naturaleza multidimensional,[<a href="#cit/section_4.1">1</a>] y una cantidad de instrumentos elaborados originalmente para su investigaci&#xF3;n tambi&#xE9;n se usan en la pr&#xE1;ctica cl&#xED;nica. La mayor&#xED;a de estos instrumentos incluyen dimensiones de s&#xED;ntomas adem&#xE1;s de la intensidad del   cansancio, tales como la incidencia y consecuencias del cansancio cr&#xF3;nico, momento del cansancio, s&#xED;ntomas relacionados con este y acciones para el autocuidado.[<a href="#cit/section_4.2">2</a>-<a href="#cit/section_4.10">10</a>] La investigaci&#xF3;n tambi&#xE9;n contribuy&#xF3; con una medida de 10 puntos validados para su uso en ni&#xF1;os.[<a href="#cit/section_4.11">11</a>]</p><p id="_282" tabindex="-1">Sin embargo, una gran parte del tiempo que se emplea en la pr&#xE1;ctica cl&#xED;nica, debido a la carga que se percibe entre proveedor y paciente, los ex&#xE1;menes de detecci&#xF3;n dependen por lo general de un solo punto para la tasa de intensidad del cansancio.[<a href="#cit/section_4.12">12</a>-<a href="#cit/section_4.15">15</a>] De acuerdo con las pautas del  National Comprehensive Cancer Network (NCCN), la tasa de cansancio cr&#xF3;nico de 4 o m&#xE1;s en una escala de 0 a 10 (donde 10 es cansancio cr&#xF3;nico muy intenso) se eval&#xFA;a a&#xFA;n m&#xE1;s en cuanto a los factores contribuyentes como el dolor, la aflicci&#xF3;n emocional, la anemia, el sue&#xF1;o, la nutrici&#xF3;n y el grado de actividad. Es entonces que se le da tratamiento a estas morbilidades relacionadas.[<a href="#cit/section_4.16">16</a>] Un estudio con pacientes ambulatorios con tumores s&#xF3;lidos (N = 148)  evalu&#xF3; la utilidad de los ex&#xE1;menes de detecci&#xF3;n de un solo punto para s&#xED;ntomas, como cansancio cr&#xF3;nico y dolor.[<a href="#cit/section_4.12">12</a>] Los investigadores se&#xF1;alaron que las evaluaciones de un solo punto pueden ser el primer paso para ayudar a la identificaci&#xF3;n de pacientes que requieren evaluaci&#xF3;n integral de los s&#xED;ntomas. Los pacientes que se identifican mediante el uso de un instrumento de un solo punto se someten a una evaluaci&#xF3;n integral para determinar la sintomatolog&#xED;a cl&#xED;nicamente relevante.[<a href="#cit/section_4.12">12</a>,<a href="#cit/section_4.13">13</a>]</p><section id="_283"><h3 id="_283_toc">Instrumentos de m&#xFA;ltiples puntos</h3><p id="_284" tabindex="-1"> La
            literatura ambigua y la carencia de medios espec&#xED;ficos para medir el cansancio crearon dificultades para establecer pautas de evaluaci&#xF3;n y
            control. La evaluaci&#xF3;n integral del paciente con cansancio cr&#xF3;nico comienza con la
            obtenci&#xF3;n concienzuda de sus antecedentes, para describir la modalidad de cansancio e identificar todos los factores que contribuyen a este. Se  podr&#xED;a incluir los siguientes aspectos en la evaluaci&#xF3;n
            inicial:</p><div class="pdq-content-list"><ul id="_285"><li>Modalidad de autoinforme sobre el cansancio como su inicio, duraci&#xF3;n e intensidad,
            as&#xED; como los factores que lo agravan y alivian.</li><li>Tipo y grado de la enfermedad y de sus s&#xED;ntomas o los efectos secundarios
            relacionados con el tratamiento.
            </li><li>Historial de tratamiento.</li><li>F&#xE1;rmacos actuales.</li><li>Modalidad de dormir, descansar, h&#xE1;bitos de relajaci&#xF3;n, costumbres y
            ritos.</li><li>Ingesta de alimentos y cualquier cambio de apetito o de peso.
            </li><li>Efectos del cansancio en las actividades cotidianas y el estilo de
            vida.</li><li>Evaluaci&#xF3;n psiqui&#xE1;trica, como la evaluaci&#xF3;n de la depresi&#xF3;n.</li><li>Reconocimiento f&#xED;sico completo, que incluya el modo de caminar, la postura y
            el rango de movimiento.
            </li><li>Cumplimiento con el tratamiento.</li><li>Desempe&#xF1;o en el trabajo.</li><li>Recursos econ&#xF3;micos.</li><li>Otros factores contribuyentes (por ejemplo, anemia, disnea, debilidad muscular).</li></ul></div><p id="_286" tabindex="-1">Se presta atenci&#xF3;n espec&#xED;fica a los factores subyacentes que contribuyen
            al cansancio y que pueden ser corregibles, como los siguientes:[<a href="#cit/section_4.17">17</a>,<a href="#cit/section_4.18">18</a>]</p><div class="pdq-content-list"><ul id="_287"><li>Anemia.</li><li>Depresi&#xF3;n.</li><li>Ansiedad.</li><li>Dolor.</li><li>Deshidrataci&#xF3;n.</li><li>Deficiencias nutricionales (por ejemplo, proteicas, cal&#xF3;ricas, vitam&#xED;nicas).</li><li>Medicamentos sedativos (por ejemplo opioides, benzodiacepinas).</li><li>Tratamientos neurot&#xF3;xicos.</li><li>Infecci&#xF3;n.</li><li>Fiebre.</li><li>Trastornos del sue&#xF1;o.</li><li>Inmovilidad.</li></ul></div><p id="_288" tabindex="-1">Los criterios propuestos para la CRF  relacionado con el c&#xE1;ncer se enumeran
            <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_290">m&#xE1;s adelante</a>.  Se adoptaron dichos criterios para incluirse en la <em>Clasificaci&#xF3;n Estad&#xED;stica Internacional de Enfermedades y Problemas Relacionados con la Salud,
            D&#xE9;cima edici&#xF3;n, Modificaci&#xF3;n Cl&#xED;nica</em>  (CIE-10-CM).[<a href="#cit/section_4.19">19</a>]  </p><p id="_289" tabindex="-1">El definir el CRF como un s&#xED;ndrome de diagn&#xF3;stico tiene algunas posibles ventajas y desventajas.[<a href="#cit/section_4.20">20</a>] Una de las posibles ventajas es que permitir&#xED;a a los m&#xE9;dicos
            documentar la presencia o ausencia de cansancio cr&#xF3;nico en un patr&#xF3;n reproducible.
            Tambi&#xE9;n puede resultar &#xFA;til para establecer el rembolso apropiado en el
            manejo de estos hallazgos. La posible desventaja de este enfoque es
            que puede disuadir el manejo del cansancio cr&#xF3;nico que no alcanza el umbral para el
            diagn&#xF3;stico en  la CIE-10. La alternativa para el enfoque con base en el
            s&#xED;ndrome, (que se usa con frecuencia en la depresi&#xF3;n) es el enfoque con base en el s&#xED;ntoma, que se usa com&#xFA;nmente para fen&#xF3;menos como el dolor y las n&#xE1;useas.  El
            enfoque con base en el s&#xED;ndrome se usa con frecuencia para la depresi&#xF3;n. A&#xFA;n no se ha validado la
            utilidad de los criterios de la CIE-10 para el cansancio relacionado con el
            c&#xE1;ncer, que se mencionan abajo.</p><p id="_290" tabindex="-1"><strong>Criterios de la CIE-10 para el cansancio cr&#xF3;nico relacionado con el c&#xE1;ncer</strong></p><p id="_291" tabindex="-1">Los siguientes s&#xED;ntomas se presentaron cada d&#xED;a o casi todos los d&#xED;as
            durante el mismo per&#xED;odo de dos semanas en el &#xFA;ltimo mes:</p><div class="pdq-content-list"><ol id="_292" class="upper-alpha"><li>Fatiga o cansancio cr&#xF3;nico significativo, disminuci&#xF3;n de la energ&#xED;a o aumento de la necesidad
            de descansar, fuera de proporci&#xF3;n con cualquier modificaci&#xF3;n reciente del
            grado de actividad; adem&#xE1;s de cinco o m&#xE1;s de los siguientes:<div class="pdq-content-list"><ol id="_293"><li>Quejas de debilidad general, extremidades pesadas.
            </li><li>  Concentraci&#xF3;n o atenci&#xF3;n disminuida.</li><li>Disminuci&#xF3;n de la motivaci&#xF3;n o del inter&#xE9;s de participar en las actividades habituales.</li><li>Insomnio o hipersomnia.
            </li><li>  Sue&#xF1;o que no refresca ni restaura.</li><li>Percepci&#xF3;n de que se necesita luchar para superar la inactividad.</li><li>Reactividad emocional marcada (por ejemplo, tristeza, frustraci&#xF3;n o irritabilidad) ante la sensaci&#xF3;n de cansancio cr&#xF3;nico.
            </li><li>La dificultad de llevar a cabo tareas cotidianas se le atribuye a la sensaci&#xF3;n de cansancio.</li><li>Percepci&#xF3;n de que hay problemas con la memoria inmediata.</li><li> El cansancio despu&#xE9;s del ejercicio extenuante dura varias horas.
            </li></ol></div></li><li>  Los s&#xED;ntomas ocasionan una aflicci&#xF3;n cl&#xED;nica significativa o un deterioro
            en el funcionamiento social, profesional o de otras &#xE1;reas importantes del
            comportamiento.</li><li>Hay signos en la historia cl&#xED;nica, el reconocimiento m&#xE9;dico o el resultado
            de an&#xE1;lisis de que los s&#xED;ntomas surgen como consecuencia del c&#xE1;ncer o de su tratamiento.</li><li>Los s&#xED;ntomas no surgen principalmente como consecuencia de trastornos
            psiqui&#xE1;tricos simult&#xE1;neos, como una depresi&#xF3;n intensa, trastorno de
            somatizaci&#xF3;n, trastorno somatomorfo o <em>delirium</em>.</li></ol></div><p id="_294" tabindex="-1">Al igual que en el caso de otros s&#xED;ntomas puramente subjetivos como el dolor,
            puede ser necesario alentar al paciente y a otros miembros de la familia a
            mencionarle al personal m&#xE9;dico los s&#xED;ntomas de cansancio.  Al comienzo del tratamiento se les debe dar a todos los
            pacientes informaci&#xF3;n sobre la posibilidad de
            que la enfermedad subyacente o los tratamientos le produzcan cansancio cr&#xF3;nico, sobre las
            opciones para controlarlo y sobre la importancia de informar al m&#xE9;dico de
            estos s&#xED;ntomas.[<a href="#cit/section_4.17">17</a>] Los pacientes podr&#xED;an no referirse a su cansancio, a
            menos que el profesional de la salud los motive a hacerlo.   </p><p id="_295" tabindex="-1">Varias barreras obstaculizan el tratamiento apropiado del CRF.   Algunas de estas se identificaron en la fase 1 de un proyecto de tres fases actualmente en curso, relacionado con la puesta en pr&#xE1;ctica de las directrices fundamentadas en datos probatorios para el tratamiento del cansancio (NCCN).[<a href="#cit/section_4.21">21</a>]   Las barreras identificadas con mayor frecuencia fueron las siguientes:[<a href="#cit/section_4.21">21</a>,<a href="#cit/section_4.22">22</a>]</p><div class="pdq-content-list"><ul id="_296"><li>El paciente cree que el m&#xE9;dico introducir&#xED;a el tema del cansancio si fuera importante (barrera de los pacientes).</li><li>Falta de documentaci&#xF3;n sobre el cansancio (barrera profesional).</li><li>Falta de referencias para la atenci&#xF3;n de apoyo (barrera del sistema).</li></ul></div><p id="_297" tabindex="-1">Aunque no hay una norma aceptada universalmente para medir el cansancio, se
            formularon una variedad de instrumentos para evaluar el cansancio y sus efectos relacionados.[<a href="#cit/section_4.2">2</a>-<a href="#cit/section_4.6">6</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: II</a>];[<a href="#cit/section_4.7">7</a>-<a href="#cit/section_4.10">10</a>]  El cansancio
            tambi&#xE9;n se suele evaluar mediante instrumentos multidimensionales de calidad
            de vida.  Los instrumentos seleccionados para evaluar el cansancio se mencionan a
            continuaci&#xF3;n:
            </p><div class="pdq-content-list"><ul id="_298"><li> Breve inventario sobre la fatiga o cansancio cr&#xF3;nico.[<a href="#cit/section_4.4">4</a>]</li><li>Evaluaci&#xF3;n funcional de la anemia relacionada con el tratamiento del c&#xE1;ncer.[<a href="#cit/section_4.7">7</a>]</li><li>Evaluaci&#xF3;n funcional del cansancio cr&#xF3;nico relacionado con el tratamiento del c&#xE1;ncer.[<a href="#cit/section_4.8">8</a>]</li><li>Piper Fatigue Scale (versi&#xF3;n corta y larga).[<a href="#cit/section_4.3">3</a>,<a href="#cit/section_4.23">23</a>]</li><li> Escala del cansancio cr&#xF3;nico por c&#xE1;ncer de Schwartz.[<a href="#cit/section_4.9">9</a>]</li><li>Inventario de s&#xED;ntomas de cansancio cr&#xF3;nico.[<a href="#cit/section_4.6">6</a>]</li><li> El perfil de los estados de &#xE1;nimo, subescala de cansancio e inercia.[<a href="#cit/section_4.10">10</a>]</li><li>Escala visual an&#xE1;loga de Lee sobre el cansancio.[<a href="#cit/section_4.2">2</a>]</li><li>Escala del cansancio por el c&#xE1;ncer.[<a href="#cit/section_4.5">5</a>]</li><li>Inventario multidimensional de los s&#xED;ntomas de cansancio cr&#xF3;nico (versi&#xF3;n corta).[<a href="#cit/section_4.24">24</a>]</li></ul></div></section><section id="_73"><h3 id="_73_toc">Evaluaci&#xF3;n de la anemia</h3><p id="_74" tabindex="-1">La evaluaci&#xF3;n apropiada de la anemia en el paciente de c&#xE1;ncer abarca los siguientes: </p><div class="pdq-content-list"><ul id="_362"><li>Antecedentes y un examen f&#xED;sico cuidadoso.</li><li>La evaluaci&#xF3;n del recuento de sangre
            completo y de los &#xED;ndices de gl&#xF3;bulos rojos.</li><li>An&#xE1;lisis de frotis sangu&#xED;neo
            perif&#xE9;rico.</li></ul></div><p id="_363" tabindex="-1">En combinaci&#xF3;n, los datos provenientes de estas investigaciones son, por lo general, diagn&#xF3;sticos.</p><p id="_75" tabindex="-1">Un m&#xE9;todo que se usa com&#xFA;nmente para clasificar la anemia es categorizarla
            por el tama&#xF1;o de los gl&#xF3;bulos rojos medidos por el volumen corpuscular
            medio (VCM).  Las anemias microc&#xED;ticas se relacionan
            con un VCM  de 79 fl o menos, e incluyen la anemia por
            deficiencia de hierro, la talasemia y la anemia por enfermedad cr&#xF3;nica.  Las anemias
            macroc&#xED;ticas se relacionan con un VCM  mayor de 101 fl e incluyen las
            relacionadas con la deficiencia de vitamina B<sub>12</sub> o de folato, la
            mielodisplasia y la enfermedad hep&#xE1;tica.  La mayor&#xED;a de las anemias son
            normoc&#xED;ticas, lo que significa que el VCM se encuentra dentro de su estado
            normal.  Esta categor&#xED;a de anemias incluye las siguientes:[<a href="#cit/section_4.25">25</a>]
            </p><div class="pdq-content-list"><ul id="_299"><li> Anemia mielopt&#xED;sica (es decir, anemia
            relacionada con el remplazo neopl&#xE1;sico de la m&#xE9;dula &#xF3;sea).</li><li>La mayor&#xED;a de las anemias
            relacionadas con la quimioterapia.</li><li>Anemia relacionada con la disfunci&#xF3;n renal o
            hep&#xE1;tica.</li><li>Anemia hemol&#xED;tica.</li><li>Anemia apl&#xE1;sica.</li></ul></div><p id="_300" tabindex="-1">Sin embargo, una poblaci&#xF3;n mixta de
            gl&#xF3;bulos rojos que consiste en c&#xE9;lulas microc&#xED;ticas y macroc&#xED;ticas
            (anisocitosis),  puede indicar una etiolog&#xED;a combinada, por
            ejemplo, p&#xE9;rdida cr&#xF3;nica de sangre (microc&#xED;tica) que da como resultado
            reticulocitosis (macroc&#xED;tica).  En esta situaci&#xF3;n, el VCM puede estar dentro
            de su estado normal, pero la amplitud de distribuci&#xF3;n del tama&#xF1;o de los
            gl&#xF3;bulos rojos  estar&#xED;a elevada.</p><p id="_76" tabindex="-1">El an&#xE1;lisis del frotis sangu&#xED;neo perif&#xE9;rico, aunque suele pasarse por alto,
            sigue siendo un paso importante en la evaluaci&#xF3;n de la anemia.  Por ejemplo,
            las c&#xE9;lulas sangu&#xED;neas nucleadas y las de forma de l&#xE1;grima indican anemia
            mielopt&#xED;sica.  Los macroovalocitos y neutr&#xF3;filos hipersegmentados suelen
            indicar anemia megalobl&#xE1;stica.  Los eritrocitos peque&#xF1;os en diana y
            basof&#xED;licos puntiformes se relacionan con la talasemia.</p><p id="_77" tabindex="-1">Otros estudios que a veces se requieren para caracterizar la anemia en un
            paciente dado incluyen pruebas de las concentraciones de vitamina B<sub>12</sub> o folato, hierro s&#xE9;rico, transferrina y ferritina, eritropoyetina,
            prueba directa e indirecta de Coombs, examen de aspirado y biopsia de
            m&#xE9;dula &#xF3;sea.  En los pacientes de c&#xE1;ncer, la etiolog&#xED;a subyacente suele ser
            multifactorial.</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_4.1">Portenoy RK, Miaskowski C: Assessment and management of cancer-related fatigue. In: Berger A, Portenoy RK, Weissman DE, eds.: Principles and Practice of Supportive Oncology. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 109-18.</li><li id="section_4.2">Lee KA, Hicks G, Nino-Murcia G: Validity and reliability of a scale to assess fatigue. Psychiatry Res 36 (3): 291-8, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2062970&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2062970&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Piper BF, Dibble SL, Dodd MJ, et al.: The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25 (4): 677-84, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599351&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599351&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Mendoza TR, Wang XS, Cleeland CS, et al.: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85 (5): 1186-96, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10091805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10091805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Okuyama T, Akechi T, Kugaya A, et al.: Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 19 (1): 5-14, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10687321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10687321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Hann DM, Denniston MM, Baker F: Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. Qual Life Res 9 (7): 847-54, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11297027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11297027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (3 Suppl 2): 13-9, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9253779&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Cella D: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales. Version 4. Evanston, Ill: Evanston Northwestern Healthcare, 1997.</li><li id="section_4.9">Schwartz AL: The Schwartz Cancer Fatigue Scale: testing reliability and validity. Oncol Nurs Forum 25 (4): 711-7, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599354&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9599354&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">McNair D, Lorr M, Droppelman L, et al.: Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service, 1971.</li><li id="section_4.11">Hinds PS, Yang J, Gattuso JS, et al.: Psychometric and clinical assessment of the 10-item reduced version of the Fatigue Scale-Child instrument. J Pain Symptom Manage 39 (3): 572-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Butt Z, Wagner LI, Beaumont JL, et al.: Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 35 (1): 20-30, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17959345&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17959345&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Kirsh KL, Passik S, Holtsclaw E, et al.: I get tired for no reason: a single item screening for cancer-related fatigue. J Pain Symptom Manage 22 (5): 931-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11728796&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11728796&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Strasser F, M&#xFC;ller-K&#xE4;ser I, Dietrich D: Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. J Pain Symptom Manage 38 (4): 505-14, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19822275&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19822275&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Temel JS, Pirl WF, Recklitis CJ, et al.: Feasibility and validity of a one-item fatigue screen in a thoracic oncology clinic. J Thorac Oncol 1 (5): 454-9, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409899&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409899&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Cella D, Peterman A, Passik S, et al.: Progress toward guidelines for the management of fatigue. Oncology (Huntingt) 12 (11A): 369-77, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10028520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10028520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Groopman JE: Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 12 (3): 335-44; discussion 345-6, 351, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9534184&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Portenoy RK, Itri LM: Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4 (1): 1-10, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10337366&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10337366&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Sadler IJ, Jacobsen PB, Booth-Jones M, et al.: Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 23 (5): 406-16, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12007758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12007758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Borneman T, Piper BF, Sun VC, et al.: Implementing the Fatigue Guidelines at one NCCN member institution: process and outcomes. J Natl Compr Canc Netw 5 (10): 1092-101, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18053431&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18053431&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Passik SD, Kirsh KL, Donaghy K, et al.: Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 24 (5): 481-93, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12547048&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12547048&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Reeve BB, Stover AM, Alfano CM, et al.: The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. Breast Cancer Res Treat 136 (1): 9-20, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22933027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22933027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Stein KD, Jacobsen PB, Blanchard CM, et al.: Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27 (1): 14-23, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14711465&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14711465&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Armitage JO: Management of anemia in patients with cancer. Clinical Oncology Updates  1: 1-12, 1998.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _78
      field_pdq_section_title:
        - format: plain_text
          value: 'Intervención'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_78" class="pdq-sections"><p id="_79" tabindex="-1">Gran parte de la informaci&#xF3;n sobre las intervenciones para aliviar el cansancio cr&#xF3;nico se relaciona con sujetos saludables, o personas cuyo cansancio muscular
            es la etiolog&#xED;a primaria del problema, o en las que  el cansancio es secundario a la
            anemia relacionada con el tratamiento.[<a href="#cit/section_5.1">1</a>,<a href="#cit/section_5.2">2</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: II</a>];[<a href="#cit/section_5.3">3</a>,<a href="#cit/section_5.4">4</a>]  Sin una determinaci&#xF3;n de los
            mecanismos que causan  cansancio cr&#xF3;nico en los pacientes de c&#xE1;ncer, las intervenciones
            deben orientarse al control de s&#xED;ntomas y al apoyo emocional.  Aunque se hicieron algunas recomendaciones para el control del cansancio   en los pacientes de
            oncolog&#xED;a, &#xE9;stas son de naturaleza te&#xF3;rica o anecd&#xF3;tica y, en general, no fueron el foco de la evaluaci&#xF3;n cient&#xED;fica.</p><p id="_373" tabindex="-1">En un estudio que se public&#xF3; en 2013 de pacientes con c&#xE1;ncer en estadio avanzado (N = 152),  mostr&#xF3; que el tratamiento de los s&#xED;ntomas (por ejemplo, dolor, n&#xE1;useas y disminuci&#xF3;n del apetito) puede tener un efecto positivo importante en el cansancio cr&#xF3;nico. En este estudio de 12 semanas, se asign&#xF3; al azar a los pacientes a vigilancia y tratamiento seg&#xFA;n el protocolo de los s&#xED;ntomas f&#xED;sicos coordinado por una enfermera o atenci&#xF3;n usual (el tratamiento de los s&#xED;ntomas comprendido en la atenci&#xF3;n est&#xE1;ndar del c&#xE1;ncer). Los pacientes del grupo de intervenci&#xF3;n recibieron tratamiento personalizado para cualquiera de los s&#xED;ntomas molestos. Los grados de cansancio cr&#xF3;nico, seg&#xFA;n la medici&#xF3;n del Inventario Multidimensional del Cansancio Cr&#xF3;nico, exhibieron una disminuci&#xF3;n considerable en el grupo de intervenci&#xF3;n en comparaci&#xF3;n con el grupo de atenci&#xF3;n usual. El grupo de intervenci&#xF3;n tambi&#xE9;n mostr&#xF3; mejoras en los siguientes aspectos:[<a href="#cit/section_5.5">5</a>]</p><div class="pdq-content-list"><ul id="_374"><li>Dimensiones espec&#xED;ficas del cansancio cr&#xF3;nico.</li><li>Interferencia del cansancio cr&#xF3;nico con la vida diaria.</li><li>Carga general de los s&#xED;ntomas.</li><li>S&#xED;ntomas de depresi&#xF3;n y ansiedad.</li></ul></div><p id="_375" tabindex="-1">Es necesario realizar estudios similares en los que se investigue si el tratamiento de los s&#xED;ntomas f&#xED;sicos y psicol&#xF3;gicos espec&#xED;ficos puede aliviar el cansancio cr&#xF3;nico e identificar las poblaciones de pacientes que podr&#xED;an beneficiarse de dicho tratamiento. Un posible mensaje de este estudio puede ser que el cansancio cr&#xF3;nico sea un s&#xED;ntoma primario o secundario (resultado de otros s&#xED;ntomas molestos). Por lo tanto, la evaluaci&#xF3;n de los pacientes para determinar el s&#xED;ntoma adecuado para realizar la intervenci&#xF3;n es, probablemente, la forma m&#xE1;s eficaz de ayudar a los pacientes a mejorar su calidad de vida relacionada con la salud.</p><p id="_80" tabindex="-1">Dado que  la etiolog&#xED;a y los mecanismos del cansancio y la astenia en el paciente de
            c&#xE1;ncer no se pueden determinar, hay una variaci&#xF3;n considerable en las
            pautas habituales respecto al manejo de este s&#xED;ntoma.  El enfoque del tratamiento m&#xE9;dico est&#xE1; por lo general dirigido a la identificaci&#xF3;n de s&#xED;ntomas correlacionados espec&#xED;ficos, potencialmente reversibles, como en los siguientes ejemplos:
            </p><div class="pdq-content-list"><ul id="_301"><li>Los pacientes
            con cansancio cr&#xF3;nico y dolor pueden someterse a una valoraci&#xF3;n cuantitativa de los f&#xE1;rmacos analg&#xE9;sicos.</li><li>Los
            pacientes con cansancio cr&#xF3;nico y anemia pueden recibir una transfusi&#xF3;n de eritrocitos
            concentrados, intervenciones nutricionales que incluyen alimentos ricos en
            hierro, suplementos de hierro o vitaminas para corregir una deficiencia
            subyacente o inyecciones de epoetina &#x3B1;.</li><li>Los pacientes deprimidos y con
            cansancio cr&#xF3;nico se pueden tratar con f&#xE1;rmacos antidepresivos y psicoestimulantes.</li></ul></div><p id="_302" tabindex="-1">A veces es &#xFA;til considerar la posibilidad de suspender los f&#xE1;rmacos que se puedan
            retirar de forma inocua.  No hay un modo reconocido de evaluar y tratar el cansancio cr&#xF3;nico, pero hay una serie creciente de ensayos cl&#xED;nicos que se idearon
            para atender este problema en el paciente de c&#xE1;ncer.</p><section id="_376"><h3 id="_376_toc">Tratamiento de la anemia</h3><p id="_377" tabindex="-1">La mejor forma de manejar la anemia en los pacientes de c&#xE1;ncer es tratar
            la causa subyacente.  Cuando esta no es clara o no hay un remedio espec&#xED;fico,
            entonces el tratamiento es de apoyo. Se toman en cuenta las intervenciones nutricionales,
            como la ingesta de complementos y de alimentos altos en nutrientes, adem&#xE1;s de otras modalidades de tratamiento. La
            transfusi&#xF3;n de gl&#xF3;bulos rojos concentrados es el tratamiento que m&#xE1;s se usa y
            la forma m&#xE1;s r&#xE1;pida de aliviar los s&#xED;ntomas en los pacientes de c&#xE1;ncer con
            anemia sintom&#xE1;tica.  Con la transfusi&#xF3;n, hay una probabilidad muy alta de
            lograr el aumento de las concentraciones de hemoglobina y los riesgos de
            complicaciones son bajos.  No obstante, realizar transfusiones repetidas puede ser
            complicado y el riesgo de infecci&#xF3;n de trasmisi&#xF3;n hem&#xE1;tica puede
            preocupar a los pacientes.  Otros riesgos comprenden una reacci&#xF3;n aguda a la
            trasfusi&#xF3;n, enfermedad de injerto contra hu&#xE9;sped relacionada con esta,
            modulaci&#xF3;n inmunitaria sutil que aparece con la trasfusi&#xF3;n y exceso de hierro
            para aquellos que reciben varias trasfusiones.[<a href="#cit/section_5.6">6</a>]
            </p><p id="_378" tabindex="-1">En varios estudios comunitarios grandes, se examin&#xF3; la eficacia de la epoetina &#x3B1; y de la darbepoetina &#x3B1; [<a href="#cit/section_5.7">7</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>];[<a href="#cit/section_5.8">8</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>] en el tratamiento de la anemia relacionada con el c&#xE1;ncer en pacientes que recib&#xED;an quimioterapia.[<a href="#cit/section_5.2">2</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: II</a>];[<a href="#cit/section_5.9">9</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: III</a>];[<a href="#cit/section_5.10">10</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>] En pocos de los estudios de epoetina &#x3B1; se us&#xF3; un dise&#xF1;o abierto sin aleatorizaci&#xF3;n y se incluyeron criterios de valoraci&#xF3;n objetivos  (reacci&#xF3;n de la hemoglobina, condiciones necesarias para la transfusi&#xF3;n) y evaluaci&#xF3;n subjetiva del cansancio cr&#xF3;nico y de la calidad de vida. En este &#xE1;mbito, la epoetina &#x3B1; ha sido eficaz al aumentar las concentraciones de hemoglobina y al disminuir  las condiciones necesarias para la transfusi&#xF3;n. Asimismo, la epoetina &#x3B1; se ha relacionado con una mejora del estado funcional y de la calidad de vida, independientemente de la respuesta tumoral. En varios estudios de epoetina &#x3B1; y de darbepoetina &#x3B1; se us&#xF3; un dise&#xF1;o controlado aleatorizado. Estos estudios difirieron en t&#xE9;rminos de la dosis farmacol&#xF3;gica y la frecuencia de administraci&#xF3;n. En una revisi&#xF3;n de los metan&#xE1;lisis de estudios abiertos aleatorizados, se concluy&#xF3; que estos f&#xE1;rmacos son eficaces en el tratamiento del CRF,[<a href="#cit/section_5.11">11</a>] pero tambi&#xE9;n se generaron profundas inquietudes con respecto a la seguridad de los datos y a los resultados adversos relacionados con estos f&#xE1;rmacos. Los autores concluyeron que el riesgo relacionado con estos f&#xE1;rmacos supera los beneficios en el tratamiento del CRF y, por ende, no se deben usar.</p><p id="_379" tabindex="-1">La FDA realiz&#xF3; una revisi&#xF3;n intensiva de la seguridad de la informaci&#xF3;n de los estudios de estos f&#xE1;rmacos.[<a href="#cit/section_5.12">12</a>] En la revisi&#xF3;n se mostr&#xF3; que en los pacientes con c&#xE1;nceres de mama, de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as, de cabeza y cuello, linfoide y de cuello uterino, los f&#xE1;rmacos estimulantes de la eritropoyesis (FEE) disminuyeron la supervivencia general o aumentaron el riesgo de progresi&#xF3;n o recidiva tumorales. En la revisi&#xF3;n tambi&#xE9;n se observ&#xF3; que los FEE aumentan el riesgo de episodios cardiovasculares y tromboemb&#xF3;licos graves cuando se administraron con concentraciones m&#xE1;s altas de hemoglobina (13,5&#x2013;14 g/dl).</p><p id="_380" tabindex="-1">Sobre la base de estas conclusiones, la FDA orden&#xF3; la revisi&#xF3;n de las fichas t&#xE9;cnicas de los FEE para incluir una advertencia actualizada, una nueva advertencia especial e instrucciones sobre indicaciones y posolog&#xED;a. La advertencia especial incluye informaci&#xF3;n sobre el riesgo m&#xE1;s alto de mortalidad por episodios cardiovasculares o tromboemb&#xF3;licos y por progresi&#xF3;n o recidiva tumorales. Las directrices de la American Society of Clinical Oncology (ASCO) y de la American Society of Hematology (ASH) de 2010 recomiendan lo siguiente:[<a href="#cit/section_5.13">13</a>]</p><div class="pdq-content-list"><ul id="_381"><li>De acuerdo a la ficha t&#xE9;cnica aprobada por la FDA,[<a href="#cit/section_5.14">14</a>] el uso de estos f&#xE1;rmacos se debe restringir al tratamiento de la anemia (concentraci&#xF3;n de hemoglobina &lt;10 g/dl) causada por la quimioterapia mielodepresora paliativa simult&#xE1;nea y se debe descontinuar al completar un ciclo de quimioterapia. (Lo anterior no corresponde al s&#xED;ndrome mielodispl&#xE1;sico de riesgo bajo.)[<a href="#cit/section_5.13">13</a>]</li><li>De acuerdo con la ficha t&#xE9;cnica aprobada por la FDA, se debe usar la dosis m&#xE1;s baja posible, con el objetivo de evitar transfusiones eritrocitarias, ya que las dosis m&#xE1;s altas aumentan el riesgo de episodios cardiovasculares y tromboemb&#xF3;licos.</li><li>La dosis inicial y la modificaci&#xF3;n deben seguir las indicaciones de la ficha t&#xE9;cnica aprobada por la FDA.[<a href="#cit/section_5.15">15</a>,<a href="#cit/section_5.16">16</a>] Se deben descontinuar los FEE si no hay respuesta despu&#xE9;s de 6 a 8 semanas (aumento de hemoglobina &lt;1&#x2013;2 g/dl o ninguna disminuci&#xF3;n de las condiciones necesarias para transfusi&#xF3;n).</li><li>La ficha t&#xE9;cnica aprobada por la FDA indica que el FEE no est&#xE1; indicado en  los pacientes que se someten a quimioterapia mielodepresora curativa. Sin embargo, las recomendaciones de ASCO/ASH de 2010 indican que el uso de FEE en &#xE1;mbitos curativos y paliativos se debe guiar por el juicio cl&#xED;nico, los objetivos del tratamiento y la preferencia del paciente.[<a href="#cit/section_5.13">13</a>]</li></ul></div><p id="_382" tabindex="-1">En una revisi&#xF3;n de Cochrane, se concluy&#xF3; que los FEE proporcionan una reducci&#xF3;n cl&#xED;nicamente significativa del cansancio cr&#xF3;nico en los pacientes an&#xE9;micos que se someten a quimioterapia.[<a href="#cit/section_5.11">11</a>] No obstante, sobre la base de las inquietudes de seguridad se&#xF1;aladas por la FDA y en vista de los efectos secundarios identificados, en esta revisi&#xF3;n se concluy&#xF3;, m&#xE1;s adelante, que los FEE no se deben usar en la pr&#xE1;ctica cl&#xED;nica  para el cansancio cr&#xF3;nico.[<a href="#cit/section_5.11">11</a>] Los m&#xE9;dicos inician las conversaciones con los pacientes y sus familiares sobre los riesgos y los beneficios de los FEE.</p><p id="_383" tabindex="-1">En febrero de 2010, la FDA aprob&#xF3; y orden&#xF3; un programa de control de riesgo para informar a los profesionales de la salud  y a sus pacientes sobre el riesgo de los FEE.[<a href="#cit/section_5.12">12</a>,<a href="#cit/section_5.17">17</a>] Este programa comprende una gu&#xED;a espec&#xED;fica de medicamentos para los pacientes que, junto con la advertencia de salud p&#xFA;blica de la FDA,[<a href="#cit/section_5.18">18</a>], indica que los FEE no est&#xE1;n aprobados o indicados en el tratamiento del cansancio cr&#xF3;nico en los pacientes de c&#xE1;ncer.</p></section><section id="_81"><h3 id="_81_toc">Psicoestimulantes</h3><p id="_303" tabindex="-1">Una de las categor&#xED;as m&#xE1;s populares de intervenci&#xF3;n farmacol&#xF3;gica evaluadas para la fatiga o cansancio cr&#xF3;nico relacionado con el c&#xE1;ncer (CRF) son los psicoestimulantes (ver el <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_312">Cuadro 2</a>). Los psicoestimulantes son f&#xE1;rmacos que interact&#xFA;an con los neurotransmisores y receptores  del cerebro para aumentar la funci&#xF3;n de la corteza. Los diferentes tipos de psicoestimulantes trabajan a trav&#xE9;s de diversos mecanismos para producir actividades en el cerebro, compatibles con una mejor&#xED;a a corto plazo en los &#xED;ndices de energ&#xED;a y las actividades psicomotoras. Estos medicamentos tambi&#xE9;n podr&#xED;an mejorar el humor, la atenci&#xF3;n y la concentraci&#xF3;n en ciertas poblaciones. Entre los psicoestimulantes en el mercado se encuentran los siguientes:</p><div class="pdq-content-list"><ul id="_329"><li>Metilfenidato.</li><li>Dextroanfetamina.</li><li>Pemolina.</li><li>Modafinilo.</li><li>Armodafinilo.</li><li>Cafe&#xED;na sin receta m&#xE9;dica.</li></ul></div><p id="_304" tabindex="-1">El respaldo inicial a la hip&#xF3;tesis sobre si los psicoestimulantes podr&#xED;an mejorar el CRF surge principalmente de las vivencias anecd&#xF3;ticas cl&#xED;nicas. Estos medicamentos no est&#xE1;n aprobados por la Administraci&#xF3;n de F&#xE1;rmacos y Alimentos de los EE.UU. (FDA) para el tratamiento del CRF. Sin embargo, los datos probatorios preliminares recopilados de estudios controlados aleatorizados [<a href="#cit/section_5.19">19</a>-<a href="#cit/section_5.21">21</a>] indican que estos medicamentos podr&#xED;an ser &#xFA;tiles en una subpoblaci&#xF3;n de pacientes que presentan cansancio cr&#xF3;nico intenso.  Hay por lo menos siete ensayos cl&#xED;nicos aleatorizados que eval&#xFA;an los psicoestimulantes para el  CRF: seis con metilfenidato, y uno con modafinilo. Solo uno de estos ensayos aleatorizados [<a href="#cit/section_5.19">19</a>] mostr&#xF3; diferencias significativas entre el grupo bajo placebo y el grupo bajo metilfenidato  con relaci&#xF3;n al desenlace del cansancio cr&#xF3;nico.</p><p id="_306" tabindex="-1">El  &#xFA;nico estudio que mostr&#xF3;  una mejor&#xED;a significativa sobre el placebo para el CRF, us&#xF3; una mediana de dosis de 27,7 mg del is&#xF3;mero-D metilfenidato como estudio de intervenci&#xF3;n.[<a href="#cit/section_5.19">19</a>] La poblaci&#xF3;n beneficiada consisti&#xF3; en mujeres que completaron cursos de quimioterapia para mama o c&#xE1;ncer de ovario. El dise&#xF1;o del estudio incorpor&#xF3; una valoraci&#xF3;n cuantitativa con el efecto, de forma tal, que algunos pacientes que pudieron haberse beneficiado recibieron m&#xE1;s de 27,7 mg del f&#xE1;rmaco. M&#xE1;s a&#xFA;n, 11&#xA0;% de los participantes en este ensayo se retir&#xF3; debido a los efectos adversos, en comparaci&#xF3;n con 1&#xA0;% en el grupo bajo placebo. Por el contrario, un ensayo igual de numeroso, aleatorizado, controlado, asign&#xF3; a los pacientes de manera aleatorizada con enfermedad inicial o avanzada, ambos tanto dentro como fuera del tratamiento, a recibir 54 mg  de una preparaci&#xF3;n de metilfenidato de acci&#xF3;n prolongada que equival&#xED;a a 27 mg de is&#xF3;mero-D o un placebo; este ensayo no encontr&#xF3; diferencia alguna entre los dos grupos en ninguno de los resultados sobre cansancio cr&#xF3;nico.[<a href="#cit/section_5.22">22</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>] Hubo diferencias significativas entre grupos en cuanto al nerviosismo y la p&#xE9;rdida de apetito, donde el grupo bajo metilfenidato observ&#xF3; un puntaje m&#xE1;s precario en ambos efectos secundarios.</p><p id="_307" tabindex="-1">Los f&#xE1;rmacos m&#xE1;s recientes que promueven el llamado estado de alerta: modafinilo y armodafinilo  reci&#xE9;n se comienzan a estudiar en los casos de CRF. El modafinilo es una no anfetamina, de acci&#xF3;n central, estimulante del sistema nervioso central.[<a href="#cit/section_5.23">23</a>] El armodafinilo es el enanti&#xF3;mero-R del modafinilo y un agonista adrenoceptor &#x3B1;-1.[<a href="#cit/section_5.24">24</a>] El modafinilo y armodafinilo est&#xE1;n aprobados por la FDA para la narcolepsia, la apnea obstructiva del sue&#xF1;o y los trastornos por cambio de horario. Ninguno de estos f&#xE1;rmacos est&#xE1; aprobado por la FDA para el tratamiento del CRF. El uso de estos f&#xE1;rmacos tampoco est&#xE1; indicado para  ni&#xF1;os y adolescentes. El mecanismo de acci&#xF3;n del modafinilo y armodafinilo es diferente al de las anfetaminas, pero no logra entenderse el mecanismo mediante el que estos f&#xE1;rmacos mejoran la vigilia. Con base  en un par de ensayos pilotos abiertos prometedores, [<a href="#cit/section_5.25">25</a>,<a href="#cit/section_5.26">26</a>] un ensayo aleatorizado, controlado, numeroso evalu&#xF3; el modafinilo para el CRF mediante el uso de 200 mg contra placebo en m&#xE1;s de 850 pacientes que recib&#xED;an quimioterapia. Los pacientes ten&#xED;an que presentar un puntaje de cansancio de por lo menos 2 de 10 para ser admitidos en este estudio, el que no logr&#xF3; mostrar diferencias significativas entre grupos durante cuatro cursos de quimioterapia.[<a href="#cit/section_5.21">21</a>] Debido a que el armodafinilo es nuevo en el mercado, no se han publicado investigaciones sobre su posible incidencia en el CRF. Se necesita m&#xE1;s investigaci&#xF3;n para identificar si el modafinilo y el armodafinilo pueden aliviar el cansancio cr&#xF3;nico y la poblaci&#xF3;n de sobrevivientes de c&#xE1;ncer que se podr&#xED;a beneficiar de estos en mayor medida.</p><p id="_308" tabindex="-1">Hay datos exploratorios tanto con el modafinilo como con el  armodafinilo, que indican que los pacientes con un cansancio grave o enfermedad m&#xE1;s avanzada podr&#xED;an recibir un mayor beneficio de estos f&#xE1;rmacos.[<a href="#cit/section_5.21">21</a>,<a href="#cit/section_5.22">22</a>] Un estudio peque&#xF1;o (n = 13), aleatorizado, controlado con placebo [<a href="#cit/section_5.20">20</a>] que us&#xF3; metilfenidato (escalonado hasta 30 mg/d&#xED;a) como modo de intervenci&#xF3;n, no logr&#xF3; mostrar diferencia estad&#xED;stica alguna en las medidas de los primeros resultados, en el  puntaje total del Inventario Breve de Cansancio Cr&#xF3;nico (BFI) o la subescala sobre interferencia con la actividad. Sin embargo,  el grupo de metilfenidato mostr&#xF3; reducciones significativas en el puntaje  de la subescala de gravedad del BFI, en comparaci&#xF3;n con las disminuciones observadas en el grupo de placebo. La mediana en el puntaje de gravedad en al inicio fue de 6,5 para el grupo de metilfenidato y 5,7 para el grupo bajo placebo, al situar a estos pacientes en una categor&#xED;a del cansancio cr&#xF3;nico m&#xE1;s intenso. Un an&#xE1;lisis secundario del ensayo de fase lll en el que se evalu&#xF3; modafinilo contra placebo para el CRF, tambi&#xE9;n revel&#xF3; que los pacientes con cansancio cr&#xF3;nico m&#xE1;s intenso pudieron beneficiarse del primero.[<a href="#cit/section_5.21">21</a>] Se necesita m&#xE1;s investigaci&#xF3;n para evaluar si los psicoestimulantes resultan beneficiosos en los pacientes que presentan un  CRF m&#xE1;s grave.</p><p id="_310" tabindex="-1">Entre los efectos secundarios de los psicoestimulantes que se describen con mayor frecuencia est&#xE1;n los siguientes:[<a href="#cit/section_5.19">19</a>,<a href="#cit/section_5.21">21</a>,<a href="#cit/section_5.22">22</a>,<a href="#cit/section_5.27">27</a>,<a href="#cit/section_5.28">28</a>]</p><div class="pdq-content-list"><ul id="_364"><li> Insomnio.</li><li>Euforia.</li><li>Dolor de cabeza.</li><li>N&#xE1;useas.</li><li>Ansiedad.</li><li>Cambios de humor.</li></ul></div><p id="_365" tabindex="-1">Las dosis altas y el uso a largo plazo pueden ocasionar:</p><div class="pdq-content-list"><ul id="_366"><li> Anorexia.</li><li>Pesadillas.</li><li>Insomnio.</li><li>Euforia.</li><li>Paranoia.</li><li>Presuntas complicaciones cardiovasculares.</li></ul></div><p id="_367" tabindex="-1">  Los pacientes de c&#xE1;ncer presentan un mayor riesgo de complicaciones cardiovasculares, dependiendo del tipo de c&#xE1;ncer y su tratamiento (es decir, reg&#xED;menes quimioterap&#xE9;uticos cardiot&#xF3;xicos). Con el uso de psicoestimulantes, las complicaciones cardiovasculares pueden surgir a&#xFA;n en pacientes sin ning&#xFA;n factor de riesgo significativo.[<a href="#cit/section_5.20">20</a>] En un estudio que us&#xF3; metilfenidato como intervenci&#xF3;n para el tratamiento de CRF en pacientes con c&#xE1;ncer de pr&#xF3;stata, 6 de un total de 16 pacientes (27&#xA0;%)  en el grupo de metilfenidato tuvieron que abandonar el ensayo debido a un aumento en la presi&#xF3;n arterial y taquicardia. Es importante notar que ninguno de estos pacientes estaba bajo tratamiento con reg&#xED;menes quimioterap&#xE9;uticos cardiot&#xF3;xicos conocidos, como las antraciclinas.[<a href="#cit/section_5.20">20</a>] Resulta de suma importancia llevar una vigilancia cuidadosa y continua de ciertos par&#xE1;metros cardiovasculares (sobretodo presi&#xF3;n arterial y pulso) cuando se usan psicoestimulantes para el tratamiento del CRF. En ciertos casos complejos, se deber&#xED;a considerar el uso de servicios de cardiolog&#xED;a. Se piensa que los problemas cardiovasculares son menos riesgosos con el uso de modafinilo y armodafinilo. Es importante evaluar la respuesta del paciente   en t&#xE9;rminos de riesgo y beneficio y los efectos secundarios cuando estos f&#xE1;rmacos se usan en el tratamiento del CRF.</p><p id="_311" tabindex="-1">El prospecto del envase en todos los medicamentos estimulantes Schedule IV  tiene avisos en la envoltura que indican el riesgo de farmacodependencia o  psicodependencia. Adem&#xE1;s, los avisos en la envoltura de ciertos medicamentos estimulantes (productos de metilfenidato y dexmetilfenidato) indican el riesgo de episodios psic&#xF3;ticos.[<a href="#cit/section_5.27">27</a>] Otros medicamentos estimulantes (productos de anfetaminas, dextroanfetamina, dimesilato de lisdexanfetamina, metanfetamina y mezclas de sales de productos de la anfetamina) contienen avisos en los que se alerta a los m&#xE9;dicos que el uso incorrecto de estos medicamentos puede ocasionar efectos cardiovasculares adversos graves, como la muerte s&#xFA;bita.[<a href="#cit/section_5.29">29</a>]</p><table id="_312" class="table-default expandable-container"><caption>Cuadro 2.  Estimulantes de acci&#xF3;n central para los pacientes adultos de c&#xE1;ncer
            </caption><colgroup><col width="33.33%"><col width="33.33%"><col width="33.33%"></colgroup><THead><tr><th>F&#xE1;rmaco</th><th>Dosis</th><th>Efectos secundarios principales y comentarios</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="3">ABC = &#xE1;rea bajo la curva; IMAO = inhibidor de la monoamina oxidasa; IRSS = inhibidor selectivo de la reabsorci&#xF3;n de la serotonina.</td></tr></TFoot><tbody><tr><td rowspan="2">Dextroanfetamina (Dexedrina)</td><td>2,5 mg/d (inicio)</td><td rowspan="2">Programa II.  Potencial de interacci&#xF3;n importante con  citalopram y venlafaxina.</td></tr><tr><td>5&#x2013;30 mg/d in 2 a 3 dosis dividida</td></tr><tr><td rowspan="2">Metilfenidato (Ritalin)</td><td>2,5 mg/d (inicio)</td><td rowspan="2">Programa II. Las comidas grasosas pueden aumentar el   ABC. Concentraci&#xF3;n m&#xE1;xima 102 horas despu&#xE9;s de la ingesta. No usar con IMAO ya que puede precipitar una crisis hipertensiva. Los antidepresivos que aumentan la norepinefrina pueden causar un aumento en los efectos secundarios por anfetamina. El uso simult&#xE1;neo con los IRSS puede producir un aumento de las concentraciones de IRSS.</td></tr><tr><td>Valoraci&#xF3;n cuantitativa de hasta 54 mg/d (27 mg is&#xF3;mero-D)</td></tr><tr><td rowspan="2">Modafinilo (Provigil)</td><td>50&#x2013;100 mg (inicio)</td><td rowspan="2">Programa IV. Evite manejar u operar maquinarias hasta familiarizarse con los efectos. No se debe tomar antes de acostarse. La concentraci&#xF3;n m&#xE1;xima es de  2&#x2013;4 horas. Los alimentos disminuyen la absorci&#xF3;n alrededor de una hora, pero no afecta la biodisponibilidad. Disminuye la eficacia de las p&#xED;ldoras anticonceptivas.</td></tr><tr><td>100&#x2013;200 mg cada ma&#xF1;ana</td></tr><tr><td rowspan="2">Armodafinilo (Nuvigil)</td><td>50 mg (inicio)</td><td rowspan="2">Programa IV. Evite manejar u operar maquinarias hasta familiarizarse con los efectos. No se debe tomar antes de acostarse. La concentraci&#xF3;n m&#xE1;xima es de  2 horas si est&#xE1; en ayunas, disminuye hasta 4 horas si hay alguna ingesta pero la comida no afecta la biodisponibilidad. Disminuye la eficacia de las p&#xED;ldoras anticonceptivas.</td></tr><tr><td>25&#x2013;250 mg cada ma&#xF1;ana</td></tr></tbody></table><p id="_85" tabindex="-1">Sobre la base de una experiencia cl&#xED;nica limitada y el reconocimiento de la carencia de datos probatorios obtenidos en ensayos cl&#xED;nicos aleatorizados controlados, podr&#xED;a ser razonable considerar el uso de psicoestimulantes, tales como el metilfenidato o modafinilo para el tratamiento del cansancio cr&#xF3;nico intenso, en particular, por per&#xED;odos breves (un par de semanas) en pacientes con enfermedad avanzada. Cuando se toma en cuenta el uso de estos medicamentos, es importante obtener un consentimiento informado,  junto con una discusi&#xF3;n sobre riesgos, beneficios y alternativas. Es muy importante vigilar de forma continua los par&#xE1;metros cardiovasculares durante el uso de estos medicamentos, sobre todo en pacientes con antecedentes de problemas cardiovasculares y en aquellos bajo tratamiento con reg&#xED;menes quimioterap&#xE9;uticos cardiot&#xF3;xicos conocidos (por ejemplo, antraciclinas). En ciertos casos, podr&#xED;a ser necesario consultar un servicio de cardiolog&#xED;a. En estos momentos no se aconseja el uso de tratamiento estimulante a largo plazo debido a que la informaci&#xF3;n disponible sobre sus efectos negativos y sus beneficios es limitada.</p></section><section id="_384"><h3 id="_384_toc">Otras intervenciones farmacol&#xF3;gicas</h3><section id="_385"><h4 id="_385_toc">Bupropi&#xF3;n</h4><p id="_386" tabindex="-1">El bupropi&#xF3;n es un antidepresivo estimulante con un mecanismo de acci&#xF3;n principalmente dopamin&#xE9;rgico y noradren&#xE9;rgico. En datos preliminares de un estudio abierto peque&#xF1;o (N = 21), se indica que la forma de bupropi&#xF3;n de liberaci&#xF3;n prolongada (LP) tiene potencial de ser un f&#xE1;rmaco terap&#xE9;utico eficaz para tratar el CRF, con s&#xED;ntomas depresivos concomitantes o sin estos.[<a href="#cit/section_5.30">30</a>]  En este estudio no se presentaron convulsiones, un efecto secundario poco frecuente, pero grave de este f&#xE1;rmaco (la dosis m&#xE1;xima de bupropi&#xF3;n de LP que se us&#xF3; en este estudio fue de 300 mg).
            </p></section><section id="_387"><h4 id="_387_toc">Dexametasona</h4><p id="_388" tabindex="-1">La dexametasona es un f&#xE1;rmaco antinflamatorio potente que se ha evaluado recientemente para el tratamiento del cansancio cr&#xF3;nico en pacientes con c&#xE1;ncer en estadio avanzado. Se asign&#xF3; al azar a 84 pacientes a recibir 4 mg de dexametasona dos veces por d&#xED;a o placebo por 14 d&#xED;as. El criterio de valoraci&#xF3;n primario fue la disminuci&#xF3;n del cansancio cr&#xF3;nico desde el inicio hasta el d&#xED;a 15, seg&#xFA;n la medici&#xF3;n con la escala Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Los investigadores tambi&#xE9;n evaluaron la depresi&#xF3;n, la ansiedad y el sufrimiento por los s&#xED;ntomas. En el grupo que recibi&#xF3; dexametasona, los puntajes promedio de la escala FACIT-F (<em>P</em> = 0,005) y el d&#xED;a 15 (<em>P</em> = 0,008). El bienestar y el sufrimiento f&#xED;sicos tambi&#xE9;n fueron significativamente mejores en el grupo de dexametasona. El puntaje emocional y el sufrimiento general por los s&#xED;ntomas no presentaron una diferencia importante. Los episodios adversos, seg&#xFA;n la medici&#xF3;n de Common Terminology Criteria for Adverse Events, versi&#xF3;n 3.0, no fue diferente entre los grupos.</p><p id="_389" tabindex="-1">Una de las limitaciones de este estudi&#xF3; consisti&#xF3; en que solo dur&#xF3; dos semanas y es bien sabido que el uso de dexametasona a largo plazo est&#xE1; relacionado con efectos secundarios indeseados. Por lo tanto, es necesario realizar m&#xE1;s investigaci&#xF3;n sobre el riesgo versus el beneficio de tratar el cansancio cr&#xF3;nico con dexametasona por m&#xE1;s de dos semanas. Dado que el cansancio cr&#xF3;nico est&#xE1; relacionado con grados altos de inflamaci&#xF3;n, este estudio es valioso en cuanto a la evaluaci&#xF3;n de la dexametasona como f&#xE1;rmaco antinflamatorio para aliviar el cansancio cr&#xF3;nico.[<a href="#cit/section_5.31">31</a>] Los investigadores no evaluaron los biomarcadores inflamatorios; por ende, es necesario repetir la prueba del concepto de que la modificaci&#xF3;n de la inflamaci&#xF3;n puede reducir el cansancio cr&#xF3;nico.</p></section><section id="_390"><h4 id="_390_toc">Complementos alimentarios</h4><p id="_391" tabindex="-1">Los complementos alimentarios comprenden otras intervenciones farmacol&#xF3;gicas para el CRF, a menudo populares.</p><section id="_392"><h5 id="_392_toc">L-carnitina</h5><p id="_393" tabindex="-1">La L-carnitina es un complemento alimentario que se usa ampliamente y que se considera &#xFA;til en el tratamiento del CRF por su funci&#xF3;n en el metabolismo de energ&#xED;a celular y la capacidad de la carnitina para disminuir las citocinas proinflamatorias. Los datos prometedores de ensayos piloto condujeron a la realizaci&#xF3;n y la conclusi&#xF3;n de un estudio grande  (N = 376) de fase III en un &#xE1;mbito de grupo de cooperaci&#xF3;n de m&#xFA;ltiples sitios. Se asign&#xF3; al azar a participantes con cansancio cr&#xF3;nico moderado o intenso a recibir 10 g de levocarnitina o placebo por cuatro semanas. El criterio de valoraci&#xF3;n primario fue el cambio en el grado de cansancio cr&#xF3;nico promedio. A pesar de los aumentos en los valores promedio de L-carnitina,  no hubo diferencia estad&#xED;sticamente significativa en el cansancio cr&#xF3;nico de ambos grupos; ambos grupos notificaron una disminuci&#xF3;n del cansancio cr&#xF3;nico en trascurso del estudio.[<a href="#cit/section_5.32">32</a>]</p></section><section id="_394"><h5 id="_394_toc">Ginseng</h5><p id="_395" tabindex="-1">El ginseng, otro complemento popular que se usa para tratar la fatiga o  cansancio cr&#xF3;nico,  tambi&#xE9;n se ha sometido a evaluaci&#xF3;n en ensayos cl&#xED;nicos grandes de m&#xFA;ltiples sitios. Con base en un estudio prometedor de b&#xFA;squeda de dosis de fase II,[<a href="#cit/section_5.33">33</a>] se complet&#xF3; un ensayo aleatorizado controlado con placebo de fase III que cont&#xF3; con 364 pacientes de c&#xE1;ncer que se somet&#xED;an a tratamiento anticanceroso o que hab&#xED;an completado el tratamiento. Los participantes se asignaron al azar a recibir 2000 mg de ginseng estadounidense (en espec&#xED;fico, de Wisconsin)  en forma de ra&#xED;z molida en c&#xE1;psula o un placebo con la misma presentaci&#xF3;n. El criterio de valoraci&#xF3;n primario fue el cambio en los puntajes de cansancio cr&#xF3;nico seg&#xFA;n el Inventario multidimensional de los S&#xED;ntomas de Cansancio Cr&#xF3;nico (versi&#xF3;n corta).  A las cuatro semanas, el grupo que recibi&#xF3; ginseng present&#xF3; una tendencia hacia una mejor&#xED;a significativa, mientras que a las ocho semanas, hubo una diferencia cl&#xED;nicamente importante y significativa que favoreci&#xF3; el grupo de ginseng. No hubo efectos secundarios perceptibles a lo largo del ensayo ni entre los dos grupos ni en cada uno de estos.[<a href="#cit/section_5.34">34</a>]</p></section></section></section><section id="_89"><h3 id="_89_toc">Ejercicio</h3><p id="_90" tabindex="-1">Estudios  preliminares [<a href="#cit/section_5.35">35</a>-<a href="#cit/section_5.37">37</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>];[<a href="#cit/section_5.38">38</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: II</a>];[<a href="#cit/section_5.39">39</a>,<a href="#cit/section_5.40">40</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: III</a>];[<a href="#cit/section_5.41">41</a>,<a href="#cit/section_5.42">42</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: IV</a>] indican que el ejercicio
            (incluso caminar lenta o r&#xE1;pidamente) tiene posibles beneficios para las
            personas con c&#xE1;ncer. Entre los beneficios que se observaron en estos estudios
            cl&#xED;nicos se encuentran el aumento de la energ&#xED;a f&#xED;sica, el est&#xED;mulo
            del apetito o de la capacidad de funcionamiento, con mejor&#xED;as de
            la calidad de vida y en muchos aspectos del estado psicol&#xF3;gico (tales
            como mejor concepto de la vida, sentimiento de bienestar, aumento en el sentido de
            participaci&#xF3;n y habilidad para enfrentarse a los obst&#xE1;culos del c&#xE1;ncer y su
            tratamiento).  </p><p id="_317" tabindex="-1">Varios an&#xE1;lisis y directrices trazadas por el National Comprehensive Cancer Network delinean estudios numerosos que sustentan los efectos beneficiosos del ejercicio en el cansancio cr&#xF3;nico.[<a href="#cit/section_5.43">43</a>,<a href="#cit/section_5.44">44</a>] En ensayos cl&#xED;nicos aleatorizados, se observ&#xF3; una reducci&#xF3;n de 35&#xA0;% del cansancio y una mejor&#xED;a de 30&#xA0;% en la vitalidad, donde los efectos m&#xE1;s fuertes, en algunos estudios se muestran durante el tratamiento del c&#xE1;ncer, y en otros, despu&#xE9;s de este.[<a href="#cit/section_5.43">43</a>,<a href="#cit/section_5.45">45</a>] Muchos ensayos iniciales sobre programas de ejercicios se enfocaron en mujeres con c&#xE1;ncer de mama, pero estudios posteriores incluyeron hombres con c&#xE1;ncer de pr&#xF3;stata, mieloma m&#xFA;ltiple y c&#xE1;ncer colorrectal.[<a href="#cit/section_5.46">46</a>] Algunos estudios, como el siguiente mostraron debilidad metodol&#xF3;gica :[<a href="#cit/section_5.47">47</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>][<a href="#cit/section_5.48">48</a>]</p><div class="pdq-content-list"><ul id="_254"><li>Sesgo en la selecci&#xF3;n y muestras que no son representativas.</li><li>Inscripci&#xF3;n de pacientes en ensayos aleatorizados.</li><li>Poca constancia en los ejercicios, como forma de intervenci&#xF3;n.</li><li>Evaluaciones muy variadas de
            las variables de investigaci&#xF3;n y las medidas de los resultados.</li><li>Carencia de grupos de control adecuados.</li></ul></div><p id="_255" tabindex="-1">En dos ensayos aleatorizados controlados se demostr&#xF3; el beneficio del ejercicio para reducir la fatiga durante el tratamiento del c&#xE1;ncer de mama. En un ensayo de un programa de ejercicio aer&#xF3;bico de 12 semanas, no se observ&#xF3; una mejora significativa en la fatiga 3 y 6 meses despu&#xE9;s de cumplir con el mismo en comparaci&#xF3;n con la atenci&#xF3;n habitual.[<a href="#cit/section_5.49">49</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>]  En otro ensayo en el que se compar&#xF3; el ejercicio f&#xED;sico de baja y alta intensidad (30 minutos por d&#xED;a, 5 d&#xED;as por semana) con la atenci&#xF3;n habitual, se observ&#xF3; que el ejercicio de intensidad m&#xE1;s alta fue beneficioso para reducir la fatiga.[<a href="#cit/section_5.50">50</a>]  Entre las limitaciones de ambos estudios, se incluye la falta de un grupo de control con placebo y tasas bajas de participaci&#xF3;n.  La baja participaci&#xF3;n es un hallazgo habitual en los estudios de ejercicio con pacientes de c&#xE1;ncer; ello indica la necesidad de abordajes adaptados para superar las barreras. Los beneficios demostrados en estos estudios son reforzados por una revisi&#xF3;n de Cochrane de 56 estudios (con 4068 participantes), en la que se concluy&#xF3; que el ejercicio aer&#xF3;bico redujo significativamente la fatiga durante o despu&#xE9;s del tratamiento del c&#xE1;ncer.[<a href="#cit/section_5.51">51</a>]</p><p id="_256" tabindex="-1">En un estudio con 545 pacientes sobrevivientes de c&#xE1;ncer de mama, quienes en promedio ten&#xED;an seis meses posdiagn&#xF3;stico, el aumento de la actividad f&#xED;sica fue congruente tanto con una mejor&#xED;a del funcionamiento f&#xED;sico como con una reducci&#xF3;n del cansancio y el dolor corporal. La actividad f&#xED;sica previa al diagn&#xF3;stico se relacion&#xF3; con un mejor funcionamiento f&#xED;sico a los 39 meses pero, por lo general, no se relacion&#xF3; con los s&#xED;ntomas. El aumento en la actividad f&#xED;sica despu&#xE9;s del c&#xE1;ncer estuvo relacionado con menos cansancio y dolor, y mejor funcionamiento f&#xED;sico. Se encontr&#xF3; una relaci&#xF3;n significativamente positiva entre la actividad f&#xED;sica recreativa que va de moderada a vigorosa pero que no inclu&#xED;a los quehaceres dom&#xE9;sticos. Este estudio indica que los sobrevivientes de c&#xE1;ncer podr&#xED;an disminuir el cansancio y el dolor corporal y estar en mejores condiciones de llevar a cabo sus actividades cotidianas mediante el aumento en sus actividades f&#xED;sicas recreativas despu&#xE9;s del c&#xE1;ncer.[<a href="#cit/section_5.52">52</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: II</a>] </p><p id="_92" tabindex="-1">Es dif&#xED;cil estudiar el ejercicio en los pacientes de enfermedad avanzada o
            terminal, pero puede tener beneficios similares.  En un estudio se observ&#xF3; una mejor&#xED;a en la capacidad de los pacientes de c&#xE1;ncer avanzado que estaban
            bajo atenci&#xF3;n m&#xE9;dica en centros paliativos y que segu&#xED;an un r&#xE9;gimen de fisioterapia para
            realizar sus actividades cotidianas.[<a href="#cit/section_5.53">53</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: III</a>]   Adem&#xE1;s, se observ&#xF3; mayor
            satisfacci&#xF3;n con el r&#xE9;gimen fisioterap&#xE9;utico cuando aumentaba la
            participaci&#xF3;n familiar en el programa. En un estudio aleatorizado, se indic&#xF3; que el ejercicio mejor&#xF3; la fatiga durante el tratamiento del c&#xE1;ncer de mama.[<a href="#cit/section_5.54">54</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>] En un estudio de observaci&#xF3;n de pacientes con c&#xE1;ncer en estadio avanzado, se encontr&#xF3; que la fatiga fue menos grave en los pacientes que realizaban ejercicios f&#xED;sicos.[<a href="#cit/section_5.55">55</a>]</p><p id="_318" tabindex="-1">Cuando se educa a los pacientes sobre la actividad relacionada con el CRF, un objetivo importante que se debe tomar en cuenta, consiste en incluir de 3 a 5 horas semanales de actividad moderada: resulta sumamente importante que:</p><div class="pdq-content-list"><ul id="_319"><li>Los pacientes escojan un tipo de ejercicio que puedan disfrutar.</li><li>Los proveedores discutan estrategias espec&#xED;ficas de adopci&#xF3;n (tipo de ejercicio, hora del d&#xED;a, d&#xED;as de la semana, lugar para la actividad) a fin de lograr que el paciente haga de la actividad frecuente una realidad.</li></ul></div><p id="_320" tabindex="-1">Es necesario que el paciente comience con una actividad ligera por corto tiempo y vaya aumentando  su intensidad y duraci&#xF3;n. Los estudios confirmaron que esto se puede lograr de una forma inocua, tanto durante el tratamiento activo como una vez este finalice.[<a href="#cit/section_5.45">45</a>]</p><p id="_321" tabindex="-1">Entre las variantes de ejercicios que incluyen un componente mental y corporal, se encuentran las modalidades complementarias como el  qigong, tai chi y yoga, que son intervenciones populares bajo estudio por sus efectos en el CRF. Estas modalidades son &#xFA;nicas en el sentido que incorporan elementos cognoscitivos y espirituales mediante el movimiento, estiramiento y equilibrio. En un estudio m&#xE1;s o menos grande se evalu&#xF3; el uso m&#xE9;dico del qigong en el CRF en un grupo heterog&#xE9;neo de 162 pacientes que se somet&#xED;an a tratamiento contra el c&#xE1;ncer o que lo hab&#xED;an terminado.[<a href="#cit/section_5.56">56</a>] Este estudio inform&#xF3; sobre una mejor&#xED;a significativa del cansancio cr&#xF3;nico y varios otros aspectos de la calidad de vida en el grupo de intervenci&#xF3;n, en oposici&#xF3;n al tratamiento habitual.</p><p id="_322" tabindex="-1">La intervenci&#xF3;n qigong se llev&#xF3; a cabo en sesiones de grupo durante 90 minutos, dos veces por semana, para un total de 10 semanas, lo que constituy&#xF3; un total de 1800 minutos de tratamiento.  El grupo bajo tratamiento habitual no particip&#xF3; en reuniones de grupo o interacci&#xF3;n alguna con los proveedores. Resulta por lo tanto dif&#xED;cil determinar si los efectos del qigong contribuyeron de alguna manera o m&#xE1;s all&#xE1; de lo que lo hicieron los grupos interactivos no espec&#xED;ficos. Tambi&#xE9;n se desconoce durante cu&#xE1;nto tiempo deben permanecer los sobrevivientes practicando el qigong para retener los beneficios. No se presentaron efectos adversos  durante este estudio, de tal forma que aparte del tiempo y los recursos empleados, resulta dif&#xED;cil identificar alg&#xFA;n inconveniente en animar a los pacientes a que adopten este tipo de actividad.  Un punto fuerte muy importante en este estudio sobre el qigong, fue la obtenci&#xF3;n de suero  para medir los marcadores inflamatorios. Hacia el final de la d&#xE9;cima semana, la prote&#xED;na reactiva C  en los pacientes bajo el grupo m&#xE9;dico de qigong disminuy&#xF3; en 3,6 mg/L, mientras que los pacientes en el grupo de tratamiento habitual presentaron un aumento de este marcador de  19,57 mg/L. Esto constituy&#xF3; una diferencia estad&#xED;stica significativa.[<a href="#cit/section_5.56">56</a>]</p><p id="_396" tabindex="-1">En un segundo estudio peque&#xF1;o (N = 96) en el que se compar&#xF3; un grupo que practic&#xF3; qigong con un grupo de control en lista de espera, se evalu&#xF3; el cansancio cr&#xF3;nico seg&#xFA;n el BFI como resultado secundario, as&#xED; como la medici&#xF3;n biol&#xF3;gica del cortisol en saliva. En este estudio no se encontr&#xF3; diferencia significativa en el cansancio cr&#xF3;nico o en el cortisol entre los grupos. La dosis de intervenci&#xF3;n en este estudio, que incluy&#xF3; cinco sesiones de radioterapia de 40 minutos por seis semanas en mujeres con diagn&#xF3;stico de c&#xE1;ncer de mama, fue mucho m&#xE1;s baja que la dosis de intervenci&#xF3;n en el grupo m&#xE1;s grande descrito anteriormente.[<a href="#cit/section_5.57">57</a>]</p><p id="_397" tabindex="-1">La principal debilidad que limit&#xF3; la interpretaci&#xF3;n y la integraci&#xF3;n de ambos estudios, a pesar de los resultados diferentes, es que no se intent&#xF3; controlar la atenci&#xF3;n o cualquiera de los aspectos sociales de la intervenci&#xF3;n.</p></section><section id="_185"><h3 id="_185_toc">Terapia cognitivo-conductual</h3><p id="_186" tabindex="-1">La terapia cognitiva-conductual (TCC) se ha usado por mucho tiempo a fin de tratar una variedad de problemas psicofisiol&#xF3;gicos; la psicoterapia se enfoca en los pensamientos (cogniciones) y las conductas funcionales pertinentes para los problemas que se presentan.   En un ensayo cl&#xED;nico aleatorizado con 98 sobrevivientes de diferentes tipos de c&#xE1;ncer (grupo de intervenci&#xF3;n = 50, control en lista de espera = 48) que presentaban cansancio grave no atribuible a una causa som&#xE1;tica espec&#xED;fica se les proporcion&#xF3; TCC individual.[<a href="#cit/section_5.58">58</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>]   Esta se enfoc&#xF3; en el modelo &#xFA;nico de cada participante de los siguientes seis factores posibles que pueden servir para perpetuar su cansancio despu&#xE9;s del tratamiento del c&#xE1;ncer: </p><div class="pdq-content-list"><ul id="_323"><li>Manejo precario de la vivencia del c&#xE1;ncer.</li><li>Miedo a que la enfermedad recidive.</li><li>Insuficiencia cognoscitiva relacionada con el cansancio cr&#xF3;nico.</li><li>Irregularidad en los patrones de sue&#xF1;o.</li><li>Irregularidad en la actividad.</li><li>Apoyo social precario  o interacci&#xF3;n social negativa.</li></ul></div><p id="_324" tabindex="-1">El n&#xFA;mero de sesiones terap&#xE9;uticas vari&#xF3; de acuerdo al n&#xFA;mero de factores perpetuantes (rango: 5&#x2013;26 sesiones de una hora; mediana:  12,5 sesiones); los resultados muestran una disminuci&#xF3;n cl&#xED;nicamente significativa en la gravedad del cansancio y la disfunci&#xF3;n f&#xED;sica.</p></section><section id="_93"><h3 id="_93_toc">Actividad y descanso</h3><p id="_94" tabindex="-1">Los profesionales de la salud pueden asesorar a los pacientes de c&#xE1;ncer para
            formular un programa de actividad y descanso que, con base en la
            evaluaci&#xF3;n de su modalidad de cansancio, les permitan utilizar la
            energ&#xED;a mucho mejor. Cualquier cambio en la rutina diaria requiere un consumo adicional de
            energ&#xED;a.  Se aconseja a los individuos con c&#xE1;ncer que establezcan
            prioridades y mantengan un horario razonable.  Los profesionales de la salud
            pueden ayudar a los pacientes al suministrarles informaci&#xF3;n sobre los servicios
            complementarios disponibles para ayudarles con sus actividades y
            responsabilidades diarias.  Una consulta de tratamiento ocupacional puede ser &#xFA;til
            en la evaluaci&#xF3;n de m&#xE9;todos de conservaci&#xF3;n de energ&#xED;a. Unos buenos h&#xE1;bitos de
            sue&#xF1;o, que incluyan evitar acostarse en la cama a menos que no sea para
            dormir, reducir las siestas a no m&#xE1;s de una hora, evitar los ruidos que
            distraigan (como el de la radio o la televisi&#xF3;n) al dormir, puede ayudar a
            mejorar el sue&#xF1;o y los ciclos de actividad.</p></section><section id="_95"><h3 id="_95_toc">Educaci&#xF3;n del paciente</h3><p id="_97" tabindex="-1">Informar a los pacientes acerca del riesgo de fatiga y educarlos con estrategias para reducir la fatiga son complementos valiosos de otras estrategias de manejo consideradas en este sumario. Sin embargo, en una revisi&#xF3;n Cochrane sobre intervenciones educativas para la fatiga relacionada con el c&#xE1;ncer en adultos, se  advierte que dichas intervenciones deben ser parte de un abordaje m&#xE1;s amplio para controlar la fatiga.[<a href="#cit/section_5.59">59</a>]</p><p id="_98" tabindex="-1">Entre las t&#xE9;cnicas espec&#xED;ficas para el control del cansancio se encuentran las
            siguientes:</p><div class="pdq-content-list"><ul id="_135"><li> Diferenciar entre el cansancio y la depresi&#xF3;n.</li><li>Evaluar la presencia de correlaciones corregibles o causas del cansancio (por ejemplo, deshidrataci&#xF3;n, desequilibrio electrol&#xED;tico, disnea y anemia).</li><li>Evaluar los patrones de descanso y actividad durante el d&#xED;a, al igual que
            durante un per&#xED;odo de tiempo.</li><li>Determinar el grado de cansancio de atenci&#xF3;n y estimular el uso de un plan
            de actividades que restaure la atenci&#xF3;n (tales como caminar, cuidar el jard&#xED;n
            o mirar los p&#xE1;jaros).</li><li>Orientar al paciente con anticipaci&#xF3;n sobre la posibilidad de que se presente cansancio y sobre la modalidad del  cansancio que se relaciona con cada tratamiento en
            particular.</li><li>Estimular actividades y programas planificados de ejercicio seg&#xFA;n las
            limitaciones individuales, y hacer que los objetivos sean realistas, al tener
            presente el estado de la enfermedad y los reg&#xED;menes de tratamiento.</li><li>Educar a los individuos y las familias acerca del cansancio relacionado con
            el c&#xE1;ncer y su tratamiento.</li><li>Ayudar a que las personas con c&#xE1;ncer y sus familias identifiquen las
            actividades que producen el cansancio y adopten estrategias espec&#xED;ficas para
            modificarlas.</li><li>Sugerir cambios individualizados del medio ambiente o de actividad que
            puedan contrarrestar el cansancio.</li><li>Mantener la hidrataci&#xF3;n y nutrici&#xF3;n adecuadas.</li><li>Recomendar fisioterapia para las personas con d&#xE9;ficit
            neuromusculoesquel&#xE9;tico.</li><li>Recomendar terapia respiratoria a las personas cuya disnea sea un factor
            que contribuya al cansancio.</li><li>Programar las actividades cotidianas importantes durante las horas de menos
            cansancio y eliminar las actividades no esenciales que produzcan tensi&#xF3;n nerviosa.</li><li>Atender el efecto negativo de los factores psicol&#xF3;gicos y sociales que
            producen tensi&#xF3;n nerviosa y pensar c&#xF3;mo evitarlos o modificarlos.</li><li>Evaluar la eficacia de las intervenciones para el cansancio de manera regular y
            sistem&#xE1;tica.[<a href="#cit/section_5.60">60</a>]</li></ul></div></section><p id="_149" tabindex="-1">En un ensayo controlado, con pacientes que dieron cuenta de s&#xED;ntomas tales como grupos de dolores y cansancio mientras recib&#xED;an quimioterapia, una intervenci&#xF3;n conductual de enfermer&#xED;a produjo mejor&#xED;as en la calidad de vida y disminuy&#xF3; la carga de s&#xED;ntomas en relaci&#xF3;n con el cuidado en general.[<a href="#cit/section_5.61">61</a>,<a href="#cit/section_5.62">62</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: I</a>]  Estos interesantes resultados necesitan de una mayor exploraci&#xF3;n en otras poblaciones de pacientes que no sean mujeres con c&#xE1;nceres ginecol&#xF3;gicos o de mama.</p><p id="_325" tabindex="-1">En la medida en que los investigadores y m&#xE9;dicos aprenden sobre el dolor, los conceptos falsos y la carencia de conocimientos podr&#xED;an constituir una barrera importante, por parte de los  pacientes y los proveedores, para llegar a una evaluaci&#xF3;n y tratamiento exitosos. Un estudio cuasiexperimental prob&#xF3; un enfoque educacional multisist&#xE9;mico para mejorar el manejo  tanto el dolor como del cansancio cr&#xF3;nico.[<a href="#cit/section_5.63">63</a>] y consisti&#xF3; en lo siguiente:</p><div class="pdq-content-list"><ul id="_326"><li>Educaci&#xF3;n y evaluaci&#xF3;n de los pacientes en cuanto al manejo del dolor y el cansancio cr&#xF3;nico mediante llamadas telef&#xF3;nicas cada dos semanas durante tres meses.</li><li>Educaci&#xF3;n del proveedor sobre la evaluaci&#xF3;n y tratamiento del dolor y el cansancio cr&#xF3;nico, incluido un bolet&#xED;n mensual.</li><li>Esfuerzos para relacionarse con la comisi&#xF3;n de asesor&#xED;a interna.</li><li>Direcci&#xF3;n de los esfuerzos hacia los enfermeros dedicados a la investigaci&#xF3;n con el objetivo de que deriven a los pacientes a los servicios de cuidados de apoyo tan pronto como sea posible.</li></ul></div><p id="_327" tabindex="-1">Durante un per&#xED;odo de tres meses, la intervenci&#xF3;n educativa dio como resultado un aumento en los conocimientos y una disminuci&#xF3;n en las barreras relacionadas con el manejo del dolor y el cansancio cr&#xF3;nico. Es importante notar que entre las barreras clave relacionadas con el manejo del cansancio cr&#xF3;nico se encuentran las siguientes creencias:[<a href="#cit/section_5.63">63</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: II</a>] </p><div class="pdq-content-list"><ul id="_328"><li>El cansancio cr&#xF3;nico es inevitable.</li><li>El cansancio cr&#xF3;nico puede indicar el empeoramiento de la enfermedad.</li><li>El tratamiento del c&#xE1;ncer es m&#xE1;s importante que el tratamiento del cansancio cr&#xF3;nico.</li><li>La informaci&#xF3;n sobre el cansancio cr&#xF3;nico puede hacer que al paciente se le perciba como un quejumbroso.</li></ul></div><section id="_TrialSearch_78_sid_5"><h3 id="_TrialSearch_78_sid_5_toc">Ensayos cl&#xED;nicos en curso</h3><p id="_TrialSearch_78_25" tabindex="-1">Realizar una <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">b&#xFA;squeda avanzada</a> en ingl&#xE9;s de los ensayos cl&#xED;nicos sobre c&#xE1;ncer auspiciados por el NCI que ahora aceptan pacientes. La b&#xFA;squeda se puede simplificar por ubicaci&#xF3;n del ensayo, tipo de tratamiento, nombre del f&#xE1;rmaco y otros criterios. Tambi&#xE9;n se dispone de <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">informaci&#xF3;n general</a> sobre los ensayos cl&#xED;nicos. </p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_5.1">Arendt J, Borbely AA, Franey C, et al.: The effects of chronic, small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study. Neurosci Lett 45 (3): 317-21, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6728321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6728321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060566&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Gibson H, Edwards RH: Muscular exercise and fatigue. Sports Med 2 (2): 120-32, 1985 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847097&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3847097&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Hart LK: Fatigue in the patient with multiple sclerosis. Res Nurs Health  1 (4): 147-57, 1978.</li><li id="section_5.5">de Raaf PJ, de Klerk C, Timman R, et al.: Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial. J Clin Oncol 31 (6): 716-23, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23284036&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23284036&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Armitage JO: Management of anemia in patients with cancer. Clinical Oncology Updates  1: 1-12, 1998.</li><li id="section_5.7">Kotasek D, Steger G, Faught W, et al.: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39 (14): 2026-34, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12957457&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12957457&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Hedenus M, Adriansson M, San Miguel J, et al.: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122 (3): 394-403, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12877666&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12877666&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Demetri GD, Kris M, Wade J, et al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16 (10): 3412-25, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779721&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Osterborg A, Brandberg Y, Molostova V, et al.: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20 (10): 2486-94, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12011126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12011126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Minton O, Richardson A, Sharpe M, et al.: Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 7: CD006704, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20614448&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20614448&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">U.S. Food and Drug Administration: FDA Drug Safety Communication: Erythropoiesis-stimulating Agents (ESAs): Procrit, Epogen and Aranesp. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm" title="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.13">Rizzo JD, Brouwers M, Hurley P, et al.: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28 (33): 4996-5010, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20975064&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20975064&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Medication Guide: Aranesp (darbepoetin alfa). Thousand Oaks, Calif: Amgen Inc., 2012. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/ucm085918.pdf" title="https://www.fda.gov/downloads/Drugs/DrugSafety/ucm085918.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.15">Procrit Label and Epogen Label. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf" title="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.16">Aranesp (darbepoetin alfa) Label. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf" title="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.17">U.S. Food and Drug Administration: FDA announces new safety plan for agents used to treat chemotherapy-related anemia. Silver Spring, Md: U.S. Food and Drug Administration, 2010.</li><li id="section_5.18">U.S. Food and Drug Administration: Information on Erythropoiesis-stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). Silver Spring, Md: Food and Drug Administration, 2010. <a href="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm" title="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.19">Lower EE, Fleishman S, Cooper A, et al.: Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38 (5): 650-62, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19896571&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19896571&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Roth AJ, Nelson C, Rosenfeld B, et al.: Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 116 (21): 5102-10, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20665492&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20665492&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Jean-Pierre P, Morrow GR, Roscoe JA, et al.: A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116 (14): 3513-20, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20564068&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20564068&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.22">Moraska AR, Sood A, Dakhil SR, et al.: Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 28 (23): 3673-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20625123&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20625123&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.23">Medication Guide: PROVIGIL (modafinil) Tablets. North Wales, Pa: Teva Pharmaceuticals USA, Inc., 2015. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf" title="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.24">Medication Guide: NUVIGIL (armodafinil) Tablets. North Wales, Pa: Teva Pharmaceuticals USA, Inc., 2015. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231717.pdf" title="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231717.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.25">Blackhall L, Petroni G, Shu J, et al.: A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 12 (5): 433-9, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19416039&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19416039&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.26">Spathis A, Dhillan R, Booden D, et al.: Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 23 (4): 325-31, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19270033&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19270033&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.27">CONCERTA (methylphenidate HCl) Extended-release Tablets. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2013. <a href="https://www.janssenmd.com/pdf/concerta/concerta_pi.pdf" title="https://www.janssenmd.com/pdf/concerta/concerta_pi.pdf">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.28">Prommer E: Modafinil: is it ready for prime time? J Opioid Manag 2 (3): 130-6, 2006 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17319446&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17319446&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.29">ADDERALL XR (mixed salts of a single-entity amphetamine), CII. Lexington, Mass: Shire US Inc., 2015. <a href="http://www.shirecontent.com/PI/PDFS/AdderallXR_USA_ENG.PDF" title="http://www.shirecontent.com/PI/PDFS/AdderallXR_USA_ENG.PDF">Available online</a>. Last accessed January 4, 2018.</li><li id="section_5.30">Moss EL, Simpson JS, Pelletier G, et al.: An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 15 (3): 259-67, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16041840&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16041840&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.31">Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al.: Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31 (25): 3076-82, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23897970&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23897970&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.32">Cruciani RA, Zhang JJ, Manola J, et al.: L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol 30 (31): 3864-9, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22987089&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22987089&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.33">Barton DL, Soori GS, Bauer BA, et al.: Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18 (2): 179-87, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19415341&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19415341&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.34">Barton DL, Liu H, Dakhil SR, et al.: Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105 (16): 1230-8, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23853057&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23853057&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.35">Segal R, Evans W, Johnson D, et al.: Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 19 (3): 657-65, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157015&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157015&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.36">Milne HM, Wallman KE, Gordon S, et al.: Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 108 (2): 279-88, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17530428&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17530428&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.37">Courneya KS, Friedenreich CM, Sela RA, et al.: The group psychotherapy and home-based physical exercise (group-hope) trial in cancer survivors: physical fitness and quality of life outcomes. Psychooncology 12 (4): 357-74, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12748973&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12748973&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.38">Schneider CM, Hsieh CC, Sprod LK, et al.: Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. Cancer 110 (4): 918-25, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17582616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17582616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.39">Friendenreich CM, Courneya KS: Exercise as rehabilitation for cancer patients. Clin J Sport Med 6 (4): 237-44, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8894336&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8894336&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.40">Mustian KM, Griggs JJ, Morrow GR, et al.: Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Support Care Cancer 14 (7): 732-41, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16482444&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16482444&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.41">Winningham ML: Walking program for people with cancer. Getting started. Cancer Nurs 14 (5): 270-6, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1933847&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1933847&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.42">Galv&#xE3;o DA, Newton RU: Review of exercise intervention studies in cancer patients. J Clin Oncol 23 (4): 899-909, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15681536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15681536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.43">Cramp F, Daniel J: Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev  (2): CD006145, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425939&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425939&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.44">Kangas M, Bovbjerg DH, Montgomery GH: Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 134 (5): 700-41, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18729569&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18729569&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.45">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20870636&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.46">Jacobsen PB, Donovan KA, Vadaparampil ST, et al.: Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 26 (6): 660-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18020836&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18020836&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.47">Pickett M, Mock V, Ropka ME, et al.: Adherence to moderate-intensity exercise during breast cancer therapy. Cancer Pract 10 (6): 284-92, 2002 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12406050&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12406050&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.48">Carayol M, Delpierre C, Bernard P, et al.: Population-, intervention- and methodology-related characteristics of clinical trials impact exercise efficacy during adjuvant therapy for breast cancer: a meta-regression analysis. Psychooncology 24 (7): 737-47, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25483860&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25483860&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.49">Mutrie N, Campbell AM, Whyte F, et al.: Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ 334 (7592): 517, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17307761&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17307761&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.50">van Waart H, Stuiver MM, van Harten WH, et al.: Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. J Clin Oncol 33 (17): 1918-27, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25918291&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25918291&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.51">Cramp F, Byron-Daniel J: Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11: CD006145, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23152233&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23152233&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.52">Alfano CM, Smith AW, Irwin ML, et al.: Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. J Cancer Surviv 1 (2): 116-28, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18648952&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18648952&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.53">Yoshioka H: Rehabilitation for the terminal cancer patient. Am J Phys Med Rehabil 73 (3): 199-206, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7515247&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7515247&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.54">Mock V, Frangakis C, Davidson NE, et al.: Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology 14 (6): 464-77, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15484202&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15484202&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.55">Peters ME, Goedendorp MM, Verhagen SA, et al.: Exploring the contribution of psychosocial factors to fatigue in patients with advanced incurable cancer. Psychooncology 23 (7): 773-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24458595&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.56">Oh B, Butow P, Mullan B, et al.: Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Ann Oncol 21 (3): 608-14, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19880433&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19880433&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.57">Chen Z, Meng Z, Milbury K, et al.: Qigong improves quality of life in women undergoing radiotherapy for breast cancer: results of a randomized controlled trial. Cancer 119 (9): 1690-8, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23355182&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23355182&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.58">Gielissen MF, Verhagen S, Witjes F, et al.: Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 24 (30): 4882-7, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17050873&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17050873&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.59">Bennett S, Pigott A, Beller EM, et al.: Educational interventions for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 11: CD008144, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27883365&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27883365&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.60">Winningham ML, Nail LM, Burke MB, et al.: Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 21 (1): 23-36, 1994 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8139999&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.61">Given B, Given CW, McCorkle R, et al.: Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29 (6): 949-56, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12096292&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.62">Ream E, Richardson A, Alexander-Dann C: Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage 31 (2): 148-61, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488348&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488348&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.63">Borneman T, Koczywas M, Sun VC, et al.: Reducing patient barriers to pain and fatigue management. J Pain Symptom Manage 39 (3): 486-501, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303026&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20303026&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _114
      field_pdq_section_title:
        - format: plain_text
          value: 'Consideraciones posteriores al tratamiento'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_114" class="pdq-sections"><p id="_115" tabindex="-1">Esta secci&#xF3;n de postratamiento se cre&#xF3; en especial para aquellos
            individuos con c&#xE1;ncer que no recibieron tratamiento antineopl&#xE1;sico
            durante seis meses. Hay dos razones por las que se cre&#xF3; una secci&#xF3;n separada:
            en primer lugar, la etiolog&#xED;a del problema es diferente para el individuo que se somete a  tratamiento, que para aquellos que no lo hacen;  en
            segundo lugar, las estrategias de intervenci&#xF3;n y la informaci&#xF3;n se pueden
            adaptar mejor de manera que puedan satisfacer los requisitos de ambas
            poblaciones.
            </p><p id="_116" tabindex="-1">El cansancio es un problema distinto para los individuos despu&#xE9;s de terminar el tratamiento. Se propusieron muchas teor&#xED;as para explicar la
            etiolog&#xED;a del cansancio que presenta el paciente bajo tratamiento y para explicar
            el efecto de ese tratamiento en su calidad de vida. Pero muchas de estas
            teor&#xED;as no se aplican a la poblaci&#xF3;n que concluy&#xF3; su tratamiento.  No
            obstante, el cansancio contin&#xFA;a siendo un asunto importante para los individuos
            que ya no se someten a tratamiento y que no presentan enfermedad.
            </p><p id="_117" tabindex="-1">Hay indicios de que el cansancio afecta la calidad de vida de las personas sobrevivientes de c&#xE1;ncer de un modo significativo. En el entorno m&#xE9;dico en
            general, la vivencia del cansancio cr&#xF3;nico en los sobrevivientes de c&#xE1;ncer es
            similar a la que presentan los pacientes con s&#xED;ndrome de cansancio cr&#xF3;nico.[<a href="#cit/section_6.1">1</a>] Se hicieron pocos estudios que indiquen las repercusiones del cansancio cr&#xF3;nico
            en la calidad de vida; algunos ejemplos se incluyen a continuaci&#xF3;n:
            </p><div class="pdq-content-list"><ul id="_136"><li>Un 50&#xA0;% de los 29 sobrevivientes de c&#xE1;ncer que se sometieron a trasplantes de
            m&#xE9;dula &#xF3;sea expresaron sentir cansancio moderado o grave por m&#xE1;s de un a&#xF1;o despu&#xE9;s
            del trasplante. El cansancio fue uno de los tres asuntos m&#xE1;s negativos
            que se estudiaron y tuvo mayor repercusi&#xF3;n en la calidad de vida que cualquier otro
            problema f&#xED;sico.[<a href="#cit/section_6.2">2</a>]</li><li>Un 56&#xA0;% de las 125 personas con trasplante de m&#xE9;dula &#xF3;sea mencionaron tener
            cansancio constante entre 6 y 18 a&#xF1;os despu&#xE9;s del trasplante.[<a href="#cit/section_6.3">3</a>]</li><li>En 687 sobrevivientes de varios tipos de c&#xE1;ncer evaluados despu&#xE9;s del
            tratamiento para estudiar asuntos relacionados con la calidad de vida, el
            cansancio fue uno de los tres asuntos que afectaban la calidad de vida de manera
            m&#xE1;s negativa.[<a href="#cit/section_6.4">4</a>]</li><li>Cerca de 90 pacientes con diagn&#xF3;stico de linfoma de Hodgkin o de linfoma
            no Hodgkin, 30 pacientes manifestaron tener falta de energ&#xED;a a los 32 meses en
            promedio despu&#xE9;s del diagn&#xF3;stico.[<a href="#cit/section_6.5">5</a>]</li><li>Un 37&#xA0;% de 403 individuos con el linfoma de Hodgkin dijeron que su grado de
            energ&#xED;a no regres&#xF3; a niveles satisfactorios aun nueve a&#xF1;os despu&#xE9;s del
            tratamiento, como mediana.[<a href="#cit/section_6.6">6</a>]</li><li>Un 26&#xA0;% de los sobrevivientes de linfoma de Hodgkin sufren de cansancio
            persistente a los seis meses despu&#xE9;s del tratamiento, de los cuales un 50&#xA0;% se relaciona con problemas
            psicol&#xF3;gicos. El aumento de la edad y la ausencia de s&#xED;ntomas psicol&#xF3;gicos
            previos no predijeron casos de cansancio cr&#xF3;nico.[<a href="#cit/section_6.7">7</a>]</li><li> Un 75&#xA0;% de 162 mujeres tratadas con radiaci&#xF3;n para el c&#xE1;ncer de mama y 61&#xA0;%
            de 173 mujeres tratadas con quimioterapia para el mismo c&#xE1;ncer describieron
            tener una disminuci&#xF3;n de energ&#xED;a de 2 a 10 a&#xF1;os despu&#xE9;s de concluir el
            tratamiento.[<a href="#cit/section_6.8">8</a>]  En una encuesta cruzada llevada a cabo por separado entre mujeres que completaron su tratamiento para el c&#xE1;ncer de mama en una mediana de 29 meses previos a la encuesta, 38&#xA0;% presentaron cansancio grave, en comparaci&#xF3;n con el 11&#xA0;% de un grupo de control igual.[<a href="#cit/section_6.9">9</a>] </li><li>Se inform&#xF3; de cansancio cr&#xF3;nico en mujeres sobrevivientes de trasplante aut&#xF3;geno de m&#xE9;dula
            &#xF3;sea   y dosis altas  de tratamiento
            quimioterap&#xE9;utico de linfomas de 4 a 10 a&#xF1;os despu&#xE9;s del tratamiento.[<a href="#cit/section_6.10">10</a>]</li><li>Casi un tercio de las sobrevivientes de c&#xE1;ncer de mama, diez a&#xF1;os despu&#xE9;s del tratamiento, manifestaron sentir cansancio cr&#xF3;nico.[<a href="#cit/section_6.11">11</a>]</li></ul></div><p id="_126" tabindex="-1">A pesar de que muchos estudios documentaron la incidencia de cansancio en
            aquellos que ya no se someten a tratamiento del c&#xE1;ncer, se desconoce el mecanismo espec&#xED;fico
            del cansancio.  Debido a que este es un problema
            multifac&#xE9;tico, es dif&#xED;cil determinar su etiolog&#xED;a.</p><p id="_127" tabindex="-1">La informaci&#xF3;n disponible sobre el cansancio en  los ni&#xF1;os sobrevivientes de c&#xE1;ncer procede de la literatura m&#xE9;dica, que describe los efectos psicol&#xF3;gicos y
            cognoscitivos posteriores al tratamiento. En un estudio, los resultados
            cognoscitivos se evaluaron en ni&#xF1;os, 3 a 4 a&#xF1;os despu&#xE9;s de diagnostic&#xE1;rseles
            c&#xE1;ncer de cerebro. El cansancio fue un factor contribuyente al desempe&#xF1;o escolar
            precario.[<a href="#cit/section_6.12">12</a>]
            </p><p id="_128" tabindex="-1">En otro estudio, se evalu&#xF3; a los sobrevivientes de leucemia linfobl&#xE1;stica aguda para determinar su d&#xE9;ficit cognoscitivo posterior al tratamiento y se
            observ&#xF3; que presentaban un efecto t&#xED;pico del cansancio. Se cree que este fue un
            factor en la variaci&#xF3;n de los resultados de sus pruebas.[<a href="#cit/section_6.13">13</a>] Anecd&#xF3;ticamente,
            los individuos que recibieron irradiaci&#xF3;n al t&#xF3;rax e irradiaci&#xF3;n total al cuerpo, se quejan de cansancio y muestran mayor necesidad de dormir.
            </p><p id="_129" tabindex="-1">Las personas tratadas con &#xE9;xito contra el c&#xE1;ncer corren el
            riesgo de presentar una serie de complicaciones espec&#xED;ficas en los &#xF3;rganos que
            son secundarios a su tratamiento.[<a href="#cit/section_6.14">14</a>] La fatiga que se presenta en la poblaci&#xF3;n
            despu&#xE9;s del tratamiento, enfatiza la importancia de seguir atendiendo a estos
            pacientes.  La persistencia de la fatiga despu&#xE9;s del tratamiento exige que
            este se eval&#xFA;e con cuidado a fin de descartar las condiciones fisiol&#xF3;gicas
            contribuyentes.
            </p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_6.1">Servaes P, van der Werf S, Prins J, et al.: Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 9 (1): 11-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147137&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147137&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Whedon M, Stearns D, Mills LE: Quality of life of long-term adult survivors of autologous bone marrow transplantation. Oncol Nurs Forum 22 (10): 1527-35; discussion 1535-7, 1995 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8577621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8577621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Bush NE, Haberman M, Donaldson G, et al.: Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med 40 (4): 479-90, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7725122&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7725122&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Ferrell BR, Grant M, Dean GE, et al.: Bone tired: the experience of fatigue and its impact on quality of life. Oncol Nurs Forum  23 (10): 1539-47, 1996.</li><li id="section_6.5">Devlen J, Maguire P, Phillips P, et al.: Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 295 (6604): 955-7, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3119124&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3119124&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Fobair P, Hoppe RT, Bloom J, et al.: Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4 (5): 805-14, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3486256&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Loge JH, Abrahamsen AF, Ekeberg, et al.: Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J Pain Symptom Manage 19 (2): 91-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10699536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10699536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Berglund G, Bolund C, Fornander T, et al.: Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 27 (9): 1075-81, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1683557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1683557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Servaes P, Verhagen S, Bleijenberg G: Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 13 (4): 589-98, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12056710&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12056710&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">Knobel H, Loge JH, Nord&#xF8;y T, et al.: High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage 19 (6): 446-56, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10908825&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10908825&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16400678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Radcliffe J, Packer RJ, Atkins TE, et al.: Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 32 (4): 551-4, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1456739&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1456739&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Brouwers P: Neuropsychological abilities of long-term survivors of childhood leukemia. In: Aaronsen NK, Beckmann J, eds.: The Quality of Life of Cancer Patients. New York: Raven Press, 1987, pp 153-65.</li><li id="section_6.14">Baker F, Denniston M, Smith T, et al.: Adult cancer survivors: how are they faring? Cancer 104 (11 Suppl): 2565-76, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16258929&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _140
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (07/20/2017)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_140" class="pdq-sections"><p id="_210" tabindex="-1">Los sumarios del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci&#xF3;n.  Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_407" tabindex="-1"><strong><a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_12">Factores contribuyentes</a></strong></p><p id="_408" tabindex="-1">Se agreg&#xF3; <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_280">texto</a> para indicar que factores similares a los observados en pacientes de c&#xE1;ncer en estadio temprano tambi&#xE9;n contribuyen a la fatiga en pacientes de c&#xE1;ncer en estadio avanzado e incurable (se cit&#xF3; a Peters et al. como referencia 48).</p><p id="_409" tabindex="-1"><strong><a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_78">Intervenci&#xF3;n</a></strong></p><p id="_410" tabindex="-1">Se agreg&#xF3; a <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_317">Carayol et al.</a> como referencia 48.</p><p id="_411" tabindex="-1">Se revis&#xF3; el <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_255">texto</a> sobre los beneficios de la reducci&#xF3;n de la fatiga durante el tratamiento del c&#xE1;ncer (se cit&#xF3; a Mutrie et al. como referencia 49, a van Waart  et al. como referencia 50 y a Cramp et al. como referencia 51).</p><p id="_412" tabindex="-1">Se agreg&#xF3; <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_92">texto</a> para indicar que, en un estudio de observaci&#xF3;n de pacientes con c&#xE1;ncer en estadio avanzado, se encontr&#xF3; que la fatiga fue menos grave en los pacientes que realizaban ejercicios f&#xED;sicos (se cit&#xF3; a Peters et al. como referencia 55).</p><p id="_413" tabindex="-1">Se revis&#xF3; el <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_97">texto</a> acerca de la funci&#xF3;n de la educaci&#xF3;n del paciente para controlar la fatiga (se cit&#xF3; a Bennett et al. como referencia 59).</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/cuidados-medicos-apoyo" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/cuidados-medicos-apoyo">Consejo editorial  del PDQ sobre los cuidados m&#xE9;dicos de apoyo y los cuidados paliativos</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre la fisiopatolog&#xED;a y el tratamiento de la fatiga. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/cuidados-medicos-apoyo" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/cuidados-medicos-apoyo">Consejo editorial  del PDQ sobre los cuidados m&#xE9;dicos de apoyo y los cuidados paliativos</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="" tabindex="-1">Los revisores principales del sumario sobre Fatiga son:</p><div class="pdq-content-list"><ul id=""><li>Andrea Barsevick, PhD (Thomas Jefferson University)</li><li>Joseph Bubalo, PharmD, BCPS, BCOP (Oregon Health and Science University Hospital)</li><li>Esme Finlay, MD (University of New Mexico)</li><li>Heather C. Justice, MSPAP, PA-C (Milligan College)</li><li>Jayesh Kamath, MD, PhD (University of Connecticut Health Center)</li><li>Diane Von Ah, PhD, RN, FAAN (Indiana University School of Nursing)</li></ul></div><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial  del PDQ sobre los cuidados m&#xE9;dicos de apoyo y los cuidados paliativos emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/cuidados-medicos-apoyo">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; sobre los cuidados m&#xE9;dicos de apoyo y los cuidados paliativos. PDQ Fatiga. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq" title="https://www.cancer.gov/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq">https://www.cancer.gov/espanol/cancer/tratamiento/efectos-secundarios/fatiga/fatiga-pro-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>

- entity: node
  type: pdq_cancer_information_summary
  title: 'Pruritus (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: pruritus
  moderation_state:
    value: published
  field_pdq_url:
    value: /about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq
  field_pdq_cdr_id:
    value: 62748
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Supportive care
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2016-05-05'
  field_browser_title:
    value: 'Pruritus'
  field_page_description:
    value: 'Pruritus (itching of the skin) can be a complication of cancer or its treatment. Get detailed information about the etiology, assessment, and interventions for pruritus in this summary for clinicians.'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-pdq">Go to Patient Version</a></div><p id="_2" tabindex="-1">Pruritus is usually an unpleasant sensation that elicits a desire to
            scratch, subjectively quantified by intensity, severity, location, and intractability.  It may be proposed that itch is akin to pain, as both are thought to be transmitted from skin to central nervous system (CNS) through nociceptive small-caliber C nerve fibers.[<a href="#cit/section_1.1">1</a>] Perception of pruritus, much like pain, is greatly altered by psychological and CNS factors, thereby accounting for the great subjective variability between individuals in perceived pruritus from the same pruritogen.  Because of the
            subjective nature of pruritus, the lack of a precise definition, and the lack
            of suitable animal models, pruritus is a disorder that has not been researched
            adequately.</p><p id="_307" tabindex="-1">For the purpose of this discussion, a focus will be placed on pruritus in the absence of a primary dermatosis, as is often encountered in patients receiving cancer treatment.  However, there may still be significant secondary skin change noted in the form of lichen simplex chronicus, prurigo nodules, linear excoriations, linear petechiae, or superficial erosions in places the patient can reach to scratch (either with fingernails, back scratchers, or makeshift tools).</p><p id="_308" tabindex="-1">It is estimated that pruritus is a manifestation of an underlying systemic disease in approximately 10% to 25% of affected individuals. Nondermatologic conditions that can lead to generalized pruritus include the following:[<a href="#cit/section_1.2">2</a>]</p><div class="pdq-content-list"><ul id="_309"><li>Hepatic, renal, or thyroid dysfunction.</li><li>Lymphoma, myeloproliferative disorders (e.g., polycythemia vera, hypereosinophilic syndrome), and chronic lymphocytic leukemia.</li><li>HIV or parasitic infections.</li><li>Neuropsychiatric disorders.</li></ul></div><p id="_310" tabindex="-1">Despite the wide array of diseases that may present with pruritus, a systematic evaluation of the differential using a good history, review of systems, and appropriate blood work will lead to a rational and finite group of etiologies. Then correction of the underlying cause (if possible) and treatment of the pruritus with currently available therapies may ensue.</p><p id="_1_4" tabindex="-1">In this summary, unless otherwise stated, evidence and practice issues as they relate to adults are discussed.  The evidence and application to practice related to children may differ significantly from information related to adults.  When specific information about the care of children is available, it is summarized under its own heading.</p><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Schmelz M: A neural pathway for itch. Nat Neurosci 4 (1): 9-10, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11135635&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11135635&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Weisshaar E, Fleischer AB Jr, Bernhard JD, et al.: Pruritus and dysesthesia. In: Bolognia JL, Jorizzo JL, Schaffer JV: Dermatology. 3rd ed. [Philadelphia, Pa]: Elsevier Saunders, 2012, pp 111-25.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _6
      field_pdq_section_title:
        - format: plain_text
          value: 'Etiology/Pathophysiology'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_6" class="pdq-sections"><p id="_7" tabindex="-1">When a primary dermatitis is present, the differential may be narrowed by the history and physical findings, such as with stigmata of atopic dermatitis, psoriasis, scabies, allergic contact dermatitis, or primary cutaneous lymphoma.  Biopsy of skin dermatitis may be extraordinarily helpful in this scenario if the etiology is not readily evident from history and physical exam alone.  In contrast, Table 1 provides a list of differential diagnoses for when there is little or no primary dermatitis identifiable.  Where available, the incidence of pruritus in that condition is given.</p><table id="_342" class="table-default expandable-container"><caption>Table 1.  Pruritus Differential With Little or No Primary Dermatitis</caption><colgroup><col width="50.00%"><col width="50.00%"></colgroup><THead><tr><th>Disease State</th><th>Prevalence of Pruritus (%)</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="2">HMG-CoA = 3-hydroxy-3-methyl-glutaryl&#x2013;coenzyme A; IgE = immunoglobulin E.</td></tr></TFoot><tbody><tr><td>Neoplastic</td><td>&#xA0;</td></tr><tr><td>&#x2013; Hodgkin disease</td><td>30 [<a href="#cit/section_2.1">1</a>]</td></tr><tr><td>&#x2013; Non-Hodgkin lymphoma</td><td>15 [<a href="#cit/section_2.2">2</a>]</td></tr><tr><td>&#x2013; Leukemias</td><td>5 [<a href="#cit/section_2.3">3</a>]</td></tr><tr><td>&#x2013; Carcinoid syndrome</td><td>&#xA0;</td></tr><tr><td>&#x2013; Paraproteinemias</td><td>&#xA0;</td></tr><tr><td>Iron deficiency anemia</td><td>&#xA0;</td></tr><tr><td>Polycythemia rubra vera</td><td>&#x2264;50 [<a href="#cit/section_2.4">4</a>]</td></tr><tr><td>Hyper-IgE syndromes</td><td>&#xA0;</td></tr><tr><td>Parasitic helminthic infection</td><td>&#xA0;</td></tr><tr><td>Drug-induced eosinophilia</td><td>&#xA0;</td></tr><tr><td>Chronic renal insufficiency</td><td>57 [<a href="#cit/section_2.5">5</a>]</td></tr><tr><td>Liver disease</td><td>&#xA0;</td></tr><tr><td>&#x2013; Primary biliary cirrhosis</td><td>69 [<a href="#cit/section_2.6">6</a>]</td></tr><tr><td>&#x2013; Viral hepatitis infection</td><td>15 [<a href="#cit/section_2.7">7</a>]</td></tr><tr><td>&#x2013; Cholestatic disease</td><td>&#xA0;</td></tr><tr><td>&#x2013; Autoimmune hepatitis</td><td>&#xA0;</td></tr><tr><td>Thyroid dysfunction</td><td>&#xA0;</td></tr><tr><td>&#x2013; Hashimoto thyroiditis</td><td>&#xA0;</td></tr><tr><td>&#x2013; Hypothyroidism</td><td>&#xA0;</td></tr><tr><td>&#x2013; Hyperthyroidism</td><td>&#xA0;</td></tr><tr><td>Medication induced</td><td>&#xA0;</td></tr><tr><td>&#x2013; Opioids (codeine, morphine, butorphanol)</td><td>&#xA0;</td></tr><tr><td>&#x2013; Hydroxyethyl starch</td><td>&#xA0;</td></tr><tr><td>&#x2013; Antimalarials (chloroquine, hydroxychloroquine, quinacrine)</td><td>&#xA0;</td></tr><tr><td>&#x2013; 8-methoxypsoralen</td><td>&#xA0;</td></tr><tr><td>&#x2013; Beta blockers</td><td>&#xA0;</td></tr><tr><td>&#x2013; Hormones (estrogens, testosterone, progestins, anabolic steroids)</td><td>&#xA0;</td></tr><tr><td>&#x2013; Phenothiazines</td><td>&#xA0;</td></tr><tr><td>&#x2013; Aspirin</td><td>&#xA0;</td></tr><tr><td>&#x2013; HMG-CoA reductase inhibitors</td><td>&#xA0;</td></tr><tr><td>Diabetes mellitus</td><td>&#xA0;</td></tr><tr><td>HIV infection</td><td>&#xA0;</td></tr><tr><td>Post-herpetic neuralgia</td><td>&#x2264;60 [<a href="#cit/section_2.8">8</a>]</td></tr><tr><td>Pregnancy</td><td>18 [<a href="#cit/section_2.3">3</a>]</td></tr><tr><td>Xerosis</td><td>&#xA0;</td></tr><tr><td>Psychogenic (somatization, anxiety, depression, neurosis)</td><td>&#xA0;</td></tr><tr><td>Stroke sequelae</td><td>&#xA0;</td></tr><tr><td>Multiple sclerosis</td><td>&#xA0;</td></tr></tbody></table><p id="_8" tabindex="-1">As evident from the differential, a solid history and physical are essential for sorting through the possibilities.  To corroborate the clinical impression, it is also possible to use a limited number of laboratory and radiological examinations to rule in or rule out many of the possibilities.  Refer to the <a href="/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq#link/_34">Assessment</a> section of this summary for more information.
            </p><p id="_11" tabindex="-1">Hypothesized mechanisms of pruritus have been inferred from studies of pain because pain and itching share common molecular and neurophysiological
            mechanisms.[<a href="#cit/section_2.9">9</a>]  Both itch and pain sensations result from the activation of a
            network of free nerve endings at the dermal-epidermal junction.  Activation may
            be the result of internal or external thermal, mechanical, chemical, or
            electrical stimulation.  The cutaneous nerve stimulation is activated or
            mediated by several substances, including the following:</p><div class="pdq-content-list"><ul id="_311"><li>Histamine.</li><li> Vasoactive peptides.</li><li>Enkephalins.</li><li>Substance P (a tachykinin that affects smooth muscle).</li><li>Prostaglandins.</li></ul></div><p id="_312" tabindex="-1">It is believed that nonanatomic factors (such as psychological
            stress, tolerance, and presence and intensity of other sensations and/or
            distractions) determine itch sensitivity in different regions of the body.</p><p id="_12" tabindex="-1">The itch impulse is transmitted along the same neural pathway as pain impulses,
            i.e., traveling from peripheral nerves to the dorsal horn of the spinal cord,
            across the cord via the anterior commissure, and ascending along the
            spinothalamic tract to the laminar nuclei of the contralateral thalamus.
            Thalamocortical tracts of tertiary neurons are believed to relay the impulse
            through the integrating reticular activating system of the thalamus to several
            areas of the cerebral cortex.  Factors that are believed to enhance the
            sensation of itch include dryness of the epidermis and dermis, anoxia of
            tissues, dilation of the capillaries, irritating stimuli, and psychological
            responses.[<a href="#cit/section_2.9">9</a>-<a href="#cit/section_2.12">12</a>]
            </p><p id="_13" tabindex="-1">The motor response of scratching follows the perception of itch.  Scratching is
            modulated at the corticothalamic center and is a spinal reflex.  Itching may be relieved for 15 to 25 minutes after scratching.  The mechanism
            through which the itch is relieved by scratching is unknown.  It is
            hypothesized that scratching generates sensory impulses that break circuits
            in the relay areas of the spinal cord.  Scratching may actually enhance the
            sensation of itching, creating a characteristic itch-scratch-itch cycle.  Other
            physical stimuli such as vibration, heat, cold, and ultraviolet radiation
            diminish itching and increase the release of proteolytic enzymes, potentially
            eliciting the itch-scratch-itch cycle.</p><p id="_14" tabindex="-1">A pinprick near or in the same dermatome as an itchy point will abolish the
            itch sensation.[<a href="#cit/section_2.11">11</a>]  It is known that hard scratching may substitute pain for
            the itch, and in some instances, the patient might find pain the more tolerable
            sensation.  It is thought that spinal modulation of afferent stimuli (Gate
            theory) and central mechanisms may play a role in the relief of itch.[<a href="#cit/section_2.11">11</a>]
            </p><p id="_15" tabindex="-1">Hypothesized pathogenesis of pruritus associated with underlying disease states
            are varied.  Biliary, hepatic, renal, and malignant diseases are thought to
            produce pruritus through circulating toxic substances.  Histamine released from
            circulating basophils and the release of leukopeptidase from white blood cells
            may trigger pruritus associated with lymphomas and leukemias.  Elevated blood
            levels of kininogen in Hodgkin lymphoma, release of histamine or bradykinin
            precursors from solid tumors, and release of serotonin in carcinoids may all be
            related to pruritus.[<a href="#cit/section_2.10">10</a>,<a href="#cit/section_2.13">13</a>]
            </p><p id="_16" tabindex="-1">People receiving cytotoxic chemotherapy, radiation therapy, and/or biologic response
            modifiers for treatment of malignancy are likely to experience pruritus.  This
            same population is quite likely to be exposed to many of the other etiologic
            factors relating to pruritus, ranging from nutritionally related xerosis (dry
            skin) to radiation desquamation, chemotherapy-induced and biologic agent&#x2013;induced side
            effects, antibiotic reactions, and other drug sensitivities. Because many of these therapies lead to decreased cell turnover, skin can become thin, atrophic, and dehydrated.  Long-term xerosis may also occur with poor recovery of sweat, sebaceous, and apocrine gland function after a course of cytotoxic therapy.</p><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Gobbi PG, Attardo-Parrinello G, Lattanzio G, et al.: Severe pruritus should be a B-symptom in Hodgkin's disease. Cancer 51 (10): 1934-6, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6831358&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6831358&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Kumar SS, Kuruvilla M, Pai GS, et al.: Cutaneous manifestations of non-Hodgkin's lymphoma. Indian J Dermatol Venereol Leprol 69 (1): 12-5, 2003 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17642814&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17642814&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Weisshaar E, Dalgard F: Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 89 (4): 339-50, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19688144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19688144&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Diehn F, Tefferi A: Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 115 (3): 619-21, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11736946&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11736946&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Duque MI, Thevarajah S, Chan YH, et al.: Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 66 (3): 184-91, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16995341&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16995341&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Rishe E, Azarm A, Bergasa NV: Itch in primary biliary cirrhosis: a patients' perspective. Acta Derm Venereol 88 (1): 34-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18176748&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18176748&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Cribier B, Samain F, Vetter D, et al.: Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol 78 (5): 355-7, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779254&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9779254&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Oaklander AL, Bowsher D, Galer B, et al.: Herpes zoster itch: preliminary epidemiologic data. J Pain 4 (6): 338-43, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14622691&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14622691&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Greaves MW: Pathophysiology of pruritus. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds.: Dermatology in General Medicine. 3rd ed. New York, NY: McGraw-Hill, 1987, Chapter 7, pp 74-78.</li><li id="section_2.10">Abel EA, Farber EM: Malignant cutaneous tumors. In: Rubenstein E, Federman DD, eds.: Scientific American Medicine. New York: Scientific American, Inc, Chapter 2: Dermatology, Section XII, 1-20, 1992.</li><li id="section_2.11">Bernhard JD: Clinical aspects of pruritus. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds.: Dermatology in General Medicine. 3rd ed. New York, NY: McGraw-Hill, 1987, Chapter 7, pp 78-90.</li><li id="section_2.12">Duncan WC, Fenske NA: Cutaneous signs of internal disease in the elderly. Geriatrics 45 (8): 24-30, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2199335&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2199335&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.13">Abel EA, Farber EM: Drug eruptions and urticaria. In: Rubenstein E, Federman DD, eds.: Scientific American Medicine. New York: Scientific American, Inc, Chapter 2: Dermatology, Section VI, 1-11, 1990.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _34
      field_pdq_section_title:
        - format: plain_text
          value: 'Assessment'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_34" class="pdq-sections"><p id="_35" tabindex="-1">Pruritus is a symptom, not a diagnosis or disease.  Generalized pruritus should be investigated because of its strong medical significance, as outlined above (refer to the <a href="/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq#link/_6">Etiology/Pathophysiology</a> section of this summary for more information), particularly if it is interfering with daily activities or sleep, and/or is intractable. Assessment of pruritus must incorporate an accurate and thorough history and
            physical examination.[<a href="#cit/section_3.1">1</a>]</p><p id="_36" tabindex="-1">The history includes the following data:
            </p><div class="pdq-content-list"><ul id="_104"><li>Location, onset, duration, and intensity of itching.</li><li>Effect on activities of daily living or sleep.</li><li>Factors that relieve and aggravate itching.</li><li>Other family members or pets affected.</li><li>History of pruritus.</li><li>History of malignant disease.</li><li>Current malignant disease and treatment.</li><li>Nonmalignant systemic diseases.</li><li>Use of medications (analgesics, antibiotics, and other prescription and nonprescription drugs, including illicit drugs).</li><li>Nutritional and fluid level status.</li><li>Social history (hobbies, occupation, sexual history, and travel).</li><li>Current skin care practices.</li><li>Patient&#x2019;s emotional state.</li></ul></div><p id="_52" tabindex="-1">Physical examination will provide data from assessment of the following:</p><div class="pdq-content-list"><ul id="_105"><li>All skin surfaces for signs of infection.</li><li>All skin surfaces for signs of primary dermatitis (e.g., drug reaction, psoriasis, atopic dermatitis, connective tissue disease, and lichen planus).</li><li>All skin surfaces for signs of secondary dermatitis (e.g., macular erythema, dryness, excoriation, linear petechiae, prurigo nodules, and lichen simplex chronicus).</li><li>Environmental factors (temperature, humidity).</li><li>Physical factors (tight, constrictive clothing).</li><li>Skin turgor, texture, color, temperature, and cutaneous neoplasms.</li></ul></div><p id="_313" tabindex="-1">First-line studies should include the following:</p><div class="pdq-content-list"><ul id="_314"><li>Complete blood count with differential and platelet count.</li><li>Renal function (blood urea nitrogen, serum creatinine).</li><li>Hepatic function (transaminases, alkaline phosphatase, bilirubin).</li><li>Lactate dehydrogenase.</li><li>Thyroid function (thyroid-stimulating hormone, thyroxin levels).</li><li>Chest x-ray.</li><li>Erythrocyte sedimentation rate.</li></ul></div><p id="_315" tabindex="-1">Second-line laboratory studies guided by review of systems and physical exam may include the following:</p><div class="pdq-content-list"><ul id="_316"><li>Skin biopsy (routine histology with and without direct immunofluorescence).</li><li>HIV screening.</li><li>Serum iron, total iron-binding capacity, and ferritin.</li><li>Fasting glucose and hemoglobin A1C.</li><li>Parathyroid function (calcium, phosphate, and parathyroid hormone levels).</li><li>Viral hepatitis screening.</li><li>Serum immunoglobulin E levels.</li><li>Serum protein electrophoresis/serum immunofixation electrophoresis.</li><li>Tissue transglutaminase and endomysial antibodies.</li><li>Serum tryptase, histamine, and/or chromogranin-A levels.</li><li>Urine for sediment; 24-hour urine collection for 5-hydroxyindoleacetic acid (5-HIAA; serotonin metabolite) and methylimidazoleacetic acid (MIAA; histamine metabolite).</li><li>Stool for occult blood, ova, and parasite.</li></ul></div><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Weisshaar E, Fleischer AB Jr, Bernhard JD, et al.: Pruritus and dysesthesia. In: Bolognia JL, Jorizzo JL, Schaffer JV: Dermatology. 3rd ed. [Philadelphia, Pa]: Elsevier Saunders, 2012, pp 111-25.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _59
      field_pdq_section_title:
        - format: plain_text
          value: 'Interventions'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_59" class="pdq-sections"><p id="_303" tabindex="-1">Note: Some citations in the text of this section are followed by a level of evidence. The PDQ Editorial Boards use a formal ranking system to help the reader judge the strength of evidence linked to the reported results of a therapeutic strategy. (Refer to the PDQ summary on <a href="/publications/pdq/levels-evidence/supportive-care">Levels of Evidence</a> for more information.)</p><p id="_317" tabindex="-1">If an underlying cause of pruritus is identified, treatment of the primary disease or correction of the underlying abnormality is primary therapy, when feasible. For example, iron supplementation in the setting of iron-deficiency anemia or thyroid supplementation for hypothyroidism should be initiated first. However, gentle skin techniques as outlined below are indicated, even if they are not expected to completely alleviate the symptoms&#x2014;they should be considered helpful adjuvant therapies.</p><p id="_318" tabindex="-1">Interventions for pruritus can be categorized into four distinct groups:</p><div class="pdq-content-list"><ol id="_319"><li>Prevention and elimination of provocative factors.</li><li>Topical therapies.</li><li>Systemic therapies.</li><li>Physical modalities.</li></ol></div><section id="_108"><h3 id="_108_toc">Prevention and Elimination of Provocative Factors</h3><p id="_68" tabindex="-1">Patients and caregivers must be included in planning and providing care to
            the extent possible.  Education is an important aspect of symptom control.
            Skin care regimens incorporate protection from the environment, good cleansing practices, and internal and
            external hydration.[<a href="#cit/section_4.1">1</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]  The intensity of the regimen and the techniques
            employed will vary according to etiologic factors and the degree of distress
            associated with the pruritus.</p><p id="_70" tabindex="-1">Adequate nutrition is essential to the maintenance of healthy skin.  An optimal
            diet should include a balance of proteins, carbohydrates, fats, vitamins,
            minerals, and fluids.  Daily fluid intake of at least 3,000 mL is
            suggested as a guideline but may not be possible for some individuals.[<a href="#cit/section_4.2">2</a>,<a href="#cit/section_4.3">3</a>]</p><p id="_71" tabindex="-1">Aggravating factors should be avoided, including the following:</p><div class="pdq-content-list"><ul id="_72"><li>Fluid loss secondary to fever, diarrhea, nausea and vomiting, or decreased
            fluid intake.</li><li>Bathing with hot water.</li><li>Using bubble baths or soaps that contain detergents.</li><li>Bathing more than once a day or bathing for longer than 30 minutes.</li><li>Using soap and adding oil early in a bath.</li><li>Using a reusable fomite for scrubbing (e.g., buff-puff or loofah sponge).</li><li>Using scents, fragrances, and perfumes.</li><li>Dry environment.</li><li>Laundering sheets and clothing with detergent containing scents, dyes, and preservatives.</li><li>Using fabric softener sheets.</li><li>Wearing tight restrictive clothing or clothing made of wool, synthetics, or other
            harsh/scratchy fabric.
            </li><li>Using underarm deodorants or antiperspirants.</li><li>Applying topical preparations containing scents, dyes, or preservatives.</li><li>Emotional stress.</li></ul></div><p id="_73" tabindex="-1">Alleviating factors should be promoted, as follows:</p><div class="pdq-content-list"><ul id="_74"><li>Applying unscented emollient creams or ointments.</li><li>Bathing in tepid water.</li><li>Using mild skin cleansers (non-soap) or soaps made for sensitive skin (e.g., Cetaphil cleanser, Dove for Sensitive Skin, Oilatum, Basis).</li><li>Using soap only for dirty areas; otherwise, water is sufficient.</li><li>Limiting bathing to 30 minutes daily or every other day.</li><li>Adding oil and using soap at the end of a bath or adding a colloidal oatmeal treatment
            early to the bath.</li><li>Gently washing, if needed, with a clean, fresh, soft cotton washcloth.</li><li>Rinsing all residue from bathing with fresh tepid water.</li><li>Drying off by patting skin instead of rubbing.</li><li>Maintaining a humid environment (e.g., using a humidifier).</li><li>Using cotton flannel blankets, if needed.</li><li>Washing sheets, clothing, and undergarments in mild soaps for infant
            clothing containing no scents, dyes, or preservatives (e.g., Dreft, All Free Clear, Tide Free and Gentle).</li><li>Using liquid fabric softener that is rinsed out in the wash (e.g., All Free Clear Fabric Softener) or avoiding fabric softener altogether.</li><li>Wearing loose-fitting clothing and clothing made of cotton or other soft
            fabrics.</li><li>Using distraction, relaxation, positive imagery, or cutaneous stimulation.</li></ul></div><p id="_320" tabindex="-1">Heat increases cutaneous blood flow and may enhance itching.  Heat also lowers
            humidity, and skin loses moisture when the relative humidity falls below 40%.
            A cool, humid environment may reverse these processes.
            Extensive bathing aggravates dry skin, and hot baths exacerbate fluid loss by causing vasodilation. The vasodilation results in increased blood flow, which   enhances itching. Tepid baths have an antipruritic effect, possibly resulting from capillary vasoconstriction.</p><p id="_321" tabindex="-1">The goal of skin cleansing is to remove dirt and prevent odor, but actual
            hygienic practices are influenced by skin type, lifestyle, and culture.
            Bathing should be limited to 30 minutes every day or every 2 days.</p><p id="_343" tabindex="-1">Many soaps are salts of fatty acids with an alkali
            base,  leading to excessive defatting of the skin lipids and altered skin pH, thus irritating the skin. Older adults or individuals with dry skin should limit use of soaps to areas with apocrine glands. Plain water should suffice for cleaning other skin surfaces. Mild soaps have less soap or detergent content. Soap is a degreaser and can also irritate skin.  Superfatted soaps deposit a film of
            oil on the skin surface, but there is no proof that they are less drying than
            other soaps, and they may be more expensive.</p><p id="_322" tabindex="-1">Residue left by detergents after bathing or used in laundering clothes and linens, as well as fabric softeners and antistatic products, may aggravate pruritus. Clothing detergent residue can be neutralized by the addition of vinegar (1 teaspoon per quart of water) to rinse water. Mild laundry soaps marketed for infant items also may offer a solution.</p><p id="_323" tabindex="-1">Loose-fitting, lightweight cotton clothes and cotton bed sheets are suggested.
            The elimination of heavy bedcovers may alleviate itching by decreasing body
            heat.  Wool and some synthetic fabrics may be irritating.  Distraction, music
            therapy, relaxation, and imagery may be useful to relieve symptoms.[<a href="#cit/section_4.4">4</a>]
            </p></section><section id="_109"><h3 id="_109_toc">Topical Therapies</h3><section id="_324"><h4 id="_324_toc">Over-the-counter products</h4><p id="_325" tabindex="-1">Some topical agents&#x2014;including cornstarch, talcum powder, perfumed powders, and bubble baths&#x2014;can irritate the skin and cause pruritus.  Cornstarch has been
            an acceptable intervention for pruritus associated with dry desquamation
            related to radiation therapy; however, it should not  be applied to moist skin surfaces,
            areas with hair, sebaceous glands, skin folds (intertriginous zones), or areas close to mucosal
            surfaces, such as the vagina and rectum.[<a href="#cit/section_4.5">5</a>,<a href="#cit/section_4.6">6</a>]  Glucose is formed when
            cornstarch is moistened, providing an excellent medium for fungal growth.[<a href="#cit/section_4.6">6</a>]</p><p id="_344" tabindex="-1">Agents with metal ions (i.e., talcum and aluminum used in antiperspirants)
            enhance skin reactions during external-beam radiation therapy and should be
            avoided throughout the course of radiation therapy.  Talcum-based agents are otherwise preferred over cornstarch-based modalities when needed, particularly for intertriginous zones. Other common ingredients
            in over-the-counter lotions and creams that may enhance skin reactions include
            alcohol, topical antibiotics, and topical anesthetics.</p><p id="_326" tabindex="-1">If pruritus is thought to be primarily related to dry skin, interventions to
            improve skin hydration can be employed.  The main source of hydration for skin
            is moisture from the vasculature of underlying tissues.  Water, not lipid,
            regulates the pliability of the epidermis, providing the rationale for using
            emollients.[<a href="#cit/section_4.7">7</a>]  Emollients reduce evaporation by forming occlusive and
            semi-occlusive films over the skin surface, encouraging the production of
            moisture in the layer of epidermis beneath the film (hence the term
            <em>moisturizer</em>).[<a href="#cit/section_4.8">8</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]
            </p><p id="_327" tabindex="-1">Knowledge about the ingredients in skin care products is essential because many
            ingredients may enhance skin reactions.  The three main ingredients of emollients
            are as follows:</p><div class="pdq-content-list"><ul id="_352"><li>Petrolatum, which is poorly absorbed by irradiated skin and is not easily removed.  A
            thick layer could produce an undesired bolus effect when applied within a
            radiation treatment field.[<a href="#cit/section_4.9">9</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]  </li><li>Lanolin, which may cause allergic sensitization in some individuals.[<a href="#cit/section_4.8">8</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</li><li>Mineral oil, which is used in combination with
            petrolatum and lanolin to create creams and lotions and may be an active
            ingredient in bath oils.</li></ul></div><p id="_353" tabindex="-1">Other ingredients added to these products&#x2014;such as
            thickeners, opacifiers, preservatives, fragrances, and colorings&#x2014;may cause
            allergic skin reactions.</p><p id="_328" tabindex="-1">Product selection and recommendations must be made in consideration of each
            patient&#x2019;s unique needs and should incorporate variables such as the
            individual&#x2019;s skin, the desired effect, the consistency and texture of the
            preparation, and its cost and acceptability to the patient.[<a href="#cit/section_4.1">1</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]  Emollient creams
            or lotions should be applied at least two or three times daily and after
            bathing.  Gels with a local anesthetic (0.5%&#x2013;5% lidocaine) can be used on some small areas (with the caveat that gels are composed of mostly alcohol-based vehicles), as often as every 2 hours if necessary.[<a href="#cit/section_4.10">10</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</p><p id="_329" tabindex="-1">Over-the-counter products containing menthol, camphor, pramoxine, or capsaicin can be used for certain areas of worst pruritus.  These substances soothe, cool, or inhibit itch sensations, thereby raising the threshold for itch perception. Capsaicin-based therapies are more likely to be beneficial in pruritus of neuropathic origin.[<a href="#cit/section_4.11">11</a>]</p><p id="_330" tabindex="-1">If significant skin breakdown from scratching has occurred or there is evidence of impetiginization, the use of dilute bleach baths, as is done for the atopic dermatitis population, may be helpful.  A half-cup of plain unscented sodium hypochlorite (bleach) is added to half a tub of tap water for soaking at the beginning of the bath period.  If sponge bathing is required, this is equivalent to approximately 5 mL of bleach to 1 gal of water.</p></section><section id="_331"><h4 id="_331_toc">Prescription products</h4><p id="_332" tabindex="-1">Topical steroids can reduce itching, but they reduce blood flow
            to the skin, resulting in thinning of the skin and increased susceptibility to
            injury.[<a href="#cit/section_4.12">12</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]
            They should therefore be reserved for pruritic skin with associated primary dermatitis or inflammatory etiologies.  Some practitioners may formulate their own mixture of dilute steroid-containing moisturizer to serve this purpose by compounding menthol 0.5% and fluocinonide 0.0125% into a Vanicream base (fluocinonide 0.05% 60 g, menthol 480 mg, and Vanicream QSAD 240 g).  Topical steroids should not be applied to skin surfaces inside a radiation field during treatment but may be used successfully for postradiation-induced dermatitis after the treatment course has concluded.</p><p id="_333" tabindex="-1">For more-severe xerosis or keratoderma, humectants may be indicated.  These not only provide an occlusive or semi-occlusive barrier for water, but also chemically exfoliate an excessively cornified layer while drawing dermal fluid into the epidermal compartment.  Choices include salicylic acid 6% cream, ammonium lactate 12% cream, or creams and ointments containing urea 10% to 50%.[<a href="#cit/section_4.13">13</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]  These can significantly improve skin pliability and reduce fissuring, but care must be taken that they do not get into fissures because they can cause stinging sensations on open erosions.</p></section></section><section id="_354"><h3 id="_354_toc">Systemic Therapies</h3><p id="_355" tabindex="-1">Systemic medications useful in the management of pruritus include those directed toward the underlying disease or control of symptoms. Antibiotics can reduce symptoms associated with infection. Oral antihistamines may provide symptomatic relief in histamine-related itching; however, they are not considered useful in pruritus of neuropathic origin. It is believed that the sedative effect of antihistamines adds to their antipruritic efficacy; therefore, a higher dose of antihistamine at bedtime may produce desirable potentiation of the antipruritic effect by also providing this sedative effect. If one antihistamine is ineffective, one from another class may provide relief (see Table 2).</p><p id="_356" tabindex="-1">Second-generation antihistamines have several advantages over first-generation antihistamines.[<a href="#cit/section_4.14">14</a>] Decreased activity on nonhistamine receptors results in fewer adverse effects.  Second-generation antihistamines dissociate slowly from histamine receptors, allowing for once-daily dosing.  Compared with first-generation antihistamines, second-generation antihistamines produce less central nervous system penetration and therefore less sedation.  Given these advantages, using doses of levocetirizine and desloratadine higher than those approved by the U.S. Food and Drug Administration has been suggested to provide relief for some patients with chronic urticarial conditions.[<a href="#cit/section_4.15">15</a>] However, studies have produced conflicting results with cetirizine.[<a href="#cit/section_4.16">16</a>,<a href="#cit/section_4.17">17</a>]</p><table id="_347" class="table-default expandable-container"><caption>Table 2.  Antihistamines Used to Alleviate Pruritus<span class="sup">a</span></caption><colgroup><col width="20.00%"><col width="20.00%"><col width="20.00%"><col width="20.00%"><col width="20.00%"></colgroup><THead><tr><th>Drug Category</th><th>Medication</th><th>Dose</th><th>Comments</th><th>Reference</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="5">SR = sustained release.</td></tr><tr><td colspan="5"><span class="sup">a</span>Table abstracted from <a href="http://www.wolterskluwercdi.com/lexicomp-online/" title="http://www.wolterskluwercdi.com/lexicomp-online/">Lexicomp Online</a>. Last accessed January 31, 2016.</td></tr></TFoot><tbody><tr><td rowspan="4">First generation</td><td>Diphenhydramine</td><td>25&#x2013;100 mg q6h</td><td>&#xA0;</td><td>[<a href="#cit/section_4.18">18</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td>Hydroxyzine	</td><td>25&#x2013;50 mg q6&#x2013;8h</td><td>Abrupt withdrawal may cause confusion.</td><td>[<a href="#cit/section_4.19">19</a>]; [<a href="#cit/section_4.20">20</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Cyproheptadine	</td><td>4 mg q6&#x2013;8h</td><td>&#xA0;</td><td>[<a href="#cit/section_4.19">19</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td>Chlorpheniramine	</td><td>4 mg q4&#x2013;6h</td><td>&#xA0;</td><td>[<a href="#cit/section_4.21">21</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td rowspan="5">Second generation</td><td>Cetirizine	</td><td>5&#x2013;10 mg daily</td><td>Conflicting results when 20&#x2013;40 mg/day studied.</td><td>[<a href="#cit/section_4.16">16</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>];
            [<a href="#cit/section_4.17">17</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>]</td></tr><tr><td>Levocetirizine	</td><td>2.5&#x2013;5 mg daily</td><td>Safe to increase dose up to 20 mg daily; may provide better symptom control.</td><td>[<a href="#cit/section_4.15">15</a>,<a href="#cit/section_4.22">22</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Loratadine	</td><td>10 mg daily</td><td>&#xA0;</td><td>[<a href="#cit/section_4.23">23</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Desloratadine	</td><td>5 mg daily</td><td>Safe to increase dose up to 20 mg daily; may provide better symptom control.</td><td>[<a href="#cit/section_4.22">22</a>]</td></tr><tr><td>Fexofenadine	</td><td>60 mg q12h or 180 mg daily (SR tablet)</td><td>&#xA0;</td><td>[<a href="#cit/section_4.24">24</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr></tbody></table><p id="_357" tabindex="-1">Several alternative medications can be used to alleviate pruritus (see Table 3). Antidepressants can have strong antihistamine and antipruritic effects.[<a href="#cit/section_4.21">21</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]   Tricyclic antidepressants (TCAs) such as doxepin, amitriptyline, nortriptyline, and trimipramine have additional antihistaminic effects, making them of additional benefit in dermatological conditions such as urticaria. However, the generally more-favorable side-effect profile of selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) has made them the first-line agents in the management of psychogenic pruritus.[<a href="#cit/section_4.25">25</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>]</p><p id="_358" tabindex="-1">Aspirin seems to have reduced pruritus in some individuals with polycythemia vera, while increasing
            pruritus in others.  Thrombocytopenic cancer patients should be cautioned
            against using aspirin.  Cimetidine alone or in combination with aspirin has
            been used with some effectiveness for pruritus associated with Hodgkin lymphoma and polycythemia vera.[<a href="#cit/section_4.26">26</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>]</p><p id="_359" tabindex="-1">Novel agents that may be tried in recalcitrant cases may include gabapentin, pregabalin, and botulinum toxin injection, particularly for neurogenic itch such as post-herpetic neuralgia.[<a href="#cit/section_4.27">27</a>,<a href="#cit/section_4.28">28</a>] Aprepitant has been used successfully in the treatment of pruritus by blocking the neurokinin-1 receptor (NKR-1), which is activated by substance P.[<a href="#cit/section_4.29">29</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>]</p><table id="_348" class="table-default expandable-container"><caption>Table 3.  Alternative Medications Used to Alleviate Pruritus<span class="sup">a</span></caption><colgroup><col width="20.00%"><col width="20.00%"><col width="20.00%"><col width="20.00%"><col width="20.00%"></colgroup><THead><tr><th>Drug Category</th><th>Medication</th><th>Dose</th><th>Comments</th><th>Reference</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="5">ESRD = end-stage renal disease; GABA = gamma-aminobutyric acid; IV = intravenously; tid = 3 times a day.</td></tr><tr><td colspan="5"><span class="sup">a</span>Table abstracted from <a href="http://www.wolterskluwercdi.com/lexicomp-online/" title="http://www.wolterskluwercdi.com/lexicomp-online/">Lexicomp Online</a>. Last accessed January 31, 2016.</td></tr></TFoot><tbody><tr><td rowspan="2">Tricyclic antidepressant</td><td>Amitriptyline</td><td>25&#x2013;150 mg daily</td><td>Start as 10 mg tid or 25 mg at bedtime.</td><td>[<a href="#cit/section_4.28">28</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td>Doxepin</td><td>10&#x2013;25 mg q8h</td><td>&#xA0;</td><td>[<a href="#cit/section_4.30">30</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td rowspan="4">Selective serotonin reuptake inhibitor</td><td>Fluvoxamine</td><td>50&#x2013;100 mg daily</td><td>&#xA0;</td><td>[<a href="#cit/section_4.31">31</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>]</td></tr><tr><td>Mirtazapine</td><td>7.5&#x2013;15 mg at bedtime</td><td>No value to  &gt;15 mg.</td><td>[<a href="#cit/section_4.28">28</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td>Paroxetine</td><td>20 mg daily</td><td>&#xA0;</td><td>[<a href="#cit/section_4.32">32</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Sertraline</td><td>75&#x2013;100 mg daily</td><td>&#xA0;</td><td>[<a href="#cit/section_4.33">33</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td rowspan="2">GABA analog</td><td>Gabapentin</td><td>100&#x2013;300 mg daily, titrated to effect</td><td>Dose must be adjusted for renal dysfunction.</td><td>[<a href="#cit/section_4.34">34</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Pregabalin</td><td>75 mg daily</td><td>Dose must be adjusted for renal dysfunction.</td><td>[<a href="#cit/section_4.35">35</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td rowspan="2">Sequestrant agent</td><td>Ursodiol (ursodeoxycholic acid)</td><td>10&#x2013;15 mg/kg of body weight per day</td><td>For pruritus of cholestasis.</td><td>[<a href="#cit/section_4.36">36</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td>Cholestyramine</td><td>4&#x2013;16 g daily</td><td>For pruritus of cholestasis.</td><td>[<a href="#cit/section_4.36">36</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td rowspan="4">Opioid antagonist</td><td>Naloxone</td><td>0.2 &#xB5;g/kg of body weight per min IV</td><td>Efficacy in cholestatic pruritus; conflicting results in ESRD itch. Can cause pain by antagonizing mu-receptor.</td><td>[<a href="#cit/section_4.37">37</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]; [<a href="#cit/section_4.38">38</a>]</td></tr><tr><td>Naltrexone</td><td>25&#x2013;100 mg daily</td><td>Efficacy in cholestatic pruritus, atopic eczema; conflicting results in ESRD itch. Can cause pain by antagonizing mu-receptor.</td><td>[<a href="#cit/section_4.38">38</a>]; [<a href="#cit/section_4.39">39</a>,<a href="#cit/section_4.40">40</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Butorphanol</td><td>1&#x2013;4 mg q4&#x2013;6h intranasally</td><td>&#xA0;</td><td>[<a href="#cit/section_4.41">41</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663072&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663072&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: II</a>]</td></tr><tr><td>Nalbuphine</td><td>2.5&#x2013;5 mg IV</td><td>For opioid-induced pruritus.</td><td>[<a href="#cit/section_4.42">42</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td rowspan="7">Miscellaneous agent</td><td>Aprepitant</td><td>80 mg daily</td><td>&#xA0;</td><td>[<a href="#cit/section_4.29">29</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>]</td></tr><tr><td>Aspirin</td><td>500 mg q8&#x2013;24h</td><td>Only used for polycythemia vera. Positive and negative data.</td><td>[<a href="#cit/section_4.30">30</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Botulinum toxin</td><td>16&#x2013;25 units injected into the dermatome</td><td>&#xA0;</td><td>[<a href="#cit/section_4.28">28</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td>Capsaicin 0.025%</td><td>Apply 5 times daily &#xD7; 1 week, then 3 times daily</td><td>For neurologic pruritus.</td><td>[<a href="#cit/section_4.43">43</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Cimetidine</td><td>200 mg q6h</td><td>Only used for polycythemia vera.</td><td>[<a href="#cit/section_4.30">30</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]</td></tr><tr><td>Cyclosporine</td><td>3&#x2013;4.5 mg/kg of body weight per day</td><td>Requires close monitoring for renal toxicity.</td><td>[<a href="#cit/section_4.44">44</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr><tr><td>Pimecrolimus 1% cream</td><td>Apply twice daily</td><td>&#xA0;</td><td>[<a href="#cit/section_4.45">45</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663069&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663069&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: I</a>]</td></tr></tbody></table><p id="_360" tabindex="-1">Sequestrant agents may be effective in relieving pruritus associated with renal
            or hepatic disease through binding and removing pruritogenic substances in the
            gut and reducing bile salt concentration. Choices include ursodeoxycholic acid and cholestyramine; however, cholestyramine is not always effective and produces gastric side effects.[<a href="#cit/section_4.46">46</a>] Because of the association of pruritus with opioid receptor agonism, increased catabolism of endogenous opioids using rifampin in uremia may be beneficial.[<a href="#cit/section_4.47">47</a>]  Opioid antagonists such as naloxone, naltrexone, nalmefene, butorphanol, and nalbuphine may also have some benefit, particularly in uremic pruritus.[<a href="#cit/section_4.25">25</a>,<a href="#cit/section_4.39">39</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663087&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663087&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: III</a>]</p></section><section id="_113"><h3 id="_113_toc">Physical Modalities</h3><p id="_95" tabindex="-1">Alternatives to scratching for the relief of pruritus can help the patient
            interrupt the itch-scratch-itch cycle.  Substituting scratching with application of emollients may help reduce skin breakdown. Application of a cool washcloth or ice
            over the site may be useful.  Firm pressure at the site of itching, at a site
            contralateral to the site of itching, and at acupressure points may break the
            neural pathway.  Rubbing, pressure, and vibration can be used to relieve
            itching.[<a href="#cit/section_4.48">48</a>][<a href="/Common/PopUps/popDefinition.aspx?id=663089&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000663089&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: IV</a>]; [<a href="#cit/section_4.4">4</a>]</p><p id="_96" tabindex="-1">There are anecdotal reports of the use of transcutaneous electronic nerve
            stimulators (TENS) and acupuncture in the management of pruritus.[<a href="#cit/section_4.49">49</a>]
            Ultraviolet phototherapy has been used with limited success for pruritus
            related to uremia.[<a href="#cit/section_4.49">49</a>]</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Detz W, Berman B: Aids that preserve hydration and mitigate its loss. Consultant  24: 46-62, 1984.</li><li id="section_4.2">Lydon J, Purl S, Goodman M: Integumentary and mucous membrane alterations. In: Groenwald SL, Frogge MH, Goodman M, et al., eds.: Cancer Nursing: Principles and Practice. 2nd ed. Boston, Mass: Jones and Bartlett, 1990, pp 594-635.</li><li id="section_4.3">Pace KB, Bord MA, McCray N, et al.: Pruritus. In: McNally JC, Stair JC, Somerville ET, eds.: Guidelines for Cancer Nursing Practice. Orlando, Fla: Grune and Stratton, Inc., 1985, pp 85-88.</li><li id="section_4.4">Yasko JM, Hogan CM: Pruritus. In: Yasko J, ed.: Guidelines for Cancer Care: Symptom Management. Reston, Va: Reston Publishing Company, Inc., 1983, pp 125-129.</li><li id="section_4.5">Hassey KM: Skin care for patients receiving radiation therapy for rectal cancer. J Enterostomal Ther 14 (5): 197-200, 1987 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3655092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3655092&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Maienza J: Alternatives to cornstarch for itchiness. Oncol Nurs Forum 15 (2): 199-200, 1988 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3357836&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3357836&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Blank L: Factors which influence the water content of the stratum corneum. J Invest Dermatol  18 (2): 133-39, 1952.</li><li id="section_4.8">Klein L: Maintenance of healthy skin. J Enterostomal Ther 15 (6): 227-31, 1988 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3204210&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3204210&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Hilderley L: Skin care in radiation therapy. A review of the literature. Oncol Nurs Forum 10 (1): 51-6, 1983 Winter.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6346274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6346274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">De Conno F, Ventafridda V, Saita L: Skin problems in advanced and terminal cancer patients. J Pain Symptom Manage 6 (4): 247-56, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2030300&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2030300&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Misery L, Brenaut E, Le Garrec R, et al.: Neuropathic pruritus. Nat Rev Neurol 10 (7): 408-16, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24912513&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24912513&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Hassey KM, Rose CM: Altered skin integrity in patients receiving radiation therapy. Oncol Nurs Forum 9 (4): 44-50, 1982 Fall.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6215631&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6215631&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Nolan K, Marmur E: Moisturizers: reality and the skin benefits. Dermatol Ther 25 (3): 229-33, 2012 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22913439&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22913439&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">O'Donoghue M, Tharp MD: Antihistamines and their role as antipruritics. Dermatol Ther 18 (4): 333-40, 2005 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16297006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16297006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Nettis E, Colanardi MC, Barra L, et al.: Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 154 (3): 533-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16445787&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16445787&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Hannuksela M, Kalimo K, Lammintausta K, et al.: Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 70 (2): 127-33, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8430920&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8430920&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Asero R: Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 32 (1): 34-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17042777&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17042777&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Geltman RL, Paige RL: Symptom management in hospice care. Am J Nurs 83 (1): 78-85, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6549725&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6549725&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Levy M: Symptom control manual. In: Cassileth BR, Cassileth PA, eds.: Clinical Care of the Terminal Cancer Patient. Philadelphia, Pa: Lea and Febiger, 1982, pp 214-262.</li><li id="section_4.20">Monroe EW, Bernstein DI, Fox RW, et al.: Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung 42 (9): 1119-21, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1445478&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1445478&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Winkelmann RK: Pharmacologic control of pruritus. Med Clin North Am 66 (5): 1119-33, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6752601&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6752601&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Staevska M, Popov TA, Kralimarkova T, et al.: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 125 (3): 676-82, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20226302&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20226302&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Langeland T, Fagertun HE, Larsen S: Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy 49 (1): 22-6, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8198236&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8198236&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Kaplan AP, Spector SL, Meeves S, et al.: Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 94 (6): 662-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15984599&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15984599&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Zhang H, Yang Y, Cui J, et al.: Gaining a comprehensive understanding of pruritus. Indian J Dermatol Venereol Leprol 78 (5): 532-44, 2012 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22960808&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22960808&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Daly BM, Shuster S: Effect of aspirin on pruritus. Br Med J (Clin Res Ed) 293 (6552): 907, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3094711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3094711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.27">Scheinfeld N: The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 42 (6): 491-5, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12786883&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12786883&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.28">Yosipovitch G, Samuel LS: Neuropathic and psychogenic itch. Dermatol Ther 21 (1): 32-41, 2008 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18318883&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18318883&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.29">St&#xE4;nder S, Siepmann D, Herrgott I, et al.: Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 5 (6): e10968, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20532044&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20532044&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.30">Krajnik M, Zylicz Z: Understanding pruritus in systemic disease. J Pain Symptom Manage 21 (2): 151-68, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11226766&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11226766&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.31">St&#xE4;nder S, B&#xF6;ckenholt B, Sch&#xFC;rmeyer-Horst F, et al.: Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 89 (1): 45-51, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19197541&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19197541&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.32">Zylicz Z, Krajnik M, Sorge AA, et al.: Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 26 (6): 1105-12, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14654262&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14654262&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.33">Mayo MJ, Handem I, Saldana S, et al.: Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45 (3): 666-74, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17326161&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17326161&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.34">Gunal AI, Ozalp G, Yoldas TK, et al.: Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 19 (12): 3137-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15575002&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15575002&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.35">Solak Y, Biyik Z, Atalay H, et al.: Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) 17 (8): 710-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22909343&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22909343&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.36">Kremer AE, Oude Elferink RP, Beuers U: Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol 35 (2): 89-97, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21809485&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21809485&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.37">Bergasa NV, Alling DW, Talbot TL, et al.: Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 123 (3): 161-7, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7598296&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7598296&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.38">Wang H, Yosipovitch G: New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 49 (1): 1-11, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20465602&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20465602&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.39">Peer G, Kivity S, Agami O, et al.: Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348 (9041): 1552-4, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8950882&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8950882&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.40">Malekzad F, Arbabi M, Mohtasham N, et al.: Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 23 (8): 948-50, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19453814&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19453814&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.41">Dawn AG, Yosipovitch G: Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 54 (3): 527-31, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488311&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488311&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.42">Jannuzzi RG: Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature. Clin J Pain 32 (1): 87-93, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26650717&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26650717&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.43">Wallengren J, Klinker M: Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 32 (2 Pt 1): 287-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7829721&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7829721&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.44">Weisshaar E, Szepietowski JC, Darsow U, et al.: European guideline on chronic pruritus. Acta Derm Venereol 92 (5): 563-81, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22790094&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22790094&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.45">Kaufmann R, Bieber T, Helgesen AL, et al.: Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 61 (3): 375-81, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16436149&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16436149&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.46">Abel EA, Farber EM: Malignant cutaneous tumors. In: Rubenstein E, Federman DD, eds.: Scientific American Medicine. New York: Scientific American, Inc, Chapter 2: Dermatology, Section XII, 1-20, 1992.</li><li id="section_4.47">Miguet JP, Mavier P, Soussy CJ, et al.: Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology 72 (5 Pt 1): 924-6, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=849823&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=849823&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.48">Dangel RB: Pruritus and cancer. Oncol Nurs Forum 13 (1): 17-21, 1986 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3632855&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3632855&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.49">Bernhard JD: Clinical aspects of pruritus. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds.: Dermatology in General Medicine. 3rd ed. New York, NY: McGraw-Hill, 1987, Chapter 7, pp 78-90.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _298
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (05/05/2016)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_298" class="pdq-sections"><p id="_299" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="_351" tabindex="-1">This summary was comprehensively reviewed and extensively revised.</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" title="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care">PDQ Supportive and Palliative Care Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the pathophysiology and treatment of pruritus. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" title="https://www.cancer.gov/publications/pdq/editorial-boards/supportive-care">PDQ Supportive and Palliative Care Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="" tabindex="-1">The lead reviewers for Pruritus are:</p><div class="pdq-content-list"><ul id=""><li>Larry D. Cripe, MD (Indiana University School of Medicine)</li><li>Megan Reimann, PharmD, BCOP (Indiana University Simon Cancer Center)</li></ul></div><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a <a href="/publications/pdq/levels-evidence/supportive-care">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Supportive and Palliative Care Editorial Board. PDQ Pruritus. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq" title="https://www.cancer.gov/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq">https://www.cancer.gov/about-cancer/treatment/side-effects/skin-nail-changes/pruritus-hp-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389231]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Prurito (PDQ®)–Versión para pacientes'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /cancer/tratamiento/efectos-secundarios/cambios-piel-unas/prurito-pro-pdq
  field_pdq_cdr_id__ES:
    value: 256645
  field_pdq_audience__ES:
    value: Patients
  field_pdq_summary_type__ES:
    value: Supportive care
  field_date_posted__ES:
    value: '2019-03-11'
  field_date_updated__ES:
    value: '2016-07-21'
  field_browser_title__ES:
    value: 'Prurito'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos acerca del prurito (picazón de la piel) como complicación del cáncer y su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información general sobre el prurito'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/cancer/tratamiento/efectos-secundarios/cambios-piel-unas/prurito-pdq">Vaya a la versi&#xF3;n para profesionales de salud</a></div><div class="key-points"><h3 id="_1_kpBoxHdr" do-not-show="toc">Puntos importantes</h3><div id="_kp_section_1_1"><ul><li>Ciertas afecciones, c&#xE1;nceres y trastornos en la sangre pueden causar prurito.</li></ul></div></div><p id="_59" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prurito</a> es una sensaci&#xF3;n de picaz&#xF3;n que provoca el deseo de rascar la piel. Se puede presentar sin una erupci&#xF3;n o con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lesiones</a> en la piel. En ocasiones, el prurito se siente como dolor porque las se&#xF1;ales de la picaz&#xF3;n viajan a trav&#xE9;s de las mismas v&#xED;as   <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373935&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373935&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">nerviosas</a>. El rascado puede provocar ara&#xF1;azos  en la piel, sangrado e <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">infecciones</a>. Si le pica la piel, informe a su m&#xE9;dico para que lo pueda tratar y aliviar.</p><p id="_128" tabindex="-1"> La manera como se siente el prurito y la duraci&#xF3;n del mismo var&#xED;a de persona a persona.</p><p id="_121" tabindex="-1">La piel es el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=257523&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000257523&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xF3;rgano</a> m&#xE1;s grande del cuerpo. La funci&#xF3;n m&#xE1;s importante de la piel es proteger contra el calor, la luz solar, las lesiones y las infecciones. La piel tambi&#xE9;n es importante para la autoimagen y para la capacidad de tocar y ser tocado.</p><section id="_12"><h3 id="_56" type="keypoint" do-not-show="toc">Ciertas afecciones, c&#xE1;nceres y trastornos en la sangre pueden causar prurito.</h3><p id="_28" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prurito</a> es un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">s&#xED;ntoma</a> de una determinada <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=651193&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000651193&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">afecci&#xF3;n</a>,  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407758&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407758&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">trastorno</a> de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sangre</a> o enfermedad. Como los siguientes:</p><div class="pdq-content-list"><ul id="_62"><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">C&#xE1;ncer</a> y afecciones relacionadas con el c&#xE1;ncer.</li><li>Trastornos del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46312&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046312&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">h&#xED;gado</a>, el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46325&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046325&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ri&#xF1;&#xF3;n</a> o  la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46036&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046036&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tiroides</a>.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44129&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044129&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Diabetes mellitus</a>.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Infecci&#xF3;n</a> por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44985&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044985&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">VIH</a> o enfermedades por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44310&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044310&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">par&#xE1;sitos</a>.</li><li>Piel seca.</li><li>Reacciones a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamentos</a>.</li><li>Afecciones relacionadas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450122&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450122&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tensi&#xF3;n</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=430405&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000430405&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ansiedad</a> o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=430479&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000430479&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">depresi&#xF3;n</a>.</li></ul></div><p id="_129" tabindex="-1">No siempre se conoce la causa del prurito.</p></section></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _11
      field_pdq_section_title:
        - format: plain_text
          value: 'Causas de prurito en los pacientes de cáncer'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_11" class="pdq-sections"><div class="key-points"><h3 id="_11_kpBoxHdr" do-not-show="toc">Puntos importantes</h3><div id="_kp_section_11_2"><ul><li>Ciertos tratamientos del c&#xE1;ncer pueden causar prurito.</li><li>Se pueden usar medicamentos para los cuidados de apoyo.</li></ul></div></div><section id="_15"><h3 id="_57" type="keypoint" do-not-show="toc">Ciertos tratamientos del c&#xE1;ncer pueden causar prurito.</h3><p id="_29" tabindex="-1">Los tratamientos del c&#xE1;ncer que pueden causar prurito son la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterapia</a>, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">radioterapia</a> y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45729&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045729&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inmunoterapia</a> (terapia biol&#xF3;gica).</p><div class="pdq-content-list"><ul id="_130"><li>Cuando la quimioterapia produce prurito, es posible que sea un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=750109&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000750109&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">signo</a> de que usted es sensible a los medicamentos utilizados.</li><li>La radioterapia puede destruir las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> de la piel y producir sequedad, ardor y prurito cuando la piel se descama.</li><li>Los medicamentos usados para la inmunoterapia tambi&#xE9;n causan sequedad y picaz&#xF3;n.</li></ul></div><p id="_131" tabindex="-1">La piel se puede adelgazar y secar porque muchas de  estas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapias</a> hacen que la piel pierda la capacidad de producir c&#xE9;lulas nuevas y cicatrizar. Se puede presentar piel seca a largo plazo cuando el pelo y el funcionamiento de las  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46386&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046386&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gl&#xE1;ndulas</a> sudor&#xED;paras no vuelven a la normalidad inmediatamente despu&#xE9;s del tratamiento del c&#xE1;ncer.</p></section><section id="_82"><h3 id="_83" type="keypoint" do-not-show="toc">Se pueden usar medicamentos para los cuidados de apoyo.</h3><p id="_84" tabindex="-1">Algunos de los medicamentos que se usan para prevenir o tratar los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">s&#xED;ntomas</a> del c&#xE1;ncer pueden causar prurito; entre estos, los siguientes:  </p><div class="pdq-content-list"><ul id="_65"><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=482419&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000482419&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Medicinas</a> para el dolor como los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45054&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045054&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">opioides</a>.</li><li>Medicamentos para las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390302&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390302&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">n&#xE1;useas</a> y los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">v&#xF3;mitos</a>.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45713&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045713&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Hormonas</a> como los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46076&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046076&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estr&#xF3;genos</a>,  la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45581&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045581&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">testosterona</a> o las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=304743&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000304743&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">progestinas</a>.</li></ul></div></section></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _21
      field_pdq_section_title:
        - format: plain_text
          value: 'Evaluación del prurito'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_21" class="pdq-sections"><div class="key-points"><h3 id="_21_kpBoxHdr" do-not-show="toc">Puntos importantes</h3><div id="_kp_section_21_3"><ul><li>El primer paso para aliviar el prurito es encontrar la causa de la picaz&#xF3;n.</li><li>Para evaluar el prurito se realiza un examen f&#xED;sico,  an&#xE1;lisis de sangre y una radiograf&#xED;a de t&#xF3;rax.</li></ul></div></div><section id="_94"><h3 id="_95" type="keypoint" do-not-show="toc">El primer paso para aliviar el prurito es encontrar la causa de la picaz&#xF3;n.</h3><p id="_96" tabindex="-1">Debido a que el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prurito</a> es un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">s&#xED;ntoma</a> de una enfermedad o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=651193&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000651193&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">afecci&#xF3;n</a>, el primer paso para aliviarlo es hallar y tratar su causa.</p></section><section id="_31"><h3 id="_32" type="keypoint" do-not-show="toc">Para evaluar el prurito se realiza un examen f&#xED;sico,  an&#xE1;lisis de sangre y una radiograf&#xED;a de t&#xF3;rax.</h3><p id="_33" tabindex="-1">Para encontrar el problema que causa la picaz&#xF3;n, se pueden realizar las siguientes pruebas y procedimientos:</p><div class="pdq-content-list"><ul id="_92"><li><strong><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270871&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270871&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Examen f&#xED;sico</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=689078&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000689078&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);"> antecedentes</a></strong>: examen del cuerpo para revisar los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=750109&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000750109&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">signos</a> generales de salud; entre ellos, signos de enfermedad  como masas o cualquier otra cosa que parezca extra&#xF1;a. El m&#xE9;dico revisar&#xE1; su piel para determinar si hay algo de lo siguiente:<div class="pdq-content-list"><ul id="_87" class="list-dash"><li>Signos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">infecci&#xF3;n</a>.</li><li>Signos de una reacci&#xF3;n a un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamento</a>.</li><li>Enrojecimiento, sequedad, rasgu&#xF1;os o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lesiones</a>.</li><li>Color, textura o temperatura <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44636&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044636&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">anormales</a>.</li></ul></div><p id="_116" tabindex="-1">Tambi&#xE9;n anotar&#xE1; los antecedentes de h&#xE1;bitos de salud, enfermedades y tratamientos anteriores. Le preguntar&#xE1;n sobre los siguientes aspectos:</p><div class="pdq-content-list"><ul id="_85" class="list-dash"><li>Cu&#xE1;ndo empez&#xF3; el prurito, cu&#xE1;nto dura, cu&#xE1;n molesto es y qu&#xE9; parte del cuerpo le pica.</li><li>C&#xF3;mo afecta sus <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=430401&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000430401&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">actividades diarias</a> y el sue&#xF1;o.</li><li>Qu&#xE9; alivia o empeora el prurito.</li><li>Si otros familiares o mascotas est&#xE1;n afectados.</li><li>Si tuvo prurito anteriormente.</li><li>Tratamiento actual del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> o antecedentes de c&#xE1;ncer.</li><li>Otras enfermedades que tiene o tuvo antes, y sus tratamientos.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=482419&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000482419&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Medicinas</a> para el dolor, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45967&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045967&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antibi&#xF3;ticos</a>,  u otros medicamentos que est&#xE9; tomando, incluso drogas ilegales.</li><li>Si su <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44660&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044660&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">alimentaci&#xF3;n</a> es saludable y si toma suficientes l&#xED;quidos.</li><li>Antecedentes sociales (pasatiempos, antecedentes sexuales y de viajes).</li><li>C&#xF3;mo se cuida la piel.</li><li>El estado de su salud emocional.</li></ul></div></li><li><strong><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=304685&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000304685&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Estudios bioqu&#xED;micos de la sangre</a></strong>: procedimiento por el cual se examina una muestra de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sangre</a> para medir las cantidades de ciertas sustancias que los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=257523&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000257523&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xF3;rganos</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46683&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046683&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tejidos</a> del cuerpo liberan en la sangre. Una cantidad anormal (mayor o menor que la normal) de una sustancia puede ser signo de enfermedad en el &#xF3;rgano o el tejido que la elabora. Estos an&#xE1;lisis de sangre incluyen los siguientes:<div class="pdq-content-list"><ul id="_263" class="list-dash"><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=482348&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000482348&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Pruebas del funcionamiento renal</a>.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390293&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390293&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Pruebas del funcionamiento del h&#xED;gado</a></li><li>Prueba de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=354462&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000354462&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lactato-deshidrogenasa</a>.</li><li>Prueba del funcionamiento de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46036&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046036&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tiroides</a>.</li></ul></div></li><li><strong><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=729979&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000729979&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Recuento sangu&#xED;neo completo (RSC) con diferencial</a></strong>: procedimiento mediante el que se toma una muestra de sangre y se analiza lo siguiente:<div class="pdq-content-list"><ul id="_93" class="list-dash"><li>
            La cantidad de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46124&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046124&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gl&#xF3;bulos rojos</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45840&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045840&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">plaquetas</a>.</li><li>La cantidad y el tipo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45993&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045993&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gl&#xF3;bulos blancos</a>.</li><li>La cantidad de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45108&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045108&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hemoglobina</a> (la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prote&#xED;na</a> que transporta <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=538149&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000538149&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ox&#xED;geno</a>) en los gl&#xF3;bulos rojos.</li><li>La parte de la muestra de sangre compuesta por gl&#xF3;bulos rojos.</li></ul></div></li><li><strong><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=354461&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000354461&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Velocidad de sedimentaci&#xF3;n</a></strong>: procedimiento para el que se toma una muestra de sangre y se verifica la velocidad con que los gl&#xF3;bulos rojos se asientan en el fondo del tubo de ensayo. La tasa de sedimentaci&#xF3;n es una medida de  la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inflamaci&#xF3;n</a> que hay en el cuerpo. Una tasa de sedimentaci&#xF3;n m&#xE1;s alta de lo normal puede ser un  signo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45368&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045368&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfoma</a> u otra afecci&#xF3;n. Tambi&#xE9;n se llama velocidad de sedimentaci&#xF3;n de eritrocitos, tasa de sedimentaci&#xF3;n o VSE.</li><li><strong><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=304687&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000304687&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Radiograf&#xED;a del t&#xF3;rax</a></strong>: <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45944&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045944&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">radiograf&#xED;a</a> de los &#xF3;rganos y huesos del interior del t&#xF3;rax. Un rayo X es un tipo de haz de energ&#xED;a que puede atravesar el cuerpo y plasmarse en una pel&#xED;cula que muestra una imagen de &#xE1;reas del interior del cuerpo.</li></ul></div><p id="_132" tabindex="-1">De acuerdo con los resultados, se  pueden llevar a cabo pruebas adicionales, como una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45164&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045164&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">biopsia</a> de piel con el fin de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46450&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046450&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">diagnosticar</a> el problema y decidir el tratamiento.</p></section></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _23
      field_pdq_section_title:
        - format: plain_text
          value: 'Tratamiento del prurito'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_23" class="pdq-sections"><div class="key-points"><h3 id="_23_kpBoxHdr" do-not-show="toc">Puntos importantes</h3><div id="_kp_section_23_4"><ul><li>El tratamiento del prurito en los pacientes de c&#xE1;ncer incluye aprender cu&#xE1;les son los desencadenantes y tomar medidas para evitarlos.</li><li>Se usan distintos tipos de tratamiento para aliviar el prurito.<ul><li>Cuidado personal</li><li>Tratamientos de venta libre<ul><li>Maicena y talco</li><li>Cremas y lociones</li></ul></li><li>Medicamentos de venta con receta para aplicar en la piel</li><li>Terapias sist&#xE9;micas</li><li>Otras terapias con medicamentos</li><li>Recursos para estar c&#xF3;modo</li></ul></li></ul></div></div><section id="_98"><h3 id="_99" type="keypoint" do-not-show="toc">El tratamiento del prurito en los pacientes de c&#xE1;ncer incluye aprender cu&#xE1;les son los desencadenantes y tomar medidas para evitarlos.</h3><p id="_100" tabindex="-1">Es importante que usted y las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=648947&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000648947&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">personas a cargo del paciente</a> sepan cu&#xE1;les son los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454808&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454808&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">desencadenantes</a> de la picaz&#xF3;n, como la piel seca o los ba&#xF1;os calientes, de modo que pueda tomar medidas para evitarla. Puede ser que necesite m&#xE1;s de un tipo de tratamiento para aliviar o prevenir el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446534&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prurito</a>, proteger su  piel y mantenerse c&#xF3;modo.</p><p id="_133" tabindex="-1">Una buena <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44698&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044698&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">nutrici&#xF3;n</a> es muy importante para la salud de la piel. Una buena <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44660&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044660&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">alimentaci&#xF3;n</a>  incluye un equilibrio entre <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prote&#xED;nas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285960&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285960&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carbohidratos</a>, grasas, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44744&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044744&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitaminas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45787&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045787&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">minerales</a> y l&#xED;quidos. Consumir una alimentaci&#xF3;n balanceada y beber bastantes l&#xED;quidos ayuda a mantener la salud de la piel.  Lo mejor es consumir al menos tres <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=655098&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000655098&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">litros</a> (unas 100 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=330174&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000330174&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">onzas</a>) de l&#xED;quidos cada d&#xED;a; sin embargo, no todas  las personas pueden hacerlo.</p><p id="_134" tabindex="-1">Es importante lavar la piel todos los d&#xED;as o cada dos d&#xED;as con el fin de ayudar a remover la suciedad y mantener la piel sana.</p></section><section id="_37"><h3 id="_38" type="keypoint" do-not-show="toc">Se usan distintos tipos de tratamiento para aliviar el prurito.</h3><section id="_101"><h4 id="_102" type="keypoint" do-not-show="toc">Cuidado personal</h4><p id="_112" tabindex="-1">El cuidado personal incluye evitar los desencadenantes del prurito y cuidarse bien la piel:</p><p id="_135" tabindex="-1"><em>Los desencadenantes del prurito son los siguientes:</em></p><div class="pdq-content-list"><ul id="_136"><li>La <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44659&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044659&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">deshidrataci&#xF3;n</a> causada por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450108&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450108&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fiebre</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=306496&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000306496&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">diarrea</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390302&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390302&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">n&#xE1;useas</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390324&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">v&#xF3;mitos</a>, o poca ingesta de l&#xED;quidos.</li><li>Los ba&#xF1;os con agua caliente, o ba&#xF1;arse m&#xE1;s de una vez al d&#xED;a o durante m&#xE1;s de treinta minutos.</li><li>Los ba&#xF1;os con burbujas o los jabones que tienen detergentes.</li><li>Las esponjas reutilizables para restregarse la cara  o el cuerpo.</li><li>Las esencias, fragancias y perfumes.</li><li>Los  aceites que se agregan al principio del ba&#xF1;o.</li><li>El aire seco de los espacios interiores.</li><li>Los detergentes de ropa que tienen esencias, colorantes o conservantes.</li><li>Las toallitas suavizantes de telas.</li><li>La ropa ajustada o las prendas de lana, materiales sint&#xE9;ticos, o las telas &#xE1;speras o toscas.</li><li>Los desodorantes o antitranspirantes para las axilas.</li><li>Los  productos o cosm&#xE9;ticos que tienen esencias, colorantes o conservantes.</li><li>La <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450122&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450122&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tensi&#xF3;n</a> emocional.</li></ul></div><p id="_137" tabindex="-1"><em>Algunas maneras de aliviar la picaz&#xF3;n son las siguientes:</em></p><div class="pdq-content-list"><ul id="_138"><li>Usar cremas y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=508685&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000508685&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pomadas</a> suavizantes sin fragancias.</li><li>Ba&#xF1;arse en agua tibia durante no m&#xE1;s de treinta minutos al d&#xED;a o d&#xED;a de por medio.</li><li>Usar limpiadores de piel suaves (sin jab&#xF3;n) o jabones preparados para la piel sensible (como limpiador Cetaphil, Dove para piel sensible, Oilatum y Basis).</li><li>Agregar aceite y jab&#xF3;n al final del ba&#xF1;o o a&#xF1;adir un tratamiento coloidal de avena al principio del ba&#xF1;o.</li><li>Aplicar jab&#xF3;n solo en las &#xE1;reas sucias; de lo contrario el agua es suficiente.</li><li>Si lo necesita, restregarse suavemente con una toallita o pa&#xF1;o de algod&#xF3;n limpio, fresco y suave.</li><li>Enjuagar todo el jab&#xF3;n y otros residuos del ba&#xF1;o usando agua tibia y limpia.</li><li>Secarse mediante toques en la piel en lugar de frotarse.</li><li>Mantener el ambiente de la casa fresco y h&#xFA;medo (incluso usar un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46362&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046362&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">humidificador</a>).</li><li>Lavar las s&#xE1;banas, la ropa  y las prendas interiores con jab&#xF3;n suave o jab&#xF3;n para ropa de beb&#xE9; sin esencias, colorantes o conservantes (como Dreft, All Free Clear, Tide Free and Gentle). Se puede remover los restos de detergente al a&#xF1;adir vinagre al agua del enjuague (una cucharadita de vinagre por cada cuarto de gal&#xF3;n [casi un litro] de agua).</li><li>Usar l&#xED;quidos suavizantes para ropa que se enjuagan durante el lavado (como el suavizante de ropa All Free Clear) o evitar todo tipo de suavizante de ropa.</li><li>Usar frazadas suaves, como las de franela de algod&#xF3;n.</li><li>Vestir ropa holgada,  y prendas hechas de algod&#xF3;n o de otras telas suaves.</li><li>Utilizar <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44663&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044663&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">distracci&#xF3;n</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=640061&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000640061&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">musicoterapia</a>, relajaci&#xF3;n o  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45719&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045719&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">imaginer&#xED;a</a> positiva.</li></ul></div></section><section id="_106"><h4 id="_107" type="keypoint" do-not-show="toc">Tratamientos de venta libre</h4><p id="_238" tabindex="-1">Algunos tratamientos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44696&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044696&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">de venta libre</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=482419&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000482419&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicinas</a> que se pueden comprar sin una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44711&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044711&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">receta</a>) ayudan a prevenir o aliviar el prurito. Sin embargo, debe leer bien las etiquetas para buscar ingredientes que puedan desencadenar reacciones en la piel, como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=463134&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000463134&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">alcohol</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45967&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045967&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antibi&#xF3;ticos</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45927&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045927&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">t&#xF3;picos</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46051&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046051&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">anest&#xE9;sicos</a> t&#xF3;picos.</p><section id="_239"><h5 id="_240" type="keypoint" do-not-show="toc">Maicena y talco</h5><p id="_241" tabindex="-1">La maicena puede prevenir la picaz&#xF3;n de la piel seca causada por la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">radioterapia</a>, pero no se debe usar cuando la piel est&#xE1; h&#xFA;meda.  Cuando la maicena se humedece pueden crecer <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44571&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044571&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hongos</a>. Evite usar maicena en &#xE1;reas que est&#xE1;n cerca de las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=257212&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000257212&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">membranas mucosas</a>, como la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46646&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046646&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vagina</a> o el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46555&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046555&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">recto</a>, en los pliegues de la piel, y en las &#xE1;reas que tienen pelo o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46386&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046386&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gl&#xE1;ndulas</a> de sudor.</p><p id="_242" tabindex="-1">Algunos polvos y  antitranspirantes, como los que tienen <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=470254&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000470254&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">talco</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=639941&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000639941&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">aluminio</a>, producen irritaci&#xF3;n de la piel durante la radioterapia y se deben evitar mientras recibe el tratamiento de radioterapia.</p><p id="_243" tabindex="-1">Los tratamientos a base de talco pueden ser mejores que los de maicena para la picaz&#xF3;n que no se relaciona con la radioterapia, especialmente en el lugar donde se tocan o rozan entre s&#xED; dos superficies de la piel (como en las axilas, o entre los dedos de las manos y los pies).</p></section><section id="_244"><h5 id="_245" type="keypoint" do-not-show="toc">Cremas y lociones</h5><p id="_246" tabindex="-1">Si el prurito se relaciona con piel seca,  se pueden usar cremas o lociones emolientes. Los emolientes ayudan a calmar y suavizar la piel  y aumentar su grado de humedad. Es importante    conocer los ingredientes  de estas cremas y lociones porque algunos pueden causar reacciones en la piel. Algunos de esos ingredientes son los siguientes:</p><div class="pdq-content-list"><ul id="_247"><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=476581&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000476581&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Vaselina</a>, que no se absorbe bien en la piel tratada con radioterapia, se puede acumular mucho o ser dif&#xED;cil de limpiar.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=486452&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000486452&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Lanolina</a>, que puede causar <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=443292&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000443292&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">reacciones al&#xE9;rgicas</a> en algunas personas.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=486450&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000486450&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Aceite de vaselina</a>, que se puede combinar con vaselina espesa y lanolina en cremas y lociones, y puede ser un ingrediente de los aceites para el ba&#xF1;o.</li></ul></div><p id="_248" tabindex="-1">Otros de los ingredientes que se a&#xF1;aden a los emolientes, como los
            espesantes, conservantes, fragancias y colorantes, tambi&#xE9;n pueden causar reacciones al&#xE9;rgicas en la piel.</p><p id="_249" tabindex="-1">Las cremas o lociones emolientes se aplican por lo menos 2 o 3 veces  al d&#xED;a y despu&#xE9;s del ba&#xF1;o. Si usted no es sensible a los ingredientes de alcohol, puede aplicar geles con anest&#xE9;sicos locales (0,5&#x2013;5&#xA0;% de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=306506&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000306506&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lidoca&#xED;na</a>) en algunas &#xE1;reas peque&#xF1;as,  tan a menudo como cada 2 horas.</p><p id="_250" tabindex="-1">Para aliviar o calmar &#xE1;reas de prurito intenso, se pueden usar productos de venta libre con    <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=640055&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000640055&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mentol</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44001&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044001&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">alcanfor</a>, pramoxina o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45377&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045377&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">capsaicina</a>. Estos productos alivian, calman y disminuyen  el impulso de rascarse. Es posible que las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapias</a> a base de capsaicina act&#xFA;en mejor en el prurito relacionado con  se&#xF1;ales <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373935&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373935&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">nerviosas</a>.</p></section></section><section id="_251"><h4 id="_252" type="keypoint" do-not-show="toc">Medicamentos de venta con receta para aplicar en la piel</h4><p id="_253" tabindex="-1">Su m&#xE9;dico le puede recetar  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46601&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046601&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamentos corticoesteroideos</a> t&#xF3;picos (corticosteroides que se aplican sobre la piel) para disminuir la picaz&#xF3;n, pero pueden adelgazar la piel y hacerla m&#xE1;s sensible. No se deben usar para el prurito relacionado con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inflamaci&#xF3;n</a>. Los corticosteroides t&#xF3;picos no se deben usar  en la piel tratada con radioterapia, pero se pueden usar para disminuir la  inflamaci&#xF3;n de la piel al completar el tratamiento de radiaci&#xF3;n.</p><p id="_254" tabindex="-1">Se pueden usar cremas humectantes para retener la humedad y  quitar las capas de escamas de la piel en los casos de xerosis (piel <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44636&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044636&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">anormalmente</a> seca) o  queratodermia (una  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=651193&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000651193&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">afecci&#xF3;n</a> parecida a los callos de  la piel). Los hidratantes con ingredientes como el &#xE1;cido salic&#xED;lico, el   lactato de amonio o la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=471785&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000471785&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">urea</a> pueden  suavizar la piel pero, si se aplican sobre lesiones de la piel, pueden producir escozor.</p></section><section id="_255"><h4 id="_256" type="keypoint" do-not-show="toc">Terapias sist&#xE9;micas</h4><p id="_257" tabindex="-1">Las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45922&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045922&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapias sist&#xE9;micas</a>  viajan por el torrente de sangre hasta llegar a las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> de todo el cuerpo y afectarlas. Estas terapias pueden  ayudar a tratar la afecci&#xF3;n que causa prurito o aliviar sus <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">s&#xED;ntomas</a></p><p id="_258" tabindex="-1">El m&#xE9;dico le puede recetar un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45967&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045967&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antibi&#xF3;tico</a> si la causa del prurito es una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045364&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">infecci&#xF3;n</a>. Tambi&#xE9;n le pueden dar un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=468794&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000468794&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antihistam&#xED;nico</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a> para aliviar la picaz&#xF3;n. En ocasiones, se puede usar una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> m&#xE1;s grande  en el momento de acostarse para ayudarlo a dormir.</p></section><section id="_259"><h4 id="_260" type="keypoint" do-not-show="toc">Otras terapias con medicamentos</h4><p id="_261" tabindex="-1">En ocasiones, se pueden usar <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450118&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450118&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sedantes</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44105&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044105&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antidepresivos</a> si no funcionan otros tratamientos con  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamentos</a> para aliviar el prurito.</p><p id="_262" tabindex="-1">Es posible que la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45176&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045176&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">aspirina</a> alivie el prurito de algunos pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=426418&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000426418&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">policitemia vera</a>, pero en otros puede aumentarlo. La <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45184&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045184&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cimetidina</a> sola o combinada con aspirina  puede ayudar a controlar el prurito en pacientes con  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270800&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270800&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfoma de Hodgkin</a> y policitemia vera.</p></section><section id="_109"><h4 id="_110" type="keypoint" do-not-show="toc">Recursos para estar c&#xF3;modo</h4><p id="_111" tabindex="-1">Hay otros recursos que usted puede usar para evitar rascarse y  detener el ciclo de picaz&#xF3;n-rascado-picaz&#xF3;n. Estos recursos son los siguientes:</p><div class="pdq-content-list"><ul id="_237"><li>Aplicar emolientes para ayudar a prevenir el agrietamiento de la piel.</li><li>Colocar una toalla fresca o  hielo sobre la zona con picaz&#xF3;n.</li><li>Hacer presi&#xF3;n firme sobre la zona con picaz&#xF3;n, en  la misma zona del lado contrario del cuerpo y en los puntos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46723&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046723&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acupresi&#xF3;n</a>.</li><li>Frotar o aplicar vibraci&#xF3;n en la zona con picaz&#xF3;n.</li><li>Usar <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44740&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044740&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estimulaci&#xF3;n el&#xE9;ctrica transcut&#xE1;nea del nervio</a> (TENS) o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46724&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046724&amp;version=patient&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acupuntura</a>.</li></ul></div></section></section></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Informaci&#xF3;n sobre el PDQ</h3><p id="_AboutThis_3" tabindex="-1">El Physician Data Query (PDQ) es la base de datos integral del Instituto Nacional del C&#xE1;ncer (NCI).  La base de datos del PDQ contiene sumarios de la &#xFA;ltima informaci&#xF3;n publicada sobre  prevenci&#xF3;n, detecci&#xF3;n, gen&#xE9;tica, tratamiento, cuidados m&#xE9;dicos de apoyo, y medicina complementaria y alternativa relacionada con el c&#xE1;ncer. La mayor&#xED;a de los sumarios se redactan en dos versiones. En las versiones para profesionales de la salud se ofrece informaci&#xF3;n detallada  en lenguaje t&#xE9;cnico. Las versiones para pacientes se presentan en un lenguaje f&#xE1;cil de comprender, que no es t&#xE9;cnico. Ambas versiones contienen informaci&#xF3;n sobre el c&#xE1;ncer que es exacta y actualizada. Tambi&#xE9;n se puede consultar estos sumarios en <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">ingl&#xE9;s</a>.</p><p id="_AboutThis_4" tabindex="-1">El PDQ es uno de los servicios del NCI. El NCI pertenece a los Institutos Nacionales de la Salud (NIH). Los NIH son el centro  de investigaci&#xF3;n biom&#xE9;dica del gobierno federal. Los sumarios del PDQ se basan en un an&#xE1;lisis independiente de las publicaciones m&#xE9;dicas. No constituyen declaraciones de la pol&#xED;tica del NCI ni de los NIH.</p></section><section id="_AboutThis_5"><h3 id="_AboutThis_5_toc">Prop&#xF3;sito de este sumario </h3><p id="_AboutThis_6" tabindex="-1">Este sumario del PDQ  sobre el c&#xE1;ncer contiene informaci&#xF3;n actualizada sobre las causas y el tratamiento del prurito. El prop&#xF3;sito es  informar y ayudar a los pacientes, las familias y las personas encargadas de cuidar a los pacientes. No provee pautas o recomendaciones formales para la toma de decisiones relacionadas con la atenci&#xF3;n de la salud. </p></section><section id="_AboutThis_7"><h3 id="_AboutThis_7_toc">Revisores y actualizaciones </h3><p id="_AboutThis_8" tabindex="-1">Los Consejos editoriales redactan los sumarios de informaci&#xF3;n sobre el c&#xE1;ncer del PDQ y los actualizan. Estos Consejos est&#xE1;n integrados por expertos en el tratamiento del c&#xE1;ncer y otras especialidades relacionadas con esta enfermedad. Los sumarios se revisan con regularidad y se modifican si surge  nueva informaci&#xF3;n. La fecha de actualizaci&#xF3;n al pie de cada sumario indica cu&#xE1;ndo se hizo el cambio m&#xE1;s reciente.</p><p id="_AboutThis_9" tabindex="-1">La informaci&#xF3;n en este sumario para pacientes se basa en la versi&#xF3;n para profesionales de la salud, que el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/cuidados-medicos-apoyo" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/cuidados-medicos-apoyo">Consejo editorial  del PDQ sobre los cuidados m&#xE9;dicos de apoyo y los cuidados paliativos</a> revisa con regularidad y actualiza en caso  necesario.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Informaci&#xF3;n sobre ensayos cl&#xED;nicos </h3><p id="_AboutThis_11" tabindex="-1">Un  ensayo cl&#xED;nico es un estudio para responder a una pregunta cient&#xED;fica; por ejemplo, si un tratamiento es mejor que otro. Los ensayos se basan en estudios anteriores y lo que se aprendi&#xF3; en el laboratorio. Cada ensayo responde a ciertas preguntas cient&#xED;ficas dirigidas a encontrar formas nuevas y mejores de ayudar a los pacientes de c&#xE1;ncer. Durante los ensayos cl&#xED;nicos de tratamiento, se recopila informaci&#xF3;n sobre los efectos de un tratamiento nuevo y su eficacia. Si un ensayo cl&#xED;nico indica que un tratamiento nuevo es mejor que el tratamiento est&#xE1;ndar, el tratamiento nuevo se puede convertir en "est&#xE1;ndar". Los pacientes pueden considerar participar en un ensayo cl&#xED;nico. Algunos ensayos cl&#xED;nicos  solo aceptan a  pacientes que a&#xFA;n no comenzaron un tratamiento. </p><p id="_AboutThis_12" tabindex="-1">La lista en ingl&#xE9;s de ensayos cl&#xED;nicos del PDQ est&#xE1; disponible  en el <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">portal de Internet del NCI</a>. Para obtener m&#xE1;s informaci&#xF3;n, llamar al Servicio de Informaci&#xF3;n sobre el C&#xE1;ncer al 1-800-422-6237 (1-800-4-CANCER).</p></section><section id="_AboutThis_13"><h3 id="_AboutThis_13_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_14" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del NCI, salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_15" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_16" tabindex="-1">PDQ&#xAE; sobre los cuidados m&#xE9;dicos de apoyo y los cuidados paliativos. PDQ Prurito. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/cancer/tratamiento/efectos-secundarios/cambios-piel-unas/prurito-pro-pdq" title="https://www.cancer.gov/espanol/cancer/tratamiento/efectos-secundarios/cambios-piel-unas/prurito-pro-pdq">https://www.cancer.gov/espanol/cancer/tratamiento/efectos-secundarios/cambios-piel-unas/prurito-pro-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_17" tabindex="-1">Las im&#xE1;genes en este sumario se reproducen con el permiso del autor, el artista o la editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_18"><h3 id="_AboutThis_18_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_19" tabindex="-1">La informaci&#xF3;n en estos sumarios no debe fundamentar ninguna decisi&#xF3;n sobre reintegros de seguros. Para obtener m&#xE1;s informaci&#xF3;n sobre cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_21" tabindex="-1">En Cancer.gov/espanol, se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>. Tambi&#xE9;n se puede enviar un mensaje de correo electr&#xF3;nico mediante el <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a>.</p></section></div>
